

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2007 (30.08.2007)

PCT

(10) International Publication Number
WO 2007/096576 A1

(51) International Patent Classification:
C07D 413/12 (2006.01) *C07D 261/04* (2006.01)
A01N 43/80 (2006.01)

(74) Agents: **WARD, Steven, Paul** et al.; Intellectual Property Department, Syngenta Limited, PO Box 3538, Jealott's Hill Research Centre, Bracknell RG42 6YA (GB).

(21) International Application Number:
PCT/GB2007/000184

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date: 22 January 2007 (22.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0603891.3 27 February 2006 (27.02.2006) GB

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **SYNGENTA LIMITED** [GB/GB]; European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BOEHMER, Jutta, Elisabeth** [DE/GB]; Syngenta Limited, Jealott's Hill International Research Centre, Bracknell, Berkshire RG42 6EY (GB). **MCLACHLAN, Matthew, Murdoch, Woodhead** [NZ/GB]; Syngenta Limited, Jealott's Hill International Research Centre, Bracknell, Berkshire RG42 6EY (GB).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HERBICIDAL ISOXAZOLINE COMPOUNDS



(57) Abstract: Novel compounds of formula (I): wherein R^1 , R^2 , R^3 , R^4 , m , R^5 , R^6 , n and Y are as defined in claim 1; or N-oxides, salts and optical isomers thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to herbicidal compositions comprising them and to methods of using them to control plants or to inhibit plant growth.


HERBICIDAL ISOXAZOLINE COMPOUNDS

The present invention relates to novel, herbicidal isoxazoline compounds, to processes for their preparation, to compositions comprising those compounds, and to their use in controlling plants or in inhibiting plant growth.

Isoxazoline compounds which display a herbicidal action are described, for example, in WO 01/012613, WO 02/062770, WO 03/000686, WO 04/010165, JP 2005/035924, JP 2005/213168 and WO 06/024820. The preparation of these compounds is also described in WO 04/013106 and WO 05/095352.


Novel isoxazoline compounds which display herbicidal and growth-inhibiting properties have now been found.

The present invention accordingly relates to compounds of formula I



wherein

- R^1 and R^2 are each independently of the other hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_3 - C_8 cycloalkyl or C_3 - C_8 cycloalkyl- C_1 - C_3 alkyl, or R^1 and R^2 together with the carbon atom to which they are bonded form a C_3 - C_7 ring, R^3 and R^4 are each independently of the other hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl or C_1 - C_6 alkoxy- C_1 - C_{10} alkyl, or R^3 and R^4 together with the carbon atom to which they are bonded form a C_3 - C_7 ring, or R^1 with R^3 or R^4 and together with the carbon atoms to which they are bonded form a C_5 - C_8 ring, or R^2 with R^3 or R^4 and together with the carbon atoms to which they are bonded form a C_5 - C_8 ring;
- R^5 is halogen or C_1 - C_6 haloalkyl;
- R^6 is hydrogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxycarbonyl, halogen or C_1 - C_6 haloalkyl;
- m is 0, 1 or 2;
- n is 1, 2 or 3; and
- Y is one of the following groups



wherein

- R^7 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl, formyl, C_1 - C_{10} haloalkylcarbonyl, C_1 - C_{10} alkoxycarbonyl, C_1 - C_{10} haloalkyl, cyano, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl- C_1 - C_{10} alkyl, C_1 - C_{10} alkylsulfonyl, C_1 - C_{10} haloalkylsulfonyl, C_1 - C_{10} alkoxy- C_1 - C_{10} alkyl or phenyl which is optionally substituted by one to five substituents selected from cyano, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl or halogen; or
- R^7 is $-\text{CONR}^{13}\text{R}^{14}$ or $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} are independently of each other hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 cycloalkyl, C_1 - C_6 alkylcarbonyl, C_1 - C_6 haloalkylcarbonyl, C_1 - C_6 alkylsulfonyl, C_1 - C_6 haloalkylsulfonyl, or R^{13} and R^{14} together form a C_3 - C_8 alkylene group which optionally contains one oxygen, sulfur, amino or C_1 - C_6 alkylamino group;
- R^8 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl, formyl, C_1 - C_{10} haloalkylcarbonyl, C_1 - C_{10} alkoxycarbonyl, C_1 - C_{10} haloalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl, halogen, cyano, C_1 - C_{10} alkoxy or C_1 - C_{10} haloalkoxy, or
- R^8 is $-\text{CONR}^{15}\text{R}^{16}$, $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$ or $-\text{NR}^{15}\text{R}^{16}$ wherein R^{15} and R^{16} are independently of each other hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 cycloalkyl, C_1 - C_6 alkylcarbonyl, C_1 - C_6 haloalkylcarbonyl, C_1 - C_6 alkylsulfonyl, C_1 - C_6 haloalkylsulfonyl, or R^{15} and R^{16} together form a C_3 - C_8 alkylene group which optionally contains one oxygen, sulfur, amino or C_1 - C_6 alkylamino group;
- and to N-oxides, salts and optical isomers of compounds of formula I.

Preferably R^1 and R^2 are independently C_1 - C_{10} alkyl or C_1 - C_{10} haloalkyl, more preferably C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, most preferably methyl.

Preferably R^3 and R^4 are independently hydrogen, C_1 - C_{10} alkyl or C_1 - C_{10} haloalkyl, more preferably hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, most preferably hydrogen.


Preferably R^5 is halogen or trifluoromethyl, more preferably fluoro, chloro or trifluoromethyl, most preferably fluoro or chloro.

Preferably R^6 is hydrogen, methoxycarbonyl, C_1 - C_6 alkyl or halogen, more preferably hydrogen, methyl, fluoro or chloro, most preferably hydrogen or fluoro.

Preferably m is 1 or 2, more preferably 2.

Preferably n is 1.

5 Preferably Y is one of the following groups



Preferably R^7 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy- C_1 - C_{10} alkyl or phenyl which is optionally substituted by one to five substituents selected from cyano,
 10 C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl or halogen, more preferably hydrogen, methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, allyl, propargyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylmethyl, methoxymethyl, 2-methoxy-ethyl or phenyl, even more preferably methyl, ethyl, *iso*-propyl, *tert*-butyl, difluoromethyl, allyl, cyclopentyl, cyclobutylmethyl, 2-methoxy-ethyl or phenyl, most
 15 preferably methyl, ethyl, *iso*-propyl, *tert*-butyl, difluoromethyl, allyl, cyclopentyl, cyclobutylmethyl or 2-methoxy-ethyl.

Preferably R^8 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl, formyl, C_1 - C_{10} alkoxycarbonyl, C_1 - C_{10} haloalkyl, C_3 - C_{10} cycloalkyl, halogen, cyano, C_1 - C_{10} alkoxy or C_1 - C_{10} haloalkoxy, more preferably hydrogen, methyl, ethyl, acetyl, formyl, methoxy-
 20 carbonyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, cyclopropyl, fluoro, chloro, bromo, cyano, methoxy, difluoromethoxy, trifluoromethoxy or 2,2,2-trifluoroethoxy, even more preferably hydrogen, methyl, ethyl, acetyl, methoxycarbonyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromo-difluoromethyl, 1-fluoro-ethyl, cyclopropyl, bromo, methoxy or difluoromethoxy, most
 25 preferably hydrogen, methyl, ethyl, monofluoromethyl, trifluoromethyl, bromo or methoxy.


A group of preferred compounds of formula I comprises those wherein Y is 1,2,3-triazolyl which is optionally substituted by one to two substituents independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkylcarbonyl, formyl, C_1 - C_6 alkoxycarbonyl, C_2 -
 30 C_6 alkenyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl- C_1 - C_6 -alkyl, C_1 - C_6 alkoxy- C_1 - C_6 alkyl,

halogen, cyano, C₁-C₆alkoxy, C₁-C₆haloalkoxy or phenyl which is optionally substituted by one to five substituents selected from cyano, C₁-C₁₀alkyl, C₁-C₁₀haloalkyl or halogen, more preferably wherein Y is 1,2,3-triazolyl which is optionally substituted by one to two substituents independently selected from methyl, ethyl, *iso*-propyl, *tert*-butyl, mono-
5 fluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, acetyl, formyl, methoxycarbonyl, allyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylmethyl, 2-methoxy-ethyl, fluoro, chloro, bromo, cyano, methoxy, ethoxy, monofluoromethoxy, difluoromethoxy, trifluoromethoxy or phenyl, even more preferably wherein Y is 1,2,3-triazolyl which is optionally substituted by one to two substituents
10 independently selected from methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, acetyl, methoxycarbonyl, allyl, cyclopropyl, cyclopentyl, cyclobutylmethyl, 2-methoxy-ethyl, bromo, methoxy, difluoromethoxy or phenyl, most preferably wherein Y is 1,2,3-triazolyl which is optionally substituted by one to two substituents independently selected
15 from methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, allyl, cyclopentyl, cyclobutylmethyl, 2-methoxy-ethyl or bromo.

A group of especially preferred compounds of formula I comprises those wherein Y is 1,2,3-triazol-4-yl which is optionally substituted by one to two substituents independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkylcarbonyl, formyl, C₁-
20 C₆alkoxycarbonyl, C₂-C₆alkenyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₆-alkyl, C₁-C₆alkoxy-C₁-C₆alkyl, halogen, cyano, C₁-C₆alkoxy, C₁-C₆haloalkoxy or phenyl which is optionally substituted by one to five substituents selected from cyano, C₁-C₁₀alkyl, C₁-C₁₀haloalkyl or halogen, more preferably wherein Y is 1,2,3-triazol-4-yl which is optionally substituted by one to two substituents independently selected from methyl,
25 ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, acetyl, formyl, methoxycarbonyl, allyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylmethyl, 2-methoxy-ethyl, fluoro, chloro, bromo, cyano, methoxy, ethoxy, monofluoromethoxy, difluoromethoxy, trifluoromethoxy or phenyl, even more preferably wherein Y is 1,2,3-triazol-4-yl which
30 is optionally substituted by one to two substituents independently selected from methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, acetyl, methoxycarbonyl, allyl, cyclopropyl, cyclopentyl, cyclobutylmethyl, 2-methoxy-ethyl, bromo, methoxy, difluoromethoxy or phenyl,

most preferably wherein Y is 1,2,3-triazol-4-yl which is optionally substituted by one to two substituents independently selected from methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, allyl, cyclopentyl, cyclobutylmethyl, 2-methoxy-ethyl or bromo.

- 5 A group of especially preferred compounds of formula I comprises those wherein Y is



A group of especially preferred compounds of formula I comprises those wherein Y is 5-monofluoromethyl-2-methyl-1,2,3-triazol-4-yl.

- 10 A group of especially preferred compounds of formula I comprises those wherein Y is 2,5-dimethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-cyclopropyl-2-methyl-1,2,3-triazol-4-yl.

- 15 A group of especially preferred compounds of formula I comprises those wherein Y is 2,5-diethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-difluoromethyl-5-methyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-allyl-5-trifluoromethyl-1,2,3-triazol-4-yl.

- 20 A group of especially preferred compounds of formula I comprises those wherein Y is 2-cyclopentyl-5-trifluoromethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-cyclobutylmethyl-5-trifluoromethyl-1,2,3-triazol-4-yl.

- 25 A group of especially preferred compounds of formula I comprises those wherein Y is 2-(2-methoxy-ethyl)-5-trifluoromethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-methyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-*iso*-propyl-5-trifluoromethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-ethyl-5-trifluoromethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-ethyl-2-methyl-1,2,3-triazol-4-yl.

5 A group of especially preferred compounds of formula I comprises those wherein Y is 2-ethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 2-*iso*-propyl-5-methyl-1,2,3-triazol-4-yl.

10 A group of especially preferred compounds of formula I comprises those wherein Y is 2-methyl-5-trifluoromethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-methoxy-2-methyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-bromo-2-methyl-1,2,3-triazol-4-yl.

15 A group of especially preferred compounds of formula I comprises those wherein Y is 2-ethyl-5-methyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-difluoromethoxy-2-methyl-1,2,3-triazol-4-yl.

20 A group of especially preferred compounds of formula I comprises those wherein Y is 5-methoxycarbonyl-2-methyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-acetyl-2-methyl-1,2,3-triazol-4-yl.


A group of especially preferred compounds of formula I comprises those wherein Y is 5-bromodifluoromethyl-2-methyl-1,2,3-triazol-4-yl.

25 A group of especially preferred compounds of formula I comprises those wherein Y is 5-difluoromethyl-2-methyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 5-(1-fluoro-ethyl)-2-methyl-1,2,3-triazol-4-yl.

30 A group of especially preferred compounds of formula I comprises those wherein Y is 5-methyl-2-phenyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is




A group of especially preferred compounds of formula I comprises those wherein
5 Y is 1-*tert*-butyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein
Y is 1,5-dimethyl-1,2,3-triazol-4-yl.

A group of especially preferred compounds of formula I comprises those wherein
Y is 5-cyclopropyl-1-methyl-1,2,3-triazol-4-yl.

10 A group of especially preferred compounds of formula I comprises those wherein
Y is 1,2,3-triazol-5-yl which is optionally substituted by one to two substituents
independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkylcarbonyl, formyl, C₁-
C₆alkoxycarbonyl, C₂-C₆alkenyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₆-alkyl, C₁-
C₆alkoxy-C₁-C₆alkyl, halogen, cyano, C₁-C₆alkoxy, C₁-C₆haloalkoxy or phenyl which is
15 optionally substituted by one to five substituents selected from cyano, C₁-C₁₀alkyl, C₁-
C₁₀haloalkyl or halogen, more preferably wherein Y is 1,2,3-triazol-5-yl which is
optionally substituted by one to two substituents independently selected from methyl,
ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl,
bromodifluoromethyl, 1-fluoro-ethyl, acetyl, formyl, methoxycarbonyl, allyl,
20 cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylmethyl, 2-methoxy-ethyl, fluoro,
chloro, bromo, cyano, methoxy, ethoxy, monofluoromethoxy, difluoromethoxy, trifluoro-
methoxy or phenyl, even more preferably wherein Y is 1,2,3-triazol-5-yl which is
optionally substituted by one to two substituents independently selected from methyl,
iso-propyl, trifluoromethyl, cyclopropyl or bromo, most preferably wherein Y is 1,2,3-
25 triazol-5-yl which is optionally substituted by one to two substituents independently
selected from methyl, trifluoromethyl or bromo.

A group of especially preferred compounds of formula I comprises those wherein
Y is



A group of especially preferred compounds of formula I comprises those wherein Y is 4-bromo-1-methyl-1,2,3-triazol-5-yl.


A group of especially preferred compounds of formula I comprises those wherein
5 Y is 4-methyl-1-*iso*-propyl-1,2,3-triazol-5-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 1-methyl-4-trifluoromethyl-1,2,3-triazol-5-yl.

A group of especially preferred compounds of formula I comprises those wherein Y is 4-cyclopropyl-1-methyl-1,2,3-triazol-5-yl.


10 A group of especially preferred compounds of formula I comprises those wherein Y is 1,2,3-triazol-4-yl-1-oxide which is optionally substituted by one to two substituents independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkylcarbonyl, formyl, C₁-C₆alkoxycarbonyl, C₂-C₆alkenyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₆-alkyl, C₁-C₆alkoxy-C₁-C₆alkyl, halogen, cyano, C₁-C₆alkoxy, C₁-C₆haloalkoxy or phenyl which is
15 optionally substituted by one to five substituents selected from cyano, C₁-C₁₀alkyl, C₁-C₁₀haloalkyl or halogen, more preferably wherein Y is 1,2,3-triazol-4-yl-1-oxide which is optionally substituted by one to two substituents independently selected from methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, acetyl, formyl, methoxycarbonyl, allyl,
20 cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylmethyl, 2-methoxy-ethyl, fluoro, chloro, bromo, cyano, methoxy, ethoxy, monofluoromethoxy, difluoromethoxy, trifluoromethoxy or phenyl, most preferably wherein Y is 1,2,3-triazol-4-yl-1-oxide which is optionally substituted by one or two methyl groups.

A group of especially preferred compounds of formula I comprises those wherein
25 Y is



A group of especially preferred compounds of formula I comprises those wherein Y is 2,5-dimethyl-1,2,3-triazol-4-yl-1-oxide.

- In one embodiment the invention relates to a compound of formula I wherein
- 5 R^1 and R^2 are each independently of the other hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_3 - C_8 cycloalkyl or C_3 - C_8 cycloalkyl- C_1 - C_3 alkyl, or R^1 and R^2 together with the carbon atom to which they are bonded form a C_3 - C_7 ring, R^3 and R^4 are each independently of the other hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl or C_1 - C_6 alkoxy- C_1 - C_{10} alkyl, or
- 10 R^3 and R^4 together with the carbon atom to which they are bonded form a C_3 - C_7 ring, or R^1 with R^3 or R^4 and together with the carbon atoms to which they are bonded form a C_5 - C_8 ring, or R^2 with R^3 or R^4 and together with the carbon atoms to which they are bonded form a C_5 - C_8 ring;
- 15 R^5 is halogen or C_1 - C_6 haloalkyl; R^6 is hydrogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxycarbonyl, halogen or C_1 - C_6 haloalkyl; m is 0, 1 or 2; n is 1, 2 or 3; and Y is one of the following groups



wherein

- R^7 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl, C_1 - C_{10} haloalkylcarbonyl, C_1 - C_{10} alkoxycarbonyl, C_1 - C_{10} haloalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl- C_1 - C_{10} alkyl, C_1 - C_{10} alkylsulfonyl, C_1 - C_{10} haloalkylsulfonyl or C_1 - C_{10} alkoxy- C_1 - C_{10} alkyl;
- 25 R^8 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl, C_1 - C_{10} haloalkylcarbonyl, C_1 - C_{10} alkoxycarbonyl, C_1 - C_{10} haloalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl, halogen, C_1 - C_{10} alkoxy or C_1 - C_{10} haloalkoxy; and to N-oxides, salts and optical isomers of compounds of formula I.

Preferably R^7 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl or C_1 - C_{10} alkoxy- C_1 - C_{10} alkyl, more preferably hydrogen, methyl, ethyl, allyl, propargyl, cyclopropyl, cyclopropylmethyl, methoxymethyl, methoxymethyl, difluoromethyl or trifluoromethyl,
5 most preferably methyl.

Preferably R^8 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} haloalkyl, C_3 - C_{10} cycloalkyl, halogen, C_1 - C_{10} alkoxy or C_1 - C_{10} haloalkoxy, more preferably hydrogen, methyl, ethyl, trifluoromethyl, difluoromethyl, monofluoromethyl, cyclopropyl, fluoro, chloro, trifluoromethoxy or 2,2,2-trifluoroethoxy, most preferably methyl, trifluoromethyl or
10 monofluoromethyl.

The compounds of the invention may contain one or more asymmetric carbon atoms, for example, in the $-CR^5R^6$ - group or in the $-CR^3R^4$ -group and may exist as enantiomers (or as pairs of diastereomers) or as mixtures of such. Further, when m is 1,
15 the compounds of the invention are sulfoxides, which can exist in two enantiomeric forms, the adjacent carbon can also exist in two enantiomeric forms and the $-CR^3R^4$ -group can also exist in two enantiomeric forms. Compounds of general formula I can therefore exist as racemates, diastereoisomers, or single enantiomers, and the invention includes all possible isomers or isomer mixtures in all proportions. It is to be expected
20 that for any given compound, one isomer may be more herbicidal than another.

Alkyl groups, haloalkyl groups, hydroxyalkyl groups, alkoxy groups, haloalkoxy groups and alkylene groups can be straight or branched chain. Preferred alkyl groups, haloalkyl groups, hydroxyalkyl groups, alkoxy groups, haloalkoxy groups and alkylene groups each independently contain 1 to 4 carbons. Examples of alkyl groups are methyl,
25 ethyl, *n*- and *iso*-propyl and *n*-, *sec*-, *iso*- and *tert*-butyl, hexyl, nonyl and decyl. Examples of haloalkyl groups are difluoromethyl and 2,2,2-trifluoroethyl. Examples of hydroxyalkyl groups are 1,2-dihydroxyethyl and 3-hydroxypropyl. Examples of alkoxy groups are methoxy, ethoxy, propoxy, butoxy, hexyloxy, nonyloxy and decyloxy. Examples of haloalkoxy groups are difluoromethoxy and 2,2,2-trifluoroethoxy. Examples of alkylene groups are methylene, ethylene, *n*- and *iso*-propylene and *n*-, *sec*-, *iso*- and *tert*-butylene.
30

Cycloalkyl groups can be in mono-, bi- or tri-cyclic form. Preferred cycloalkyl groups independently contain 3 to 8 carbons. Examples of monocyclic cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

Alkenyl and alkynyl groups and haloalkenyl groups and haloalkynyl groups can be straight or branched chain. Examples of alkenyl and alkynyl groups are allyl, but-2-enyl, 3-methylbut-2-enyl, ethynyl, propargyl and but-2-ynyl. Examples of haloalkenyl and haloalkynyl groups are trifluoroallyl and 1-chloroprop-1-yn-3-yl.

5 Halogen means fluoro, chloro, bromo and iodo, preferably fluoro, chloro or bromo, more preferably fluoro or chloro.

The invention relates likewise to the salts which the compounds of formula I are able to form with amines, alkali metal and alkaline earth metal bases and quarternary ammonium bases.

10 Among the alkali metal and alkaline earth metal hydroxides as salt formers, special mention should be made of the hydroxides of lithium, sodium, potassium, magnesium and calcium, but especially the hydroxides of sodium and potassium. The compounds of formula I according to the invention also include hydrates which may be formed during the salt formation.

15 Examples of amines suitable for ammonium salt formation include ammonia as well as primary, secondary and tertiary C₁-C₁₈alkylamines, C₁-C₄hydroxyalkylamines and C₂-C₄alkoxyalkylamines, for example methylamine, ethylamine, *n*-propylamine, isopropylamine, the four butylamine isomers, *n*-amylamine, isoamylamine, hexylamine, heptylamine, octylamine, nonylamine, decylamine, pentadecylamine, hexadecylamine, 20 heptadecylamine, octadecylamine, methylethylamine, methylisopropylamine, methylhexylamine, methylnonylamine, methylpentadecylamine, methyloctadecylamine, ethylbutylamine, ethylheptylamine, ethyloctylamine, hexylheptylamine, hexyloctylamine, dimethylamine, diethylamine, di-*n*-propylamine, diisopropylamine, di-*n*-butylamine, di-*n*-amylamine, diisoamylamine, dihexylamine, diheptylamine, 25 dioctylamine, ethanolamine, *n*-propanolamine, isopropanolamine, N,N-diethanolamine, N-ethylpropanolamine, N-butylethanolamine, allylamine, *n*-butenyl-2-amine, *n*-pentenyl-2-amine, 2,3-dimethylbutenyl-2-amine, dibutenyl-2-amine, *n*-hexenyl-2-amine, propylenediamine, trimethylamine, triethylamine, tri-*n*-propylamine, triisopropylamine, tri-*n*-butylamine, triisobutylamine, tri-*sec*-butylamine, tri-*n*-amylamine, 30 methoxyethylamine and ethoxyethylamine; heterocyclic amines such as, for example, pyridine, quinoline, isoquinoline, morpholine, piperidine, pyrrolidine, indoline, quinuclidine and azepine; primary arylamines such as, for example, anilines, methoxyanilines, ethoxyanilines, o-, m- and p-toluidines, phenylenediamines, benzidines,


naphthylamines and o-, m- and p-chloroanilines; but especially triethylamine, isopropylamine and diisopropylamine.

Preferred quarternary ammonium bases suitable for salt formation correspond, for example, to the formula $[N(R_a R_b R_c R_d)]OH$ wherein R_a , R_b , R_c and R_d are each
 5 independently of the others C_1 - C_4 alkyl. Other suitable tetraalkylammonium bases with other anions can be obtained, for example, by anion exchange reactions.

The term "herbicide" as used herein means a compound that controls or modifies the growth of plants. The term "herbicidally effective amount" means the quantity of such a compound or combination of such compounds that is capable of producing a
 10 controlling or modifying effect on the growth of plants. Controlling or modifying effects include all deviation from natural development, for example: killing, retardation, leaf burn, albinism, dwarfing and the like. The term "plants" refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, and fruits. The term "locus" is intended to include soil, seeds, and seedlings, as well as established
 15 vegetation.

The compounds in Table A below illustrate the compounds of the invention.

Table A: Compounds of formula I.1



I.1

m	R ⁵	R ⁶	R ⁷	R ⁸
2	F	Cl	Me	OMe
2	F	F	Me	CF ₃
1	F	F	Me	OCHF ₂
2	H	F	Et	^c Pr
2	F	F	Et	COMe
1	F	Cl	Et	CH ₂ F
2	H	Cl	Et	CH ₂ F
2	F	Cl	Et	CHFMe
1	F	F	Me	CHFMe

m	R ⁵	R ⁶	R ⁷	R ⁸
1	H	F	Et	CH ₂ F
2	H	Cl	Me	OMe
1	F	F	Et	OCHF ₂
2	H	Cl	Me	CF ₃
1	H	Cl	Me	Et
1	F	Cl	Me	CH ₂ F
2	H	F	Et	CF ₃
2	F	F	Et	^c Pr
1	F	Cl	Me	Me
1	H	Cl	Et	COMe
2	F	Cl	Me	CH ₂ F
2	F	Cl	Me	^c Pr
1	F	Cl	Et	OCHF ₂
1	H	F	Me	CF ₃
1	F	F	Et	CHFMe
2	H	Cl	Me	CHFMe
2	F	Cl	Et	CF ₃
2	H	F	Me	Et
2	H	F	Me	OCHF ₂
1	H	Cl	Et	Me
2	H	F	Me	CH ₂ F
1	H	Cl	Me	^c Pr
2	F	Cl	Et	CH ₂ F
1	H	Cl	Et	CH ₂ F
2	F	Cl	Et	^c Pr
2	H	Cl	Me	Me
1	H	F	Et	Me
1	H	Cl	Et	^c Pr
1	H	Cl	Me	CHF ₂
1	F	Cl	Et	Et
2	F	F	Me	Me

m	R ⁵	R ⁶	R ⁷	R ⁸
1	F	Cl	Me	CHFMe
2	F	Cl	Me	Et
1	F	Cl	Et	^c Pr
2	H	Cl	Et	CF ₃
1	H	F	Et	COMe
1	H	Cl	Me	CH ₂ F
1	H	Cl	Me	OCHF ₂
2	H	Cl	Et	OCHF ₂
2	F	Cl	Me	CF ₃
1	H	Cl	Et	OMe
2	F	Cl	Me	CHF ₂
2	F	F	Et	OCHF ₂
1	F	Cl	Et	OMe
1	H	F	Me	COMe
1	F	F	Et	Et
2	F	F	Et	CHF ₂
1	F	F	Et	CH ₂ F
1	F	F	Et	OMe
1	H	F	Et	^c Pr
2	H	Cl	Me	CHF ₂
1	F	Cl	Me	CHF ₂
2	H	F	Et	Et
2	F	F	Me	OMe
2	H	Cl	Et	OMe
2	H	Cl	Me	OCHF ₂
1	F	F	Me	Me
1	F	F	Me	COMe
2	F	F	Me	^c Pr
1	F	Cl	Et	CHF ₂
1	H	F	Me	Et
1	H	Cl	Et	OCHF ₂

m	R ⁵	R ⁶	R ⁷	R ⁸
2	F	F	Me	CH ₂ F
2	F	F	Et	Me
1	F	F	Me	^c Pr
1	H	Cl	Et	CHFMe
2	H	Cl	Me	Et
2	H	Cl	Et	COMe
1	H	F	Et	OMe
1	H	F	Me	CHFMe
2	H	F	Me	CHFMe
2	F	Cl	Et	Et
1	H	F	Et	CF ₃
1	F	F	Me	Et
2	H	Cl	Et	CHFMe
1	H	F	Me	OCHF ₂
1	F	F	Et	COMe
2	F	F	Et	CH ₂ F
2	H	F	Et	OCHF ₂
2	F	Cl	Et	CHF ₂
2	F	Cl	Et	COMe
1	H	F	Et	CHFMe
2	H	Cl	Me	CH ₂ F
2	F	Cl	Me	COMe
2	H	F	Et	CHFMe
1	F	F	Me	CH ₂ F
2	H	Cl	Et	CHF ₂
1	H	F	Et	CHF ₂
1	F	F	Et	CHF ₂
2	H	F	Me	OMe
2	H	F	Me	CF ₃
2	F	F	Me	Et
1	H	Cl	Me	OMe


m	R ⁵	R ⁶	R ⁷	R ⁸
2	F	F	Me	CHF ₂
2	H	Cl	Me	^c Pr
1	F	F	Et	CF ₃
1	H	F	Me	CH ₂ F
1	F	Cl	Me	COMe
2	F	Cl	Et	OCHF ₂
2	H	F	Me	^c Pr
2	F	F	Me	OCHF ₂
2	H	F	Et	COMe
1	F	F	Me	CHF ₂
2	F	Cl	Et	Me
1	H	Cl	Et	Et
1	F	Cl	Me	OCHF ₂
1	H	F	Et	OCHF ₂
1	H	Cl	Me	Me
1	F	Cl	Me	OMe
2	F	F	Et	Et
1	F	Cl	Me	^c Pr
2	F	F	Et	CF ₃
2	H	F	Et	OMe
2	F	Cl	Et	OMe
1	F	Cl	Et	CHFMe
1	F	Cl	Me	Et
2	H	Cl	Et	Me
2	F	F	Et	OMe
2	H	F	Me	CHF ₂
1	F	Cl	Et	Me
1	H	F	Et	Et
1	F	F	Me	OMe
2	F	Cl	Me	OCHF ₂
1	H	Cl	Et	CHF ₂

m	R ⁵	R ⁶	R ⁷	R ⁸
1	F	F	Et	^c Pr
1	F	F	Et	Me
2	H	Cl	Et	^c Pr
2	F	Cl	Me	Me
1	H	F	Me	OMe
2	H	F	Me	Me
2	H	F	Et	CHF ₂
1	H	Cl	Me	CF ₃
2	F	Cl	Me	CHFMe
1	F	F	Me	CF ₃
1	H	Cl	Me	CHFMe
2	H	F	Et	CH ₂ F
2	H	F	Et	Me
1	H	Cl	Et	CF ₃
2	F	F	Et	CHFMe
1	H	F	Me	CHF ₂
2	H	F	Me	COMe
1	F	Cl	Me	CF ₃
1	F	Cl	Et	COMe
2	F	F	Me	CHFMe
2	F	F	Me	COMe
1	F	Cl	Et	CF ₃
1	H	F	Me	^c Pr
1	H	F	Me	Me
2	H	Cl	Me	COMe
1	H	Cl	Me	COMe
2	H	Cl	Et	Et

The compounds of the invention may be made by a variety of methods.


Methods of halogenation, alkylation and oxidation

1) The compounds of formula I wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and Y are as defined above, m is 1 or 2, and n is 1, can be prepared by processes known *per se*, by reacting e.g. the compounds of formula Ia




- 5 wherein R^1 , R^2 , R^3 , R^4 and Y are as defined above and m is 1 or 2, in a single step or stepwise in succession with compounds of the formula R^5 -X and/or R^6 -X, wherein R^5 is halogen and R^6 is cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxycarbonyl or halogen and X is a suitable leaving group e.g. halide, such as bromide or iodide, a carboxylate, such as acetate, an alkylsulfonate, such as methylsulfonate, an arylsulfonate, such as p-toluenesulfonate, a
- 10 haloalkylsulfonate, such as trifluoromethylsulfonate, an imide, such as succinimide, a sulfonimide, such as bis(phenylsulfonyl)imide, or an arylsulfinde, such as p-toluene-sulfinde, in the presence of a base, e.g. an alkyl-lithium compound, such as methyl-lithium, *n*-butyl-lithium or *tert*-butyl-lithium, a lithium dialkylamide, such as lithium diisopropylamide, a metal hydride, preferably an alkali metal hydride, such as sodium
- 15 hydride, or an alkali metal amide, such as sodium amide, a metal bis(tri(C_1 - C_6 alkyl)-silyl)amide, such as lithium bis(trimethylsilyl)amide, a metal alkoxide, such as potassium *tert*-butoxide, or a phosphazene base, such as N' -*tert*-butyl- N,N,N',N'',N'' -hexamethyl-phosphorimidic triamide (P_1 -*t*-Bu), 1-*tert*-butyl-2,2,4,4,4-pentakis(dimethylamino)-2-lambda⁵,4lambda⁵-catenadi(phosphazene) (P_2 -*t*-Bu), 1-ethyl-2,2,4,4,4-pentakis(dimethyl-
- 20 amino)-2-lambda⁵,4lambda⁵-catenadi(phosphazene) (P_2 -Et) and 2-*tert*-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine (BEMP), optionally in the presence of a diluent, preferably an inert solvent, e.g. a hydrocarbon, an ether, such as tetrahydrofuran, an amide, such as N,N -dimethylformamide, or a halogenated hydro-carbon, such as dichloromethane, or mixtures thereof and optionally in the presence of a
- 25 complexing agent, such as hexamethylphosphoramide or tetramethylethylenediamine in a temperature range of from -120°C to 100°C, preferably from -80°C to 50°C. Such processes are known in the literature and are described, for example, in J. Med. Chem., 2003 (46) 3021-3032; J. Org. Chem., 2003 (68) 1443-1446; J. Org. Chem., 2002 (67) 5216-5225 and J. Org. Chem., 2002 (67) 3065-3071, Heterocycles 2003 (59) 161-167 and
- 30 WO06/024820.

2) The compounds of formula I wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and Y are as defined above, m is 1 or 2, and n is 1, can be prepared by processes known *per se*, by reacting e.g. the compounds of formula Ib




- 5 wherein R^1 , R^2 , R^3 , R^4 , R^6 and Y are as defined above and m is 1 or 2, with compounds of the formula R^5 -X, wherein R^5 is halogen and X is a suitable leaving group as defined in 1), in the presence of a base as defined in 1), optionally in the presence of a diluent as defined in 1), preferably an inert solvent, and optionally in the presence of a complexing agent as defined in 1) in a temperature range of from -120°C to 100°C , preferably from
- 10 -80°C to 50°C .

3) The compounds of formula I wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and Y are as defined above, m is 1 or 2, and n is 1, can be prepared by processes known *per se*, by reacting e.g. the compounds of formula Ic



- 15 wherein R^1 , R^2 , R^3 , R^4 , R^5 and Y are as defined above and m is 1 or 2, with compounds of the formula R^6 -X, wherein R^6 is cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxycarbonyl or halogen and X is a suitable leaving group as defined in 1), in the presence of a base as defined in 1), optionally in the presence of a diluent as defined in 1) and optionally in the presence of a complexing agent as defined in 1) in a temperature range of from -120°C to 100°C ,
- 20 preferably from -80°C to 50°C .


4) The compounds of formula I wherein R^1 , R^2 , R^3 , R^4 , R^6 and Y are as defined above, R^P is hydrogen, halogen or C_1 - C_6 haloalkyl, m is 1 or 2, and n is 1, can, furthermore, be prepared by processes known *per se*



- 25 by starting from compounds of formula Id wherein R^1 , R^2 , R^3 , R^4 , R^6 and Y are as defined above and R^P is hydrogen, halogen or C_1 - C_6 haloalkyl, and reacting those

compounds with a suitable organic or inorganic oxidising agent, e.g. a peroxy acid, such as 3-chloroperoxybenzoic acid, peracetic acid or hydrogen peroxide, an alkoxyperoxide or a periodate, such as sodium periodate, optionally in the presence of a catalyst, such as ruthenium(III) chloride, optionally in the presence of a diluent, such as a halogenated hydrocarbon, e.g. dichloromethane, 1,2-dichloroethane or carbon tetrachloride, an alcohol, e.g. methanol, a polar solvent, e.g. N,N-dimethylformamide, acetonitrile, water or acetic acid, or a mixture thereof. The reactions are usually carried out in a temperature range of from -80°C to 150°C, preferably from -20°C to 120°C. Such processes are known in the literature and are described e.g. in J. Org. Chem., 2003 (68) 3849-3859; J. Med. Chem., 2003 (46) 3021-3032; J. Org. Chem., 2003 (68) 500-511; Bioorg. Med. Chem., 1999 (9) 1837-1844. One equivalent of oxidizing agent is required to convert a sulfide to the corresponding sulfoxide. Two equivalents of oxidizing agent are required to convert a sulfide to the corresponding sulfone.

5) The compounds of formula Ig wherein R¹, R², R³, R⁴, R⁵ and Y are as defined above, can be prepared, for example, by starting from compounds of formula Ie wherein R¹, R², R³, R⁴ and Y are as defined above



by reacting those compounds with a halogenating agent, e.g. bromine or an N-halosuccinimide, such as N-chlorosuccinimide or N-bromosuccinimide, to form compounds of formula If wherein R¹, R², R³, R⁴ and Y are as defined above, and X^C is halogen, optionally in the presence of a diluent, e.g. acetic acid or a halogenated hydrocarbon, such as carbon tetrachloride or dichloromethane, in a temperature range of from -80°C to 120°C, preferably from -20°C to 60°C. The compounds of formula If wherein R¹, R², R³, R⁴ and Y are as defined above and X^C is halogen can then be oxidised directly as described in 4), or optionally in a second step reacted with compounds of formula




wherein R⁵ is fluoro and M-R⁵ is a suitable salt or an organometal compound in which M is e.g. Li, MgBr, Na, K, Ag or tetraalkylammonium, optionally in the presence of a


Lewis acid, e.g. SnCl_4 , optionally in the presence of a complexing agent, e.g. hexamethylphosphoramide (HMPA) or 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), and optionally in the presence of a diluent, e.g. acetonitrile, dichloromethane, diethyl ether or tetrahydrofuran, in a temperature range of from -120°C to 100°C ,

- 5 preferably from -80°C to 80°C . Such processes are known in the literature and are described, for example, in J. Org. Chem., 1998 (63) 3706-3716; J. Chem. Soc. Perkin Trans., 1995 (22) 2845-2848; Synthesis 1982 (2), 131-132; Liebigs Annalen, 1993, 49-54 and Synth. Commun., 1990 (20) 1943-1948.

- 6) The compounds of formula Ii wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6$ and Y are as defined above, can be prepared, for example, by starting from compounds of formula Ie
10 wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4$ and Y are as defined above



- by reacting those compounds with a halogenating agent, e.g. bromine or an N-halo-succinimide, such as N-chlorosuccinimide or N-bromosuccinimide, to form compounds
15 of formula Ih wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4$ and Y are as defined above and X^{C} is halogen, optionally in the presence of a diluent, e.g. acetic acid or a halogenated hydrocarbon, such as carbon tetrachloride or dichloromethane, in a temperature range of from -80°C to 120°C , preferably from -20°C to 60°C . The compounds of formula Ih wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4$ and Y are as defined above and X^{C} is halogen can then be oxidised directly as described
20 in 4), or optionally in a second or third step reacted with compounds of formula




- wherein R^5 and / or R^6 are fluoro and M-R^5 and / or M-R^6 are a suitable salt or an
25 organometal compound in which M is e.g. Li, MgBr, Na, K, Ag or tetraalkylammonium, optionally in the presence of a Lewis acid, e.g. SnCl_4 , optionally in the presence of a complexing agent, e.g. hexamethylphosphoramide (HMPA) or 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), and optionally in the presence of a diluent, e.g. acetonitrile, dichloromethane, diethyl ether or tetrahydrofuran, in a temperature range of
30 from -120°C to 100°C , preferably from -80°C to 80°C . Such processes are known in the

literature and are described, for example, in J. Org. Chem., 1998 (63) 3706-3716; J. Chem. Soc. Perkin Trans., 1995 (22) 2845-2848; Synthesis 1982 (2), 131-132; Liebigs Annalen, 1993, 49-54 and Synth. Commun., 1990 (20) 1943-1948.

5 Methods for Coupling Reactions

7) The compounds of formula Id as defined in 4) can be prepared by reacting a compound of formula II wherein R^6 and Y are as defined above, R^P is as defined in 4) and X^A is a leaving group such as halide e.g. bromide or chloride, an alkylsulfonate, e.g. methylsulfonate, an arylsulfonate, e.g. p-toluenesulfonate, or a haloalkylsulfonate, e.g. trifluoromethylsulfonate, with thiourea, optionally in the presence of a diluent e.g. acetonitrile or an alcohol, e.g. ethanol, optionally in the presence of an alkali iodide, e.g. sodium iodide or potassium iodide, in a temperature range of from -30°C to 100°C , preferably from 0°C to 80°C , to give an isothiurea intermediate of formula IV, which is reacted with a compound of formula V



wherein R^1, R^2, R^3 and R^4 are as defined above, and X^B is a suitable leaving group such as halogen, e.g. chloro, an alkylsulfinyl group, an arylsulfinyl group, a haloalkylsulfinyl group, an alkylsulfonyl group, e.g. methylsulfonyl, an arylsulfonyl group, e.g. p-toluenesulfonyl, a haloalkylsulfonyl group, e.g. trifluoromethylsulfonyl, or nitro, in the presence of a base, such as a carbonate, e.g. potassium carbonate, sodium carbonate or potassium hydrogencarbonate, or a hydroxide, e.g. potassium hydroxide, or an alkoxide, e.g. sodium alkoxide, optionally in the presence of an alkali iodide, e.g. sodium iodide or sodium bromide, optionally in the presence of a diluent, such as an alcohol, e.g. ethanol, an ether, e.g. 1,4-dioxane or tetrahydrofuran, a polar solvent, e.g. water, acetonitrile or N,N-


20

25

dimethylformamide, or a mixture of solvents, e.g. a mixture of 1,4-dioxane and water, in a temperature range of from 20°C to 200°C, preferably from 50°C to 150°C, optionally in the presence of an inert gas e.g. nitrogen, and optionally under microwave irradiation. Such processes are known in the literature and are described, for example, in WO 04/013106 and WO 06/024820.


8) A further method of preparing intermediates of formula IV, wherein R⁶ and Y are as defined above and R^P is as defined in 4), is to react a compound of the formula III, wherein R⁶ and Y are as defined above and R^P is as defined in 4), with thiourea in the presence of an acid, for example a mineral acid, such as hydrochloric acid or hydrobromic acid, or sulfuric acid, or an organic acid, such as trifluoroacetic acid, and optionally in the presence of a diluent, such as an ether, e.g. 1,4-dioxane or tetrahydrofuran, a polar solvent, e.g. water or N,N-dimethylformamide, or a mixture of solvents, e.g. a mixture of 1,4-dioxane and water, in a temperature range of from 20°C to 270°C, preferably from 20°C to 150°C, optionally under microwave irradiation. Such processes are known in the literature and are described, for example, in Buchwald and Neilsen, JACS, 110(10), 3171-3175 (1988); Frank and Smith, JACS, 68, 2103-2104 (1946); Vetter, Syn. Comm., 28, 3219-3233 (1998). The intermediate IV is then reacted with a compound of formula V as described in 7) to yield a compound of formula Id as described in 7).

9) A further method of preparing the compounds of formula Id as defined in 4) is to react compound of the formula VI wherein R⁶ and Y are as defined above and R^P is as defined in 4),




with a compound of formula V as defined in 7), in the presence of a base, e.g. potassium carbonate, optionally in the presence of a diluent, e.g. an amide, such as N,N-dimethylformamide, or an alcohol, such as ethanol, in a temperature range of from 0°C to 100°C, preferably from 20°C to 50°C, and optionally under an inert atmosphere, e.g. nitrogen. Such processes are known in the literature and are described, for example in WO 01/012613, WO 02/062770 and WO 04/010165.

10) Alternatively, the compounds of formula Id as defined in 4) can be prepared by reacting a compound of formula V as defined in 7) with thiourea, optionally in the presence of a diluent e.g. an alcohol, e.g. ethanol, in a temperature range of from -30°C to 150°C, preferably from 0°C to 80°C, to give an isothiourea intermediate of formula VII,



which is then reacted with a compound of formula II as defined in 7) in the presence of a base, such as a carbonate, e.g. potassium carbonate, sodium carbonate or potassium hydrogencarbonate, or a hydroxide, e.g. potassium hydroxide, or an alkoxide, e.g. sodium alkoxide, optionally in the presence of a diluent, such as an alcohol, e.g. ethanol, a polar solvent, e.g. water or N,N-dimethylformamide, or a mixture of solvents, in a temperature range of from 0°C to 200°C, preferably from 0°C to 100°C. Such processes are known in the literature and are described, for example, in WO 05/095352.


11) A further method of preparing the compounds of formula Id as defined in 4) is to react an organometal reagent of the formula VIII wherein R⁶ and Y are as defined above, R^P is as defined in 4) and M^B is a group such as MgCl, MgBr, ZnBr or Li,



with a compound of formula IX wherein R¹, R², R³ and R⁴ are as defined above optionally in the presence of a diluent, e.g. an ether, such as diethyl ether or tetrahydrofuran, in a temperature range of from -150°C to 100°C, preferably from -80°C to 50°C, and optionally under an inert atmosphere, e.g. nitrogen. The disulfide of formula IX can be formed in situ or prepared separately, e.g. by oxidation of the corresponding sulfide, which in turn is described in JP 2004/224714. Similar processes are known in the literature and are described, for example in J. Chem. Soc. Chem. Commun., 1991, 993-


994, J. Chem. Soc. Perkin Trans. 1992 (24) 3371-3375, J. Org. Chem., 1989 (54) 2452-2453.

- 12) A further method of preparing the compounds of formula Id as defined in 4) is to react a compound of the formula IIa wherein R⁶ and Y are as defined above, R^P is as defined in 4) and X^C is functional group that may be cleaved as a radical, e.g. a halogen, such as bromo or chloro,



- with a radical initiator or a precursor thereof and with a compound of formula IX as defined in 11), optionally in the presence of a base, e.g. a phosphate or hydrogen phosphate such as disodium hydrogen phosphate, a carbonate, e.g. potassium carbonate, sodium carbonate or potassium hydrogencarbonate, optionally in the presence of a diluent, e.g. a polar solvent, such as water or N,N-dimethylformamide, or mixtures thereof, in a temperature range of from -50°C to 180°C, preferably from -20°C to 50°C, and optionally under an inert atmosphere, e.g. nitrogen. As radical initiator or precursors can be used e.g. sodium dithionite or sodium hydroxymethylsulfinate.


- 13) A further method of preparing the compounds of formula Id as defined in 4) is to react a compound of the formula II as defined in 7),



- with a compound of formula IX as defined in 11), in the presence of a reducing agent, e.g. a hydride, such as sodium borohydride, a metal, such as zinc, or a hydrosulfite, such as sodium hydrosulfite, optionally in the presence of a base, e.g. a hydroxide, such as sodium hydroxide, a phosphate or hydrogen phosphate, such as disodium hydrogen phosphate, or an amine, such as triethylamine, optionally in the presence of a diluent, e.g.

water, an acid, such as acetic acid or hydrochloric acid, an alcohol such as methanol, an ether such as tetrahydrofuran or mixtures thereof, in a temperature range of from -50°C to 180°C, preferably from -20°C to 50°C, and optionally under an inert atmosphere, e.g. nitrogen.


- 5 14) In the particular case that R^P is C_1 - C_6 haloalkyl, in particular perfluoroalkyl, for example trifluoromethyl, the compounds of the formula III wherein Y is as defined above and R^6 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, can be conveniently prepared by reacting carbonyl compounds of the formula XI wherein Y is as defined above and R^6 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, with a reagent R^P-X^D , wherein X^D is a
- 10 trialkylsilyl group, e.g. trimethylsilyl, in the presence of an initiator, such as a fluoride salt, e.g. caesium fluoride, tetrabutylammonium fluoride or potassium fluoride, or an alkoxide salt, and an optional diluent, such as an ether, e.g. tetrahydrofuran, 1,4-dioxane, in a temperature range of from 0°C to 100°C, preferably from 20°C to 30°C, to form the silylated intermediate of the formula XII.



- Typically the silylated intermediate of formula XII is desilylated without isolation or purification in the presence of an acid, e.g. hydrochloric acid or hydrobromic acid, or acetic acid, and optionally in the presence of an additional diluent, such as an ether, e.g. tetrahydrofuran or 1,4-dioxane, a polar solvent, e.g. water or N,N-dimethylformamide, or
- 20 a mixture of solvents, in a temperature range of from 0°C to 100°C, preferably from 20°C to 30°C, to form the compounds of the formula III. Such processes are known in the literature and are described, for example, in Chem. Rev., 1997, 97, 757-786; J. Am. Chem. Soc. 1989, 111, 393; J. Med. Chem. 1992, 35, 641; J. Org. Chem. 1992, 57, 1124. The compound of the formula III is then reacted with a compound of formula V as
- 25 defined in 7) to yield a compound of formula Id as described in 8).


General methods for making heterocyclic intermediates

- 15) The compounds of formula II as defined in 7) can be prepared by reacting compounds of formula III as defined in 8)



with a halogenating agent, such as hydrogen chloride, hydrogen bromide, phosphorous tribromide, phosphorous trichloride or thionyl chloride, or with an alkyl-, aryl- or halo-alkylsulfonyl chloride, such as methanesulfonyl chloride, p-toluenesulfonyl chloride or trifluoromethylsulfonyl chloride, or with a combination of carbon tetrabromide and triphenyl phosphine, optionally in the presence of an inert solvent, e.g. a halogenated hydrocarbon, such as dichloromethane, 1,2-dichloroethane or carbon tetrachloride, an ether, such as diethyl ether or tetrahydrofuran, or an acid, such as acetic acid, optionally in the presence of a base, e.g. an amine, such as triethyl amine, in a temperature range from -50°C to 100°C, preferably from 0°C to 50°C. Such processes are known in the literature and are described, for example, in J. Med. Chem. 2005 (48) 3438-3442, J. Org. Chem., 2005 (70) 2274-2284, Org. and Biomolecular Chem., 2005 (3) 1013-1024, Bioorg. Med. Chem. 2004 (13) 363-384, Tetrahedron Asymmetry 2004 (15) 3719-3722.


16) Alternatively, the compounds of formula IIa, wherein R^G and Y are as defined above, R^P is as defined in 4) and X^C is a leaving group such as halogen, e.g. bromo or chloro, can be prepared



by reacting compounds of formula XIII wherein R^G and Y are as defined above, R^P is as defined in 4), with compounds of formula R^{II}-X^C, wherein X^C is a leaving group such as halogen, e.g. bromo or chloro, and R^{II} is a functional group that may be cleaved to generate X^C as a radical, optionally in the presence of a diluent such as a halogenated hydrocarbon, e.g. dichloromethane, 1,2-dichloroethane or carbon tetrachloride, an ether, e.g. tetrahydrofuran, an aromatic compound, e.g. toluene, a polar solvent, e.g. acetonitrile, N,N-dimethylformamide or water, or a mixture thereof. The reactions are usually carried out in a temperature range from -50°C to 120°C, preferably from -5°C to 100°C. The reactions may be carried out optionally in the presence of light and or a radical initiator such as a peroxide, e.g. dibenzoylperoxide, or an azo compound, e.g.


2,2'-azobisisobutyronitrile (AIBN). Suitable compounds of formula $R^{11}-X^C$ include compounds in which R^{11} is a succinimido group, e.g. N-chlorosuccinimide and N-bromosuccinimide. Similar processes are known in the literature and are described, e.g. Tetrahedron, 1988 (44) 461-469; Journal of Organic Chemistry, 1981 (46) 679-686; J. Chem. Soc., Perkin Trans 1, 1985 (6), 1167-1170.

17) The compounds of formula XVa wherein Y is as defined above can conveniently be prepared




by reacting compounds of formula XIV wherein Y is as defined above with a suitable inorganic oxidising agent, such as potassium permanganate, in the presence of a base, such as sodium carbonate, in a suitable solvent, such as water. The reactions are usually carried out in a temperature range from 0°C to 150°C, preferably from 80°C to 120°C. Similar processes are known in the literature and are described, e.g. J. Heterocyclic Chem. 1987 (24) 1275-79.

18) The compounds of formula IIIa, wherein R^6 is hydrogen or C_1 - C_6 alkyl and Y is as defined above, can be prepared



by reacting a compound of formula XI wherein R^6 is hydrogen or C_1 - C_6 alkyl and Y is as defined above with a reducing agent, e.g. a metal hydride, such as diisobutyl aluminium hydride, lithium aluminium hydride, sodium borohydride, lithium borohydride, or diborane, optionally in the presence of an inert solvent, e.g. an ether, such as diethyl ether, 1,4-dioxane or tetrahydrofuran, an alcohol, such as methanol or ethanol, or an aromatic hydrocarbon, such as toluene. Such reactions are usually carried out in a temperature range from -50°C to 100°C, preferably from 0°C to 80°C. Such processes are known in the literature and are described, for example, in Tetrahedron Asymmetry, 2004 (15) 363-386; J. Med. Chem., 2002 (45) 19-31; Justus Liebigs Annalen der Chemie, 1978 (8) 1241-49.


19) Alternatively, the compounds of formula IIIb, wherein Y is as defined above, can be prepared by reacting a compound of formula XV,




wherein Y is as defined above and R¹² is hydrogen or C₁-C₁₀alkyl, with a reducing agent, e.g. a metal hydride, such as diisobutyl aluminium hydride, lithium aluminium hydride, sodium borohydride, lithium borohydride, or diborane, optionally in the presence of an inert solvent, e.g. an ether, such as diethyl ether, 1,4-dioxane or tetrahydrofuran, an alcohol, such as methanol or ethanol, or an aromatic hydrocarbon, such as toluene. Such reactions are usually carried out in a temperature range from -50°C to 100°C, preferably from 0°C to 80°C. Such processes are known in the literature and are described, for example, in Tetrahedron Asymmetry 2004 (15) 3719-3722, J. Med. Chem., 2004 (47) 2176-2179, Heterocyclic Communications 2002 (8) 385-390, J. Antibiotics, 1995 (48) 1320-1329.

15 Methods for making triazole intermediates

20) Compounds of formula XXa or compounds of formula XXb, wherein R⁷ and R⁸ are as defined above,




and R¹² is hydrogen, C₁-C₁₀alkyl, C₁-C₁₀haloalkyl, tetrahydro-pyran-2-yloxymethyl, C₁-C₁₀alkoxycarbonyl, formyl, or the group Q



wherein R^1 , R^2 , R^3 , R^4 and R^6 are as defined above, R^P is as defined in 4), and m is as defined above, preferably m is 0, can be prepared by reacting compounds of formula XVIII, wherein R^7 is as defined above, with compounds of formula XIX, wherein R^8 and R^{12} are as defined above, optionally in the presence of a catalyst, e.g. a transition metal catalyst, such as CuCl, CuI, CuBr₂, copper powder, optionally in the presence of a diluent such as a halogenated hydrocarbon, e.g. 1,2-dichloroethane or carbon tetrachloride, an ether, e.g. tetrahydrofuran or 1,4-dioxane, an aromatic compound, e.g. toluene, an alcohol, e.g. methanol, an amide, e.g. N,N-dimethylformamide, water or a mixture thereof. The reactions are usually carried out in a temperature range from -50°C to 200°C, preferably from 0°C to 160°C. Depending on the reaction conditions, compounds of formula XVa and XVb are obtained exclusively or as mixtures in varying ratios. Similar processes are known in the literature and are described in, e.g. European Journal of Organic Chemistry, 2004 3789-3791; Journal of Fluorine Chemistry, 2004 (125) 1415-1423;


21) Compounds of formula XXII, wherein R^8 is as defined above and R^{12} is as defined in 20),



can be prepared by reacting compounds of formula XXI, wherein P^1 is an organic moiety that can be cleaved after the reaction, with compounds of formula XIX, wherein R^8 is as defined above and R^{12} is as defined in 20), optionally in the presence of a catalyst, e.g. a transition metal catalyst, such as CuCl, CuI, CuBr₂, copper powder, optionally in the presence of a diluent such as a halogenated hydrocarbon, e.g. 1,2-dichloroethane or carbon tetrachloride, an ether, e.g. tetrahydrofuran or 1,4-dioxane, an aromatic compound, e.g. toluene, an alcohol, e.g. methanol, an amide, e.g. N,N-dimethylformamide, water or a mixture thereof. The reactions are usually carried out in a temperature range from -50°C to 200°C, preferably from 0°C to 160°C. The reaction initially leads to intermediates of formula XXa1 and XXb1. Depending on the reaction


conditions, compounds of formula XXa1 and XXb1 are obtained exclusively or as mixtures in varying ratios. Suitable groups P^1 include trialkylsilyl groups, such as trimethylsilyl, or optionally substituted benzyl groups, such as benzyl or 4-methoxybenzyl. The protecting group is cleaved either in situ under the reaction conditions or in a separate step. Similar processes are known in the literature and are described in, e.g. Molecular Diversity, 2003 (7) 171-174; J. Heterocyclic Chemistry, 1976 (13) 589-592; WO 04/106324; J. Med. Chem., 2004 (47) 2176-2179.

22) Alternatively, compounds of formula XXII as defined in 21) can be prepared by reacting compounds of formula XXIII



wherein MN_3 is an inorganic azide salt, usually sodium azide, with compounds of formula XIX as defined in 20), optionally in the presence of a diluent such as DMSO, toluene, acetonitrile, an alcohol, e.g. ethanol, an amide, e.g. N,N-dimethylformamide, water or a mixture thereof. The reactions are usually carried out in a temperature range from -50°C to 200°C , preferably from 0°C to 160°C . Similar processes are known in the literature and are described, e.g. US 6,051,717; Tetrahedron Letters, 2001 (42) 9114.

23) Compounds of formula XXa, XXb and / or XXc as defined in 20) can be prepared by reacting compounds of formula XXII as defined in 21) with compounds of formula $\text{R}^7\text{-X}^{\text{E}}$



wherein R^7 is as defined above and X^{E} is a suitable leaving group, such as halogen, e.g. bromide, chloride or iodide, a carboxylate, such as acetate, or an alkylsulfonate, e.g. methylsulfonate, or an arylsulfonate, e.g. p-toluenesulfonate, in the presence of a base, e.g. a carbonate, such as potassium carbonate, a hydroxide, such as potassium hydroxide,

- a metal hydride, such as sodium hydride, an amine, such as triethylamine, optionally in the presence of a diluent, e.g. an ether, such as tetrahydrofuran, an amide, such as N,N-dimethylformamide, an alcohol, such as methanol, acetonitrile or acetone or mixtures thereof, and optionally in the presence of a phase transfer catalyst, such as trimethyl-
- 5 ammonium bromide, in a temperature range of from -120°C to 200°C, preferably from -20°C to 80°C. Depending on the reaction conditions, compounds of formula XXa, XXb and XXc are obtained exclusively or as mixtures in varying ratios. Such processes are known in the literature and are described, for example, in Bioorg. Med. Chem. Lett., 2004 (14) 2401-2405; WO 04/018438 and US 4,820,844.
- 10 24) The synthesis of 1,2,3-triazoles and derivatives thereof are well known within the literature, so for a general discussion of their synthesis see Tome, A. C. Product class 13: 1,2,3-triazoles. Science of Synthesis (2004), 13 415-601; H. Wamhoff, 1,2,3-Triazoles. Comprehensive Heterocyclic Chemistry (1984), 4A 669-733; W.-Q. Fan, A. Katritzky, 1,2,3-Triazoles. Comprehensive Heterocyclic Chemistry II (1996), 4 1-127; B.
- 15 B. Sharpless Synthesis, 2005 (9) 1514-1520; K. Banert, European Journal of Organic Chemistry, 2005 3704-3714; V. P. Krivopalov, O. P. Shkurko, Russ. Chem. Rev. 2005 (74) 339-379; M. Begtrup, Acta Chemica Scandinavica (1990), 44(10), 1050-7. R. F. Coles, C. S. Hamilton, Journal of the American Chemical Society (1946), 68 1799-801; M. Begtrup Bull. Soc. Chim. Belg., 1988 (97) 573-597). Xu, Bo; Mae, Masayuki; Hong, Jiyoung A.; Li, Youhua; Hammond, Gerald B., Synthesis (2006), (5), 803-806. Mae, Masayuki; Hong, Jiyoung A.; Xu, Bo; Hammond, Gerald B. Organic Letters (2006), 8(3), 479-482. Buckle, Derek R.; Rockell, Caroline J. M. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1982), (2), 627-30. Journet, Michel; Cai, Dongwei; Hughes, David L.; Kowal, Jason J.; Larsen,
- 20 Robert D.; Reider, Paul J., Organic Process Research & Development (2005), 9(4), 490-498. US 6,051,717.

The compounds of formula I according to the invention can be used as herbicides in unmodified form, as obtained in the synthesis, but they are generally formulated into

30 herbicidal compositions in various ways using formulation adjuvants, such as carriers, solvents and surface-active substances. The formulations can be in various physical forms, e.g. in the form of dusting powders, gels, wettable powders, water-dispersible granules, water-dispersible tablets, effervescent pellets, emulsifiable concentrates, micro-

emulsifiable concentrates, oil-in-water emulsions, oil-flowables, aqueous dispersions, oily dispersions, suspo-emulsions, capsule suspensions, emulsifiable granules, soluble liquids, water-soluble concentrates (with water or a water-miscible organic solvent as carrier), impregnated polymer films or in other forms known e.g. from the Manual on
5 Development and Use of FAO Specifications for Plant Protection Products, 5th Edition, 1999. Such formulations can either be used directly or they are diluted prior to use. The dilutions can be made, for example, with water, liquid fertilisers, micronutrients, biological organisms, oil or solvents.

The formulations can be prepared e.g. by mixing the active ingredient with the
10 formulation adjuvants in order to obtain compositions in the form of finely divided solids, granules, solutions, dispersions or emulsions. The active ingredients can also be formulated with other adjuvants, such as finely divided solids, mineral oils, oils of vegetable or animal origin, modified oils of vegetable or animal origin, organic solvents, water, surface-active substances or combinations thereof. The active ingredients can also
15 be contained in very fine microcapsules consisting of a polymer. Microcapsules contain the active ingredients in a porous carrier. This enables the active ingredients to be released into the environment in controlled amounts (e.g. slow-release). Microcapsules usually have a diameter of from 0.1 to 500 microns. They contain active ingredients in an amount of about from 25 to 95 % by weight of the capsule weight. The active ingredients
20 can be in the form of a monolithic solid, in the form of fine particles in solid or liquid dispersion or in the form of a suitable solution. The encapsulating membranes comprise, for example, natural or synthetic rubbers, cellulose, styrene/butadiene copolymers, polyacrylonitrile, polyacrylate, polyesters, polyamides, polyureas, polyurethane or chemically modified polymers and starch xanthates or other polymers that are known to
25 the person skilled in the art in this connection. Alternatively, very fine microcapsules can be formed in which the active ingredient is contained in the form of finely divided particles in a solid matrix of base substance, but the microcapsules are not themselves encapsulated.

The formulation adjuvants that are suitable for the preparation of the
30 compositions according to the invention are known *per se*. As liquid carriers there may be used: water, toluene, xylene, petroleum ether, vegetable oils, acetone, methyl ethyl ketone, cyclohexanone, acid anhydrides, acetonitrile, acetophenone, amyl acetate, 2-butanone, butylene carbonate, chlorobenzene, cyclohexane, cyclohexanol, alkyl esters of

acetic acid, diacetone alcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethylformamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkylpyrrolidone, ethyl acetate, 2-ethylhexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha-pinene, d-limonene, ethyl lactate, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol acetate, glycerol diacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropylbenzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxypropanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, *n*-hexane, *n*-octylamine, octadecanoic acid, octylamine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol (PEG400), propionic acid, propyl lactate, propylene carbonate, propylene glycol, propylene glycol methyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylenesulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, propylene glycol methyl ether, diethylene glycol methyl ether, methanol, ethanol, isopropanol, and alcohols of higher molecular weight, such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, ethylene glycol, propylene glycol, glycerol, N-methyl-2-pyrrolidone and the like. Water is generally the carrier of choice for diluting the concentrates. Suitable solid carriers are, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, limestone, calcium carbonate, bentonite, calcium montmorillonite, cottonseed husks, wheat flour, soybean flour, pumice, wood flour, ground walnut shells, lignin and similar substances, as described, for example, in CFR 180.1001. (c) & (d).

A large number of surface-active substances can advantageously be used in both solid and liquid formulations, especially in those formulations which can be diluted with a carrier prior to use. Surface-active substances may be anionic, cationic, non-ionic or polymeric and they can be used as emulsifiers, wetting agents or suspending agents or for other purposes. Typical surface-active substances include, for example, salts of alkyl sulfates, such as diethanolammonium lauryl sulfate; salts of alkylarylsulfonates, such as calcium dodecylbenzenesulfonate; alkylphenol/alkylene oxide addition products, such as nonylphenol ethoxylate; alcohol/alkylene oxide addition products, such as tridecylalcohol

ethoxylate; soaps, such as sodium stearate; salts of alkylnaphthalenesulfonates, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryltrimethylammonium chloride, polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono- and di-alkylphosphate esters; and also further substances described e.g. in "McCutcheon's Detergents and Emulsifiers Annual" MC Publishing Corp., Ridgewood New Jersey, 1981.

Further adjuvants that can usually be used in pesticidal formulations include crystallisation inhibitors, viscosity modifiers, suspending agents, dyes, anti-oxidants, foaming agents, light absorbers, mixing auxiliaries, antifoams, complexing agents, neutralising or pH-modifying substances and buffers, corrosion inhibitors, fragrances, wetting agents, take-up enhancers, micronutrients, plasticisers, glidants, lubricants, dispersants, thickeners, antifreezes, microbicides, and also liquid and solid fertilisers.

The compositions according to the invention can additionally include an additive comprising an oil of vegetable or animal origin, a mineral oil, alkyl esters of such oils or mixtures of such oils and oil derivatives. The amount of oil additive in the composition according to the invention is generally from 0.01 to 10 %, based on the spray mixture. For example, the oil additive can be added to the spray tank in the desired concentration after the spray mixture has been prepared. Preferred oil additives comprise mineral oils or an oil of vegetable origin, for example rapeseed oil, olive oil or sunflower oil, emulsified vegetable oil, such as AMIGO® (Rhône-Poulenc Canada Inc.), alkyl esters of oils of vegetable origin, for example the methyl derivatives, or an oil of animal origin, such as fish oil or beef tallow. A preferred additive contains, for example, as active components essentially 80 % by weight alkyl esters of fish oils and 15 % by weight methylated rapeseed oil, and also 5 % by weight of customary emulsifiers and pH modifiers. Especially preferred oil additives comprise alkyl esters of C₈-C₂₂ fatty acids, especially the methyl derivatives of C₁₂-C₁₈ fatty acids, for example the methyl esters of lauric acid, palmitic acid and oleic acid, being of importance. Those esters are known as methyl laurate (CAS-111-82-0), methyl palmitate (CAS-112-39-0) and methyl oleate (CAS-112-62-9). A preferred fatty acid methyl ester derivative is Emery® 2230 and 2231 (Cognis GmbH). Those and other oil derivatives are also known from the Compendium of Herbicide Adjuvants, 5th Edition, Southern Illinois University, 2000.

The application and action of the oil additives can be further improved by combination with surface-active substances, such as non-ionic, anionic or cationic surfactants. Examples of suitable anionic, non-ionic and cationic surfactants are listed on pages 7 and 8 of WO 97/34485. Preferred surface-active substances are anionic surfactants of the dodecylbenzylsulfonate type, especially the calcium salts thereof, and also non-ionic surfactants of the fatty alcohol ethoxylate type. Special preference is given to ethoxylated C₁₂-C₂₂ fatty alcohols having a degree of ethoxylation of from 5 to 40. Examples of commercially available surfactants are the Genapol types (Clariant AG). Also preferred are silicone surfactants, especially polyalkyl-oxide-modified heptamethyltriloxanes which are commercially available e.g. as Silwet L-77®, and also perfluorinated surfactants. The concentration of the surface-active substances in relation to the total additive is generally from 1 to 30 % by weight. Examples of oil additives consisting of mixtures of oil or mineral oils or derivatives thereof with surfactants are Edenor ME SU®, Turbocharge® (Syngenta AG, CH) or ActipronC (BP Oil UK Limited, GB).

If desired, it is also possible for the mentioned surface-active substances to be used in the formulations on their own, that is to say without oil additives.

Furthermore, the addition of an organic solvent to the oil additive/surfactant mixture may contribute to an additional enhancement of action. Suitable solvents are, for example, Solvesso® (ESSO) or Aromatic Solvent® (Exxon Corporation). The concentration of such solvents can be from 10 to 80 % by weight of the total weight. Oil additives that are present in admixture with solvents are described, for example, in US-A-4,834,908. A commercially available oil additive disclosed therein is known by the name MERGE® (BASF Corporation). A further oil additive that is preferred according to the invention is SCORE® (Syngenta Crop Protection Canada).

In addition to the oil additives listed above, for the purpose of enhancing the action of the compositions according to the invention it is also possible for formulations of alkylpyrrolidones (e.g. Agrimax®) to be added to the spray mixture. Formulations of synthetic lattices, e.g. polyacrylamide, polyvinyl compounds or poly-1-p-menthene (e.g. Bond®, Courier® or Emerald®) may also be used. It is also possible for solutions that contain propionic acid, for example Eurogkem Pen-e-trate®, to be added to the spray mixture as action-enhancing agent.

The herbicidal compositions generally comprise from 0.1 to 99 % by weight, especially from 0.1 to 95 % by weight, compounds of formula I and from 1 to 99.9 % by weight of a formulation adjuvant which preferably includes from 0 to 25 % by weight of a surface-active substance. Whereas commercial products will preferably be formulated
 5 as concentrates, the end user will normally employ dilute formulations.

The rates of application of compounds of formula I may vary within wide limits and depend on the nature of the soil, the method of application (pre- or post-emergence; seed dressing; application to the seed furrow; no tillage application etc.), the crop plant, the grass or weed to be controlled, the prevailing climatic conditions, and other factors
 10 governed by the method of application, the time of application and the target crop. The compounds of formula I according to the invention are generally applied at a rate of from 10 to 2000 g/ha, especially from 50 to 1000 g/ha.

Preferred formulations have especially the following compositions (% = percent by weight):

15 Emulsifiable concentrates:

active ingredient:	1 to 95 %, preferably 60 to 90 %
surface-active agent:	1 to 30 %, preferably 5 to 20 %
liquid carrier:	1 to 80 %, preferably 1 to 35 %

Dusts:

20 active ingredient:	0.1 to 10 %, preferably 0.1 to 5 %
solid carrier:	99.9 to 90 %, preferably 99.9 to 99 %

Suspension concentrates:

active ingredient:	5 to 75 %, preferably 10 to 50 %
water:	94 to 24 %, preferably 88 to 30 %
25 surface-active agent:	1 to 40 %, preferably 2 to 30 %

Wettable powders:

active ingredient:	0.5 to 90 %, preferably 1 to 80 %
surface-active agent:	0.5 to 20 %, preferably 1 to 15 %
solid carrier:	5 to 95 %, preferably 15 to 90 %

30 Granules:

active ingredient:	0.1 to 30 %, preferably 0.1 to 15 %
solid carrier:	99.5 to 70 %, preferably 97 to 85 %

The following Examples further illustrate, but do not limit, the invention.

Formulation Examples for herbicides of formula I (% = % by weight)

<u>F1. Emulsifiable concentrates</u>		a)	b)	c)	d)
5	active ingredient	5 %	10 %	25 %	50 %
	calcium dodecylbenzenesulfonate	6 %	8 %	6 %	8 %
	castor oil polyglycol ether (36 mol of ethylene oxide)	4 %	-	4 %	4 %
	octylphenol polyglycol ether (7-8 mol of ethylene oxide)	-	4 %	-	2 %
10	NMP	-	-	10 %	20 %
	arom. hydrocarbon mixture	85 %	78 %	55 %	16 %

C₉-C₁₂

Emulsions of any desired concentration can be obtained from such concentrates by
15 dilution with water.

<u>F2. Solutions</u>		a)	b)	c)	d)
	active ingredient	5 %	10 %	50 %	90 %
20	1-methoxy-3-(3-methoxy- propoxy)-propane	-	20 %	20 %	-
	polyethylene glycol MW 400	20 %	10 %	-	-
	NMP	-	-	30 %	10 %
	arom. hydrocarbon mixture	75 %	60 %	-	-

C₉-C₁₂

25 The solutions are suitable for use in the form of microdrops.

<u>F3. Wettable powders</u>		a)	b)	c)	d)
	active ingredient	5 %	25 %	50 %	80 %
	sodium lignosulfonate	4 %	-	3 %	-
30	sodium lauryl sulfate	2 %	3 %	-	4 %
	sodium diisobutyl-naphthalene- sulfonate	-	6 %	5 %	6 %
	octylphenol polyglycol ether	-	1 %	2 %	-

(7-8 mol of ethylene oxide)

highly dispersed silicic acid	1 %	3 %	5 %	10 %
kaolin	88 %	62 %	35 %	-

The active ingredient is mixed thoroughly with the adjuvants and the mixture is
 5 thoroughly ground in a suitable mill, affording wettable powders which can be diluted
 with water to give suspensions of any desired concentration.

<u>F4. Coated granules</u>	a)	b)	c)
active ingredient	0.1 %	5 %	15 %
10 highly dispersed silicic acid	0.9 %	2 %	2 %
inorganic carrier	99.0 %	93 %	83 %
(diameter 0.1 - 1 mm)			
e.g. CaCO ₃ or SiO ₂			

The active ingredient is dissolved in methylene chloride and applied to the carrier by
 15 spraying, and the solvent is then evaporated off *in vacuo*.

<u>F5. Coated granules</u>	a)	b)	c)
active ingredient	0.1 %	5 %	15 %
polyethylene glycol MW 200	1.0 %	2 %	3 %
20 highly dispersed silicic acid	0.9 %	1 %	2 %
inorganic carrier	98.0 %	92 %	80 %
(diameter 0.1 - 1 mm)			
e.g. CaCO ₃ or SiO ₂			

The finely ground active ingredient is uniformly applied, in a mixer, to the carrier
 25 moistened with polyethylene glycol. Non-dusty coated granules are obtained in this
 manner.

<u>F6. Extruder granules</u>	a)	b)	c)	d)
active ingredient	0.1 %	3 %	5 %	15 %
30 sodium lignosulfonate	1.5 %	2 %	3 %	4 %
carboxymethylcellulose	1.4 %	2 %	2 %	2 %
kaolin	97.0 %	93 %	90 %	79 %

The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.

<u>F7. Dusts</u>		a)	b)	c)
5	active ingredient	0.1 %	1 %	5 %
	talcum	39.9 %	49 %	35 %
	kaolin	60.0 %	50 %	60 %

Ready-to-use dusts are obtained by mixing the active ingredient with the carriers and grinding the mixture in a suitable mill.

10

<u>F8. Suspension concentrates</u>		a)	b)	c)	d)
	active ingredient	3 %	10 %	25 %	50 %
	ethylene glycol	5 %	5 %	5 %	5 %
	nonylphenol polyglycol ether	-	1 %	2 %	-
15	(15 mol of ethylene oxide)				
	sodium lignosulfonate	3 %	3 %	4 %	5 %
	carboxymethylcellulose	1 %	1 %	1 %	1 %
	37 % aqueous formaldehyde solution	0.2 %	0.2 %	0.2 %	0.2 %
20	silicone oil emulsion	0.8 %	0.8 %	0.8 %	0.8 %
	water	87 %	79 %	62 %	38 %

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired concentration can be obtained by dilution with water.

25

The invention also relates to a method of controlling plants which comprises applying to the plants or to the locus thereof a herbicidally effective amount of a compound of formula I, or of a composition comprising such a compound.

The invention also relates to a method of inhibiting plant growth which comprises
 30 applying to the plants or to the locus thereof a herbicidally effective amount of a compound of formula I, or of a composition comprising such a compound.

The invention also relates to a method of selectively controlling grasses and weeds in crops of useful plants which comprises applying to the useful plants or locus

thereof or to the area of cultivation a herbicidally effective amount of a compound of formula I, or of a composition comprising such a compound.

Crops of useful plants in which the composition according to the invention can be used include cereals, for example barley and wheat, cotton, oilseed rape, maize, rice, soy
5 beans, sugar beet and sugar cane, especially cereals and maize.

Crops can also include trees, such as palm trees, coconut trees or other nuts, and vines such as grapes.

The grasses and weeds to be controlled may be both monocotyledonous species, for example *Agrostis*, *Alopecurus*, *Avena*, *Bromus*, *Cyperus*, *Digitaria*, *Echinochloa*,
10 *Lolium*, *Monochoria*, *Rottboellia*, *Sagittaria*, *Scirpus*, *Setaria*, *Sida* and *Sorghum*, and dicotyledonous species, for example *Abutilon*, *Amaranthus*, *Chenopodium*, *Chrysanthemum*, *Galium*, *Ipomoea*, *Nasturtium*, *Sinapis*, *Solanum*, *Stellaria*, *Veronica*, *Viola* and *Xanthium*.

Crops are to be understood as also including those crops which have been
15 rendered tolerant to herbicides or classes of herbicides (e.g. ALS-, GS-, EPSPS-, PPO- and HPPD-inhibitors) by conventional methods of breeding or by genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding is Clearfield® summer rape (canola). Examples of crops that have been rendered tolerant to herbicides by genetic engineering methods
20 include e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®.

Crops are also to be understood as being those which have been rendered resistant to harmful insects by genetic engineering methods, for example Bt maize (resistant to European corn borer), Bt cotton (resistant to cotton boll weevil) and also Bt potatoes
25 (resistant to Colorado beetle). Examples of Bt maize are the Bt 176 maize hybrids of NK® (Syngenta Seeds). The Bt toxin is a protein that is formed naturally by *Bacillus thuringiensis* soil bacteria. Examples of toxins, or transgenic plants able to synthesise such toxins, are described in EP-A-451 878, EP-A-374 753, WO 93/07278, WO 95/34656, WO 03/052073 and EP-A-427 529. Examples of transgenic plants
30 comprising one or more genes that code for an insecticidal resistance and express one or more toxins are KnockOut® (maize), Yield Gard® (maize), NuCOTIN33B® (cotton), Bollgard® (cotton), NewLeaf® (potatoes), NatureGard® and Protexcta®. Plant crops or seed material thereof can be both resistant to herbicides and, at the same time, resistant to

insect feeding ("stacked" transgenic events). For example, seed can have the ability to express an insecticidal Cry3 protein while at the same time being tolerant to glyphosate.

Crops are also to be understood as being those which are obtained by conventional methods of breeding or genetic engineering and contain so-called output
5 traits (e.g. improved storage stability, higher nutritional value and improved flavour).

Areas under cultivation include land on which the crop plants are already growing and land intended for cultivation with those crop plants.

The compounds of formula I according to the invention can also be used in combination with other herbicides. In particular, the following mixtures of the compound
10 of formula I are important:

Mixtures of a compound of formula I with S-metolachlor (549) or a compound of formula I with metolachlor (548).

Mixtures of a compound of formula I with a triazine (e.g. compound of formula I + ametryn (20), compound of formula I + atrazine (37), compound of formula I +
15 cyanazine (183), compound of formula I + dimethametryn (259), compound of formula I + metribuzin (554), compound of formula I + prometon (665), compound of formula I + prometryn (666), compound of formula I + propazine (672), compound of formula I + simazine (730), compound of formula I + simetryn (732), compound of formula I + terbumeton (774), compound of formula I + terbuthylazine (775), compound of formula I
20 + terbutryn (776), compound of formula I + trietazine (831)). Particularly preferred are mixtures of a compound of formula I with atrazine, metribuzin, prometryn or with terbuthylazine.

Mixtures of a compound of formula I with an HPPD inhibitor (e.g. compound of formula I + isoxaflutole (479), compound of formula I + mesotrione (515), compound of
25 formula I + sulcotrione (747), compound of formula I + tembotrione (CAS RN 335104-84-2), compound of formula I + topramezone (CAS RN 210631-68-8), compound of formula I + 4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]oct-3-en-2-one (CAS RN 352010-68-5), compound of
30 formula I + 4-hydroxy-3-[[2-(3-methoxypropyl)-6-(difluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]oct-3-en-2-one).

Mixtures of a compound of formula I with an HPPD inhibitor and a triazine.

Mixtures of a compound of formula I with glyphosate (419).

Mixtures of a compound of formula I with glyphosate and an HPPD inhibitor (e.g. compound of formula I + glyphosate + isoxaflutole, compound of formula I + glyphosate + mesotrione, compound of formula I + glyphosate + sulcotrione, compound of formula I + glyphosate + tembotrione, compound of formula I + glyphosate +
 5 topramezone, compound of formula I + glyphosate + 4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]oct-3-en-2-one, compound of formula I + glyphosate + 4-hydroxy-3-[[2-(3-methoxypropyl)-6-(difluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]oct-3-en-2-one).

Mixtures of a compound of formula I with glufosinate-ammonium (418).

10 Mixtures of a compound of formula I with glufosinate-ammonium and an HPPD inhibitor (e.g. compound of formula I + glufosinate-ammonium + isoxaflutole, compound of formula I + glufosinate-ammonium + mesotrione, compound of formula I + glufosinate-ammonium + sulcotrione, compound of formula I + glufosinate-ammonium + tembotrione, compound of formula I + glufosinate-ammonium + topramezone,
 15 compound of formula I + glufosinate-ammonium + 4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]oct-3-en-2-one, compound of formula I + glufosinate-ammonium + 4-hydroxy-3-[[2-(3-methoxypropyl)-6-(difluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]oct-3-en-2-one).

Mixtures of a compound of formula I with a triazolinone (e.g. compound of
 20 formula I + amicarbazone (21)).

Mixtures of a compound of formula I with an ALS inhibitor (e.g. compound of formula I + chlorsulfuron (147), compound of formula I + cinosulfuron (154), compound of formula I + cloransulam-methyl (164), compound of formula I + ethametsulfuron-methyl (306), compound of formula I + flazasulfuron (356), compound of formula I +
 25 foramsulfuron (402), compound of formula I + flumetsulam (374), compound of formula I + imazamethabenz-methyl (450), compound of formula I + imazamox (451), compound of formula I + imazapic (452), compound of formula I + imazapyr (453), compound of formula I + imazethapyr (455), compound of formula I + iodosulfuron-methyl-sodium (466), compound of formula I + metsulfuron-methyl (555), compound of formula I +
 30 nicosulfuron (577), compound of formula I + oxasulfuron (603), compound of formula I + primisulfuron-methyl (657), compound of formula I + prosulfuron (684), compound of formula I + pyriithiobac-sodium (709), compound of formula I + rimsulfuron (721), compound of formula I + sulfosulfuron (752), compound of formula I + thifensulfuron-

methyl (thiameturon-methyl) (795), compound of formula I + triasulfuron (817), compound of formula I + tribenuron-methyl (822), compound of formula I + trifloxysulfuron-sodium (833), compound of formula I + thiencarbazone (BAY636)).

Particularly preferred are mixtures of a compound of formula I with flzasulfuron, foramsulfuron, flumetsulam, imazapyr, imazethapyr, iodosulfuron-methyl-sodium, nicosulfuron, rimsulfuron, trifloxysulfuron-sodium or with 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo)-1H-1,2,4-triazol-1-ylcarbonylsulfamoyl]-5-methylthiophene-3-carboxylic acid (BAY636).

Mixtures of a compound of formula I with a PPO inhibitor (e.g. compound of formula I + fomesafen (401), compound of formula I + flumioxazin (376), compound of formula I + sulfentrazone (749), compound of formula I + [3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetic acid ethyl ester) (CAS RN 353292-31-6). Particularly preferred are mixtures of a compound of formula I with flumioxazin, sulfentrazone or [3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetic acid ethyl ester.

Mixtures of a compound of formula I with paraquat dichloride (614).

Mixtures of a compound of formula I with pendimethalin (621) or a compound of formula I with trifluralin (836). Particularly preferred are mixtures of a compound of formula I with pendimethalin.

Mixtures of a compound of formula I with metamitron (521).

Mixtures of a compound of formula I with clomazone (159).

Mixtures of a compound of formula I with metazachlor (524).

Mixtures of a compound of formula I with clodinafop-propargyl (156) or a compound of formula I with pinoxaden (CAS RN 243973-20-8).

The mixing partners of the compound of formula I may also be in the form of esters or salts, as mentioned e.g. in The Pesticide Manual, 13th Edition (BCPC), 2003. The reference to glufosinate-ammonium also applies to glufosinate, the reference to cloransulam-methyl also applies to cloransulam, and the reference to pyriithiobac-sodium also applies to pyriithiobac, etc.

The mixing ratio of the compound of formula I to the mixing partner is preferably from 1: 100 to 1000:1.

The mixtures can advantageously be used in the above-mentioned formulations (in which case "active ingredient" relates to the respective mixture of compound of formula I with the mixing partner).

Furthermore, the compounds of formula I according to the invention can also be
5 used in combination with other herbicides: compound of formula I + acetochlor (5),
compound of formula I + acifluorfen-sodium (7), compound of formula I + aclonifen (8),
compound of formula I + acrolein (10), compound of formula I + alachlor (14),
compound of formula I + alloxydim (18), compound of formula I + allyl alcohol (CAS
RN 107-18-6), compound of formula I + amidosulfuron (22), compound of formula I +
10 aminopyralid (CAS RN 150114-71-9), compound of formula I + amitrole (aminotriazole)
(25), compound of formula I + ammonium sulfamate (26), compound of formula I +
anilofos (31), compound of formula I + asulam (36), compound of formula I + atraton
(CAS RN 1610-17-9), compound of formula I + aviglycine (39), compound of formula I
+ azafenidin (CAS RN 68049-83-2), compound of formula I + azimsulfuron (43),
15 compound of formula I + BAS 800H (CAS RN 372137-35-4), compound of formula I +
BCPC (CAS RN 2164-13-8), compound of formula I + beflubutamid (55), compound of
formula I + benazolin (57), compound of formula I + bencarbazon (CAS RN 173980-
17-1), compound of formula I + benfluralin (59), compound of formula I + benfuresate
(61), compound of formula I + bensulfuron-methyl (64), compound of formula I +
20 bensulide (65), compound of formula I + bentazone (67), compound of formula I +
benzfendizone (CAS RN 158755-95-4), compound of formula I + benzobicyclon (69),
compound of formula I + benzofenap (70), compound of formula I + bifenox (75),
compound of formula I + bilanafos (bialaphos) (77), compound of formula I +
bispyribac-sodium (82), compound of formula I + borax (86), compound of formula I +
25 bromacil (90), compound of formula I + bromobutide (93), compound of formula I +
bromofenoxim (CAS RN 13181-17-4), compound of formula I + bromoxynil (95),
compound of formula I + butachlor (100), compound of formula I + butafenacil (101),
compound of formula I + butamifos (102), compound of formula I + butralin (105),
compound of formula I + butoxydim (106), compound of formula I + butylate (108),
30 compound of formula I + cacodylic acid (CAS RN 75-60-5), compound of formula I +
calcium chlorate (CAS RN 10137-74-3), compound of formula I + cafenstrole (110),
compound of formula I + carbetamide (117), compound of formula I + carfentrazone-
ethyl (121), compound of formula I + CDEA (CAS RN 2315-36-8), compound of

formula I + CEPC (CAS RN 587-56-4), compound of formula I + chlorbromuron (CAS RN 13360-45-7), compound of formula I + chlorflurenol-methyl (133), compound of formula I + chloridazon (134), compound of formula I + chlorimuron-ethyl (135), compound of formula I + chloroacetic acid (138), compound of formula I + chlorotoluron (143), compound of formula I + chlorpropham (144), compound of formula I + chlorthal-dimethyl (148), compound of formula I + cinidon-ethyl (152), compound of formula I + cinmethylin (153), compound of formula I + cisanilide (CAS RN 34484-77-0), compound of formula I + clefoxydim (CAS RN 211496-02-5), compound of formula I + clethodim (155), compound of formula I + clomeprop (160), compound of formula I + clopyralid (162), compound of formula I + CMA (CAS RN 5902-95-4), compound of formula I + 4-CPB (CAS RN 3547-07-7), compound of formula I + CPMF, compound of formula I + 4-CPP (CAS RN 3307-39-9), compound of formula I + CPPC (CAS RN 2150-32-5), compound of formula I + cresol (CAS RN 1319-77-3), compound of formula I + cumyluron (180), compound of formula I + cyanamide (182), compound of formula I + cyclanilide (186), compound of formula I + cycloate (187), compound of formula I + cyclosulfamuron (189), compound of formula I + cycloxydim (190), compound of formula I + cyhalofop-butyl (195), compound of formula I + 2,4-D (211), compound of formula I + 3,4-DA (CAS RN 588-22-7), compound of formula I + daimuron (213), compound of formula I + dalapon (214), compound of formula I + dazomet (216), compound of formula I + 2,4-DB (217), compound of formula I + 3,4-DB, compound of formula I + 2,4-DEB (CAS RN 94-83-7), compound of formula I + desmedipham (225), compound of formula I + desmetryn (CAS RN 1014-69-3), compound of formula I + dicamba (228), compound of formula I + dichlobenil (229), compound of formula I + ortho-dichlorobenzene (CAS RN 95-50-1), compound of formula I + para-dichlorobenzene (CAS RN 106-46-7), compound of formula I + dichlorprop (234), compound of formula I + dichlorprop-P (235), compound of formula I + diclofop-methyl (238), compound of formula I + diclosulam (241), compound of formula I + difenzoquat metilsulfate (248), compound of formula I + diflufenican (251), compound of formula I + diflufenzopyr (252), compound of formula I + dimefuron (256), compound of formula I + dimepiperate (257), compound of formula I + dimethachlor (258), compound of formula I + dimethenamid (260), compound of formula I + dimethenamid-P, compound of formula I + dimethipin (261), compound of formula I + dimethylarsinic acid (264), compound of formula I + dinitramine (268), compound of formula I + dinoterb (272),

compound of formula I + diphenamid (274), compound of formula I + dipropetryn (CAS
RN 4147-51-7), compound of formula I + diquat dibromide (276), compound of formula
I + dithiopyr (280), compound of formula I + diuron (281), compound of formula I +
DNOC (282), compound of formula I + 3,4-DP (CAS RN 3307-41-3), compound of
5 formula I + DSMA (CAS RN 144-21-8), compound of formula I + EBEP, compound of
formula I + endothal (295), compound of formula I + EPTC (299), compound of formula
I + esprocarb (303), compound of formula I + ethalfluralin (305), compound of formula I
+ ethephon (307), compound of formula I + ethofumesate (311), compound of formula I
+ ethoxyfen (CAS RN 188634-90-4), compound of formula I + ethoxyfen-ethyl (CAS
10 RN 131086-42-5), compound of formula I + ethoxysulfuron (314), compound of formula
I + etobenzanid (318), compound of formula I + fenoxaprop-P-ethyl (339), compound of
formula I + fentrazamide (348), compound of formula I + ferrous sulfate (353),
compound of formula I + flamprop, compound of formula I + flamprop-M (355),
compound of formula I + florasulam (359), compound of formula I + fluazifop-butyl
15 (361), compound of formula I + fluazifop-P-butyl (362), compound of formula I +
fluazolate (isopropazol) (CAS RN 174514-07-9), compound of formula I + flucarbazone-
sodium (364), compound of formula I + flucetosulfuron (CAS RN 412928-75-7),
compound of formula I + fluchloralin (365), compound of formula I + flufenacet (BAY
FOE 5043) (369), compound of formula I + flufenpyr-ethyl (371), compound of formula
20 I + flumetralin (373), compound of formula I + flumiclorac-pentyl (375), compound of
formula I + flumipropyn (flumipropin) (CAS RN 84478-52-4), compound of formula I +
fluometuron (378), compound of formula I + fluoroglycofen-ethyl (380), compound of
formula I + flupoxam (CAS RN 119126-15-7), compound of formula I + flupropacil
(CAS RN 120890-70-2), compound of formula I + flupropanate (383), compound of
25 formula I + flupyrsulfuron-methyl-sodium (384), compound of formula I + flurenol
(387), compound of formula I + fluridone (388), compound of formula I +
flurochloridone (389), compound of formula I + fluroxypyr (390), compound of formula
I + flurtamone (392), compound of formula I + fluthiacet-methyl (395), compound of
formula I + fosamine (406), compound of formula I + halosulfuron-methyl (426),
30 compound of formula I + haloxyfop (427), compound of formula I + haloxyfop-P (428),
compound of formula I + HC-252 (429), compound of formula I + hexazinone (440),
compound of formula I + imazaquin (454), compound of formula I + imazosulfuron
(456), compound of formula I + indanofan (462), compound of formula I + iodomethane

(CAS RN 74-88-4), compound of formula I + ioxynil (467), compound of formula I + isoproturon (475), compound of formula I + isouron (476), compound of formula I + isoxaben (477), compound of formula I + isoxachlortole (CAS RN 141112-06-3), compound of formula I + isoxapyrifop (CAS RN 87757-18-4), compound of formula I + karbutilate (482), compound of formula I + lactofen (486), compound of formula I + lenacil (487), compound of formula I + linuron (489), compound of formula I + MAA (CAS RN 124-58-3), compound of formula I + MAMA (CAS RN 2321-53-1), compound of formula I + MCPA (499), compound of formula I + MCPA-thioethyl (500), compound of formula I + MCPB (501), compound of formula I + mecoprop (503), compound of formula I + mecoprop-P (504), compound of formula I + mefenacet (505), compound of formula I + mefluidide (507), compound of formula I + mesosulfuron-methyl (514), compound of formula I + metam (519), compound of formula I + metamifop (mefluoxafop) (520), compound of formula I + methabenzthiazuron (526), compound of formula I + methazole (CAS RN 20354-26-1), compound of formula I + methylarsonic acid (536), compound of formula I + methyldymron (539), compound of formula I + methyl isothiocyanate (543), compound of formula I + metobenzuron (547), compound of formula I + metobromuron (CAS RN 3060-89-7), compound of formula I + metosulam (552), compound of formula I + metoxuron (553), compound of formula I + MK-616 (559), compound of formula I + molinate (560), compound of formula I + monolinuron (562), compound of formula I + MSMA (CAS RN 2163-80-6), compound of formula I + naproanilide (571), compound of formula I + napropamide (572), compound of formula I + naptalam (573), compound of formula I + neburon (574), compound of formula I + nipyraclufen (CAS RN 99662-11-0), compound of formula I + n-methyl-glyphosate, compound of formula I + nonanoic acid (583), compound of formula I + norflurazon (584), compound of formula I + oleic acid (fatty acids) (593), compound of formula I + orbencarb (595), compound of formula I + orthosulfamuron (CAS RN 213464-77-8), compound of formula I + oryzalin (597), compound of formula I + oxadiargyl (599), compound of formula I + oxadiazon (600), compound of formula I + oxaziclomefone (604), compound of formula I + oxyfluorfen (610), compound of formula I + pebulate (617), compound of formula I + penoxsulam (622), compound of formula I + pentachlorophenol (623), compound of formula I + pentanochlor (624), compound of formula I + pentoxazone (625), compound of formula I + pethoxamid (627), compound of formula I + petroleum oils (628), compound of formula I +

phenmedipham (629), compound of formula I + picloram (645), compound of formula I + picolinafen (646), compound of formula I + piperophos (650), compound of formula I + potassium arsenite (CAS RN 10124-50-2), compound of formula I + potassium azide (CAS RN 20762-80-1), compound of formula I + pretilachlor (656), compound of
5 formula I + prodiamine (661), compound of formula I + profluazol (CAS RN 190314-43-3), compound of formula I + profoxydim (663), compound of formula I + prohexadione calcium (664), compound of formula I + propachlor (667), compound of formula I + propanil (669), compound of formula I + propaquizafop (670), compound of formula I + propham (674), compound of formula I + propisochlor (667), compound of formula I +
10 propoxycarbazone-sodium (procarbazone-sodium) (679), compound of formula I + propyzamide (681), compound of formula I + prosulfocarb (683), compound of formula I + pyraclostrobin (pyrazogyl) (CAS RN 158353-15-2), compound of formula I + pyraflufen-ethyl (691), compound of formula I + pyrasulfotole (CAS RN 365400-11-9), compound of formula I + pyrazolynate (692), compound of formula I + pyrazosulfuron-ethyl (694),
15 compound of formula I + pyrazoxyfen (695), compound of formula I + pyribenzoxim (697), compound of formula I + pyributicarb (698), compound of formula I + pyridafol (CAS RN 40020-01-7), compound of formula I + pyridate (702), compound of formula I + pyriftalid (704), compound of formula I + pyriminobac-methyl (707), compound of formula I + pyrimisulfan (CAS RN 221205-90-9), compound of formula I +
20 pyroxasulfone (CAS RN 447399-55-5), compound of formula I + pyroxsulam (triflosulam) (CAS RN 422556-08-9), compound of formula I + quinclorac (712), compound of formula I + quinmerac (713), compound of formula I + quinclamine (714), compound of formula I + quizalofop (717), compound of formula I + quizalofop-P (718), compound of formula I + sequestrene, compound of formula I + sethoxydim (726),
25 compound of formula I + siduron (727), compound of formula I + SMA (CAS RN 3926-62-3), compound of formula I + sodium arsenite (CAS RN 7784-46-5), compound of formula I + sodium azide (CAS RN 26628-22-8), compound of formula I + sodium chlorate (734), compound of formula I + sulfometuron-methyl (751), compound of formula I + sulfosate (CAS RN 81591-81-3), compound of formula I + sulfuric acid
30 (755), compound of formula I + tar oils (758), compound of formula I + 2,3,6-TBA (759), compound of formula I + TCA-sodium (760), compound of formula I + tebutam (CAS RN 35256-85-0), compound of formula I + tebuthiuron (765), compound of formula I + tepaloxymid (771), compound of formula I + terbacil (772), compound of

formula I + tefuryltrione (CAS RN 473278-76-1), compound of formula I + thenylchlor (789), compound of formula I + thidiazimin (CAS RN 123249-43-4), compound of formula I + thiazafluron (CAS RN 25366-23-8), compound of formula I + thiazopyr (793), compound of formula I + thiobencarb (797), compound of formula I + tiocarbazil (807), compound of formula I + tralkoxydim (811), compound of formula I + tri-allate (816), compound of formula I + triaziflam (819), compound of formula I + tricamba (CAS RN 2307-49-5), compound of formula I + triclopyr (827), compound of formula I + triflusulfuron-methyl (837), compound of formula I + trihydroxytriazine (CAS RN 108-80-5), compound of formula I + trinexapac-ethyl (CAS RN 95266-40-3) and
10 compound of formula I + tritosulfuron (843).

The mixing partners of the compound of formula I may also be in the form of esters or salts, as mentioned e.g. in The Pesticide Manual, 13th Edition (BCPC), 2003. The reference to acifluorfen-sodium also applies to acifluorfen, and the reference to bensulfuron-methyl also applies to bensulfuron, etc.

15 The mixing ratio of the compound of formula I to the mixing partner is preferably from 1: 100 to 1000:1.

The mixtures can advantageously be used in the above-mentioned formulations (in which case "active ingredient" relates to the respective mixture of compound of formula I with the mixing partner).

20 The compounds of formula I according to the invention can also be used in combination with one or more safeners. Likewise, mixtures of a compound of formula I according to the invention with one or more further herbicides can also be used in combination with one or more safeners. The safeners can be AD 67 (MON 4660) (11), benoxacor (63), cloquintocet-mexyl (163), cyometrinil and the corresponding (Z) isomer, 25 cyprosulfamide (CAS RN 221667-31-8), dichlormid (231), fenchlorazole-ethyl (331), fenclorim (332), flurazole (386), fluxofenim (399), furilazole (413) and the corresponding R isomer, isoxadifen-ethyl (478), mefenpyr-diethyl (506), oxabetrinil (598), naphthalic anhydride (CAS RN 81-84-5) and N-isopropyl-4-(2-methoxy-benzoylsulfamoyl)-benzamide (CAS RN 221668-34-4). Particularly preferred are
30 mixtures of a compound of formula I with benoxacor (i.e. compound of formula I + benoxacor).

The safeners of the compound of formula I may also be in the form of esters or salts, as mentioned e.g. in The Pesticide Manual, 13th Edition (BCPC), 2003. The

reference to cloquintocet-mexyl also applies to a lithium, sodium, potassium, calcium, magnesium, aluminium, iron, ammonium, quaternary ammonium, sulfonium or phosphonium salt thereof as disclosed in WO 02/34048, and the reference to fenchlorazole-ethyl also applies to fenchlorazole, etc.

- 5 Preferably the mixing ratio of compound of formula I to safener is from 100:1 to 1:10, especially from 20:1 to 1:1.

The mixtures can advantageously be used in the above-mentioned formulations (in which case "active ingredient" relates to the respective mixture of compound of formula I with the safener).

- 10 Preferred mixtures of a compound of formula I with further herbicides and safeners include:

Mixtures of a compound of formula I with a triazine and a safener.

Mixtures of a compound of formula I with glyphosate and a safener.

Mixtures of a compound of formula I with glufosinate and a safener.

- 15 Mixtures of a compound of formula I with isoxaflutole and a safener.

Mixtures of a compound of formula I with isoxaflutole and a triazine and a safener.

Mixtures of a compound of formula I with isoxaflutole and glyphosate and a safener.

- 20 Mixtures of a compound of formula I with isoxaflutole and glufosinate and a safener.

Mixtures of a compound of formula I with mesotrione and a safener.

Mixtures of a compound of formula I with mesotrione and a triazine and a safener.

- 25 Mixtures of a compound of formula I with mesotrione and glyphosate and a safener.

Mixtures of a compound of formula I with mesotrione and glufosinate and a safener.

Mixtures of a compound of formula I with sulcotrione and a safener.

- 30 Mixtures of a compound of formula I with sulcotrione and a triazine and a safener.

Mixtures of a compound of formula I with sulcotrione and glyphosate and a safener.

Mixtures of a compound of formula I with sulcotrione and glufosinate and a safener.


The following Examples further illustrate, but do not limit, the invention.

5

Preparation Examples:

1) Methods for making 5,5-dimethyl-4,5-dihydro-isoxazole derivatives


Example I1: Preparation of hydroxyimino-acetic acid



10 Aqueous glyoxylic acid (50% by weight) (1 l, 9 mol) and hydroxyl amine hydrochloride (627 g, 9 mol) were mixed and concentrated. Acetonitrile (1 l) was added, the solution cooled to 5°C and filtered. The mother liquor was concentrated to 50% of the volume, stored at 5°C overnight and filtered again. This process was repeated twice. The solids were combined and dried to give hydroxyimino-acetic acid as white crystals (546 g, 68% yield).

15

Example I2: Preparation of 3-chloro-5,5-dimethyl-4,5-dihydro-isoxazole




Hydroxyimino-acetic acid (Example I1) (107 g, 1.2 mol) was dissolved in 1,2-dimethoxy-ethane (1.4 l) and heated to 70°C. N-chlorosuccinimide (NCS) (320.4 g, 2.4 mol) was added in portions within 1 hour at 70°C. The reaction mixture was stirred at 70°C for 1 hour. The reaction mixture was cooled to 5°C and potassium hydrogencarbonate (535 g, 4.45 mol) and water (54 g) were added. 2-Methyl-propene (134.6 g, 2.4 mol) was introduced into the suspension for 20 minutes at 5°C. The reaction mixture was allowed to warm to room temperature and was stirred at room temperature for 18 hours. The reaction mixture was poured onto water (1.5 l) and the mixture extracted with hexane (3x 500 ml). The combined organic extracts were washed with brine, dried over sodium sulfate and concentrated. The residue was distilled to give 3-chloro-5,5-dimethyl-4,5-dihydro-isoxazole as a liquid (60.7 g, 37.8% yield).

20

25

¹H-NMR (400 MHz, CDCl₃): 1.47 (s, 6H, Me), 2.92 (s, 2H, CH₂) ppm.

Example I3: Preparation of 5,5-dimethyl-isoxazolidin-3-one




5 Sodium (1.72 g, 75 mmol) was dissolved in methanol (30 ml) at room temperature. Hydroxy urea (3.8 g, 50 mmol) was added slowly, then ethyl dimethyl-acrylate (6.4 g, 50 mmol) was added dropwise. The reaction mixture was stored at room temperature for 18 hours. The solid was removed by filtration and the filtrate was concentrated. The residue was dissolved in water and stirred for 15 minutes, then

10 aqueous hydrochloric acid (2M) was added dropwise to acidify the mixture. The aqueous solution was extracted with chloroform. The organic extract was washed with brine, dried over magnesium sulfate and concentrated to give 5,5-dimethyl-isoxazolidin-3-one as a white solid (2.8 g, 49% yield).

¹H-NMR (400 MHz, CDCl₃): 1.43 (s, 6H, Me), 2.58 (s, 2H, CH₂) ppm.

15


Example I4: Preparation of 3-chloro-5,5-dimethyl-4,5-dihydro-isoxazole



5,5-Dimethyl-isoxazolidin-3-one (Example I3) (0.5 g, 0.57 mmol) was dissolved in phosphorus oxychloride (10 ml) and heated to reflux for 5 hours. The reaction mixture

20 was concentrated and the residue partitioned between water and diethyl ether. The phases were separated and the organic phase washed with brine, dried over magnesium sulfate and concentrated to give 3-chloro-5,5-dimethyl-4,5-dihydro-isoxazole as a brown, mobile oil (0.4 g, 69% yield).

25 Example I5: Preparation of 2-(5,5-dimethyl-4,5-dihydro-isoxazol-3-yl)-disulfide



2-(5,5-Dimethyl-4,5-dihydro-isoxazol-3-yl)-isothiourea hydrochloride (29 g, 138 mmol) (prepared as described in WO 06/068092) and potassium carbonate (39 g, 416 mmol) were dissolved in methanol (250 ml) and iodine (18 g, 100 mmol) was added in portions at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, the residue dissolved in water and the aqueous mixture extracted several times with ethyl acetate. The combined organic extracts were washed with water and brine, dried over magnesium sulfate and concentrated to give 2-(5,5-dimethyl-4,5-dihydro-isoxazol-3-yl)-disulfide as a pale yellow solid (14.1 g, 78 % yield).

2) Methods for making triazole derivatives

The synthesis of 1-*tert*-butyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester was described in Synthesis, 1985, 178-180.

1-*tert*-Butyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester was reduced as described in Example I6 to give [1-*tert*-butyl-1*H*-[1,2,3]triazol-4-yl]-methanol.


¹H-NMR (400 MHz, CDCl₃): 1.65 (s, 9H, Me), 4.76 (s, 2H, CH₂), 7.60 (s, 1H, CH) ppm.

[1-*tert*-Butyl-1*H*-[1,2,3]triazol-4-yl]-methanol was brominated as described in Example I7 to give 4-bromomethyl-1-*tert*-butyl-1*H*-[1,2,3]triazole.

¹H-NMR (400 MHz, CDCl₃): 1.65 (s, 9H, Me), 4.58 (s, 2H, CH₂), 7.63 (s, 1H, CH) ppm.

The synthesis of 5-(difluoromethyl)-2-methyl-2*H*-1,2,3-triazole-4-carboxylic acid methyl ester was described in WO 2004/018438.

Example I6: Preparation of (5-fluoromethyl-2-methyl-2*H*-[1,2,3]triazol-4-yl)-methanol and (2,5-dimethyl-2*H*-[1,2,3]triazol-4-yl)-methanol



To a solution of lithium aluminium hydride (2M in THF) (2.83 ml, 5.65 mmol) in tetrahydrofuran (10 ml) was added dropwise a solution of 5-fluoromethyl-2-methyl-2*H*-

[1,2,3]triazole-4-carboxylic acid methyl ester (prepared as described in WO 04/018438) (978 mg, 5.65 mmol) in tetrahydrofuran (10 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred at room temperature for 40 minutes. The reaction mixture was quenched by successive addition of water (200 µl), aqueous sodium hydroxide (2M) (350 µl) and water (400 µl). The precipitate was removed by filtration and the filtrate was evaporated to give a 4:1-mixture of (5-fluoromethyl-2-methyl-2*H*-[1,2,3]triazol-4-yl)-methanol and (2,5-dimethyl-2*H*-[1,2,3]triazol-4-yl)-methanol as a pale yellow liquid (610 mg, 76% yield).


¹H-NMR (400 MHz, CDCl₃): 4.19 (d, 3H, Me), 4.83 (s, 2H, CH₂), 5.52 (d, 2H, CH₂) ppm.

¹H-NMR (400 MHz, CDCl₃): 2.31 (s, 3H, Me), 4.11 (s, 3H, Me), 4.72 (s, 2H, CH₂) ppm.

The same method was used with 2-methyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (prepared as described in WO 04/018438) as the starting material to give (2-methyl-5-trifluoromethyl-2*H*-[1,2,3]triazol-4-yl)-methanol.

¹H-NMR (400 MHz, CDCl₃): 2.03 (t, 1H, OH), 4.24 (s, 3H, Me), 4.84 (d, 2H, CH₂) ppm.

Example I7: Preparation of 4-bromomethyl-5-fluoromethyl-2-methyl-2*H*-[1,2,3]triazole and 4-bromomethyl-2,5-dimethyl-2*H*-[1,2,3]triazole



The 4:1-mixture of (5-fluoromethyl-2-methyl-2*H*-[1,2,3]triazol-4-yl)-methanol and (2,5-dimethyl-2*H*-[1,2,3]triazol-4-yl)-methanol (610 mg, 4.21 mmol) (Example I6) was dissolved in diethyl ether (10 ml) under nitrogen at room temperature and phosphorous tribromide (395 µl, 4.21 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was quenched by addition of cold water, and the mixture was extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated to give a 4:1-mixture of 4-bromomethyl-5-fluoromethyl-2-methyl-2*H*-[1,2,3]triazole and 4-bromomethyl-2,5-dimethyl-2*H*-[1,2,3]-triazole as an orange liquid (954 mg).


$^1\text{H-NMR}$ (400 MHz, CDCl_3): 4.18 (d, 3H, Me), 4.57 (s, 2H, CH_2), 5.51 (d, 2H, CH_2) ppm.

$^1\text{H-NMR}$ (400 MHz, CDCl_3): 2.31 (s, 3H, Me), 4.11 (s, 3H, Me), 4.50 (s, 2H, CH_2) ppm.

- 5 The same method was used with (2-methyl-5-trifluoromethyl-2H-[1,2,3]triazol-4-yl)-methanol as the starting material to give 4-bromomethyl-2-methyl-5-trifluoromethyl-2H-[1,2,3]triazole.


$^1\text{H-NMR}$ (400 MHz, CDCl_3): 4.19 (s, 3H, Me), 4.49 (s, 2H, CH_2) ppm.

10 Example I8: Preparation of 3-(methyl-hydrazono)-butan-2-one oxime



- Butane-2,3-dione monooxime (2.6 g, 25.8 mmol) was dissolved in ethanol (100 ml) then methylhydrazine (1.13 g, 24.5 mmol) was added at room temperature. The reaction mixture was stirred at 80°C for 2 hours. Methylhydrazine (0.6 g, 12 mmol) was added and the reaction mixture stirred at 80°C for 1.5 hours. Methylhydrazine (0.6 g, 12 mmol) was added and the reaction mixture stirred at 80°C for another 1.5 hours, then at room temperature for 48 hours. The reaction mixture was concentrated to give 3-(methyl-hydrazono)-butan-2-one oxime as a pale yellow, crystalline solid (3.3 g, 100% yield).
- 15 $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.89 (s, 3H, Me), 2.11 (s, 3H, Me), 3.09 (s, 3H, Me), 4.8-5.3 (bs, 1H, OH) ppm.
- 20

Example I9: Preparation of 2,4,5-trimethyl-2H-[1,2,3]triazole 1-oxide




- 3-(Methyl-hydrazono)-butan-2-one oxime (3.3 g, 25.8 mmol) (Example I8) was dissolved in tetrahydrofuran (135 ml), then aqueous pyridine (15%) (157 ml, 0.29 mol) was added, followed by a slurry of copper(II)-sulfate (15.7 g, 62.8 mmol) in water (35 ml). The reaction mixture was stirred at 80°C for 2 hours, then cooled to room temperature and extracted three times with ethyl acetate. The combined organic extracts
- 25

were washed with aqueous copper(II) sulfate (10%), dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: methanol / dichloromethane) to give 2,4,5-trimethyl-2*H*-[1,2,3]triazole 1-oxide as colourless liquid (0.7 g, 21% yield).

5 $^1\text{H-NMR}$ (400 MHz, CDCl_3): 2.19 (s, 3H, Me), 2.23 (s, 3H, Me), 3.93 (s, 3H, Me) ppm.


Example I10: Preparation of 5-bromomethyl-2,4-dimethyl-2*H*-[1,2,3]triazole 1-oxide



N-Bromosuccinimide (NBS) (186 mg, 1.0 mmol) and 2,2'-azobisisobutyronitrile (AIBN) (14 mg, 0.087 mmol) were added to a solution of 2,4,5-trimethyl-2*H*-[1,2,3]-triazole 1-oxide (110 mg, 0.87 mmol) (Example I9) in carbon tetrachloride (7 ml). The reaction mixture was heated to 70°C for 1 hour then cooled to room temperature and filtered. The solvent was removed to give 5-bromomethyl-2,4-dimethyl-2*H*-[1,2,3]-triazole 1-oxide as a brown gum.


15 $^1\text{H-NMR}$ (400 MHz, CDCl_3): 2.31 (s, 3H, Me), 3.95 (s, 3H, Me), 4.42 (s, 2H, CH_2) ppm.

Example I11: Alternative preparation of 4-bromomethyl-2,5-dimethyl-2*H*-[1,2,3]triazole



5-Bromomethyl-2,4-dimethyl-2*H*-[1,2,3]triazole 1-oxide (4.83 g, 23.3 mmol) (Example I10) was dissolved in carbon tetrachloride (50 ml), then phosphorous tri-chloride (6.8 ml, 77.8 mol) was added dropwise. The reaction mixture was stirred at 75°C for 2.5 hours. The reaction mixture was quenched by slow addition into hot water, then cooled and diluted with cold water. The phases were separated and the aqueous phase was extracted twice with dichloromethane. The combined organic extracts were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: methanol / dichloromethane) to give 4-bromomethyl-2,5-dimethyl-2*H*-[1,2,3]triazole as a yellow oil (1.47 g, 33% yield). $^1\text{H-NMR}$ (400 MHz, CDCl_3): 2.3 (s, 3H, Me), 4.1 (s, 3H, Me), 5.5 (s, 2H, CH_2) ppm.

Example I12: Preparation of 1-(4-methoxy-benzyl)-5-methyl-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 3-(4-methoxy-benzyl)-5-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester



5

4-Methoxybenzyl azide (preparation described in e.g. J. Chem. Soc., Perkin Trans. 1, 1982 (2), 627-630) (5.47 g, 33.6 mmol) was dissolved in toluene (20 ml) and methyl-2-butynoate (6.72 ml, 67.1 mmol) was added dropwise at room temperature over 5 minutes. The reaction mixture was heated to 100°C for 14 hours. The solution was cooled to room temperature and the solvent was evaporated to yield a bright yellow liquid which was purified by column chromatography on silica gel (eluent: 0-50% ethyl acetate in hexane) to give a mixture of 1-(4-methoxy-benzyl)-5-methyl-1*H*-[1,2,3]-triazole-4-carboxylic acid methyl ester and 3-(4-methoxy-benzyl)-5-methyl-3*H*-[1,2,3]-triazole-4-carboxylic acid methyl ester as a bright yellow oil (7.35 g, 85% yield).

15 Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 2.46 (s, 3H, Me), 3.79 (s, 3H, Me), 3.94 (s, 3H, Me), 5.47 (s, 2H, CH₂), 6.82-6.88 (m, 2H, CH), 7.13 (d, 2H, CH) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 2.51 (s, 3H, Me), 3.77 (s, 3H, Me), 3.90 (s, 3H, Me), 5.80 (s, 2H, CH₂), 6.82-6.88 (m, 2H, CH), 7.28 (d, 2H, CH) ppm.

20


The same method was used with pent-2-ynoic acid ethyl ester as the starting material to give a mixture of 5-ethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 5-ethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester.

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.00 (t, 3H, Me), 1.42 (t, 3H, Me), 2.88-2.96 (m, 2H, CH₂), 3.79 (s, 3H, Me), 4.42 (q, 2H, CH₂), 5.48 (s, 2H, CH₂), 6.82-6.87 (m, 2H, CH), 7.14 (d, 2H, CH) ppm.

25

Isomer 2 (minor) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.29 (t, 3H, Me), 1.36 (t, 3H, Me), 2.88-2.96 (m, 2H, CH_2), 3.78 (s, 3H, Me), 4.35 (q, 2H, CH_2), 5.81 (s, 2H, CH_2), 6.82-6.87 (m, 2H, CH), 7.28 (d, 2H, CH) ppm.

5 Example I13: Preparation of 5-methyl-2H-[1,2,3]triazole-4-carboxylic acid methyl ester



The mixture of 1-(4-methoxy-benzyl)-5-methyl-1H-[1,2,3]triazole-4-carboxylic acid methyl ester and 3-(4-methoxy-benzyl)-5-methyl-3H-[1,2,3]triazole-4-carboxylic acid methyl ester (Example I12) (7.35 g, 28.6 mmol) was dissolved in acetonitrile / water (9:1) (100 ml) and cerium(IV) ammonium nitrate (CAN) (31.4 g, 57.2 mmol) was added. The solution was stirred at room temperature for 16 hours. The solvent was evaporated and the residue partitioned between water and ethyl acetate. The phases were separated and the aqueous phase was extracted twice with more ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated. Dichloromethane (50 ml) was added to the residue which caused a white solid to precipitate (1.77 g, 40% yield). The solid was isolated via filtration. The mother liquor was evaporated and the residue again treated with dichloromethane (50 ml). This caused more white solid to precipitate. The solid was isolated via filtration and the combined solids were dried to give 5-methyl-2H-[1,2,3]triazole-4-carboxylic acid methyl ester (2.6 g, 59% yield).


$^1\text{H-NMR}$ (400 MHz, CDCl_3): 2.62 (s, 3H, Me), 4.0 (s, 3H, Me) ppm.

The same method was used with the mixture of 5-ethyl-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester and 5-ethyl-3-(4-methoxy-benzyl)-3H-[1,2,3]triazole-4-carboxylic acid ethyl ester as the starting material to give 5-ethyl-2H-[1,2,3]triazole-4-carboxylic acid ethyl ester.

$^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.36 (t, 3H, Me), 1.42 (t, 3H, Me), 3.08 (q, 2H, CH_2), 4.44 (q, 2H, CH_2) ppm.

Example I14: Preparation of 2-ethyl-5-methyl-2H-[1,2,3]triazole-4-carboxylic acid

5 methyl ester, 3-ethyl-5-methyl-3H-[1,2,3]triazole-4-carboxylic acid methyl ester and 1-ethyl-5-methyl-1H-[1,2,3]triazole-4-carboxylic acid methyl ester



5-Methyl-2H-[1,2,3]triazole-4-carboxylic acid methyl ester (1.77 g, 12.6 mmol) (Example I13) was dissolved in N,N-dimethylformamide (12 ml) and ethyl iodide (16.3 mmol, 1.31 ml) and potassium carbonate (2.26 g, 16.3 mmol) were added at 0°C . The reaction mixture was warmed to room temperature and stirred for 5 hours under an atmosphere of nitrogen. The solution was partitioned between water and diethyl ether. The phases were separated and the aqueous phase was extracted twice with more diethyl ether. The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated to give a mixture of 2-ethyl-5-methyl-2H-[1,2,3]triazole-4-carboxylic acid methyl ester, 3-ethyl-5-methyl-3H-[1,2,3]triazole-4-carboxylic acid methyl ester and 1-ethyl-5-methyl-3H-[1,2,3]triazole-4-carboxylic acid methyl ester as a yellow oil (1.10 g, 52% yield).

Isomer 1 (major) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.6 (t, 3H, Me), 2.52 (s, 3H, Me), 3.95 (s, 3H, Me), 4.45 (q, 2H, CH_2) ppm.

Isomer 2 (middle) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.5 (t, 3H, Me), 2.54 (s, 3H, Me), 3.96 (s, 3H, Me), 4.73 (q, 2H, CH_2) ppm.

Isomer 3 (minor) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.53 (t, 3H, Me), 2.6 (s, 3H, Me), 3.95 (s, 3H, Me), 4.35 (q, 2H, CH_2) ppm.

25

The same method was used with 5-methyl-2H-[1,2,3]triazole-4-carboxylic acid ethyl ester as the starting material (prepared as described in Example I12 from ethyl-2-butyrate, followed by deprotection as described in Example I13) and *iso*-propyl iodide as reagent to give 2-*iso*-propyl-5-methyl-2H-[1,2,3]triazole-4-carboxylic acid ethyl ester,

3-*iso*-propyl-5-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 1-*iso*-propyl-5-methyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester.

Isomer 1 (major) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.38-1.44 (m, 3H, Me), 1.56-1.63 (m, 6H, Me), 2.52 (s, 3H, Me), 4.31-4.45 (m, 2H, CH_2), 4.83 (sept, 1H, CH) ppm.

5 Isomer 2 (middle) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.38-1.44 (m, 3H, Me), 1.56-1.63 (m, 6H, Me), 2.53 (s, 3H, Me), 4.31-4.45 (m, 2H, CH_2), 5.44 (sept, 1H, CH) ppm.

Isomer 3 (minor) $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.38-1.44 (m, 3H, Me), 1.56-1.63 (m, 6H, Me), 2.59 (s, 3H, Me), 4.31-4.45 (m, 2H, CH_2), 4.58 (sept, 1H, CH) ppm.

10 The same method was used with 5-ethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester as the starting material and methyl iodide as reagent to give 5-ethyl-2-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester.

$^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.32 (t, 3H, Me), 1.41 (t, 3H, Me), 2.95 (q, 2H, CH_2), 4.20 (s, 3H, Me), 4.42 (q, 2H, CH_2) ppm.

15


The same method was used with 5-ethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester as the starting material and ethyl iodide as reagent to give 2,5-diethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester.

20 $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.2-1.30 (m, 3H, Me), 1.35-1.45 (m, 3H, Me), (1.41 (t, 3H, Me), 2.95 (q, 2H, CH_2), 4.38-4.44 (m, 4H, CH_2) ppm.

The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.

25

Example I15: Preparation of 2-difluoromethyl-5-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-difluoromethyl-5-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester




Sodium hydride (60% dispersion in mineral oil) (570 mg, 14.2 mmol) was washed under nitrogen with *iso*-hexane and suspended in dry tetrahydrofuran (50 ml) in a three necked flask fitted with a dry ice condenser. A solution of 5-methyl-2*H*-[1,2,3]-triazole-4-carboxylic acid ethyl ester (2 g, 12.9 mmol) (Example I13) in tetrahydrofuran (10 ml) was added dropwise. The reaction mixture was stirred at room temperature for 30 minutes. Chlorodifluoromethane was passed through the solution for 10 minutes and the reaction mixture stirred at room temperature for 1.5 hours. More chlorodifluoromethane was passed through the solution for a few minutes and the reaction mixture stirred for another 1.5 hours. The reaction was quenched by addition of water and the mixture was extracted with ethyl acetate. The combined organic extracts were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / *iso*-hexane) to give 2-difluoromethyl-5-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (1.3 g, 49% yield) and a 1:2-mixture of 2-difluoromethyl-5-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-difluoromethyl-5-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (250 mg, 9% yield).

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.44 (t, 3H, Me), 2.80 (s, 3H, Me), 4.47 (q, 2H, CH₂), 7.64 (t, 1H, CHF₂) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.45 (t, 3H, Me), 2.60 (s, 3H, Me), 4.47 (q, 2H, CH₂), 7.33 (t, 1H, CHF₂) ppm.

The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.


Example I16: Preparation of 1-(4-methoxy-benzyl)-5-trifluoromethyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-(4-methoxy-benzyl)-5-trifluoromethyl-3*H*-[1,2,3]-triazole-4-carboxylic acid ethyl ester



5


- Ethyl 4,4,4-trifluoro-2-butynecarboxylate (prepared according to Organic Syntheses, 1992, 70, 246-55) (1.65 g, 10.1 mmol) was added to a solution of 4-methoxybenzyl azide (preparation described in e.g. J. Chem. Soc., Perkin Trans. 1, 1982 (2), 627-630) (1.65 g, 9.9 mmol) in toluene (10 ml) and the reaction mixture was stirred at room temperature for 16 hours. The mixture was concentrated and the residue purified by column chromatography on silica gel (eluent: ethyl acetate / *iso*-hexane) to give a 1.4 : 1 mixture of 1-(4-methoxybenzyl)-5-trifluoromethyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-(4-methoxybenzyl)-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (2.85 g, 87% yield).
- 15 Isomer 1 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 3.8 (s, 3H, Me), 4.4 (q, 2H, CH₂), 5.85 (s, 2H, CH₂), 6.9 (d, 2H, CH), 7.35 (d, 2H, CH) ppm.
- Isomer 2 (major) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 3.8 (s, 3H, Me), 4.45 (q, 2H, CH₂), 5.7 (s, 2H, CH₂), 6.85 (d, 2H, CH), 7.2 (d, 2H, CH) ppm.

Example I17: Preparation of 5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester



The 1.4 : 1 mixture of 1-(4-methoxy-benzyl)-5-trifluoromethyl-1*H*-
 5 [1,2,3]triazole-4-carboxylic acid ethyl ester and 3-(4-methoxy-benzyl)-5-trifluoromethyl-
 3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (2.85 g, 8.66 mmol) (Example I16) was
 dissolved in trifluoroacetic acid (TFA) (15 ml) and the mixture was heated to 60°C for 2
 hours. The reaction mixture was concentrated and the residue purified by column
 chromatography on silica gel (eluent: methanol / dichloromethane) to give 5-
 10 trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (1.75 g, 96.6% yield).
¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 4.5 (q, 2H, CH₂), 12.2-12.6 (bs, 1H, NH)
 ppm.

Example I18: Preparation of 2-methyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic
 15 acid ethyl ester, 3-methyl-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl
 ester and 1-methyl-5-trifluoromethyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester



5-Trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (2.1 g, 10.0
 mmol) (Example I17) was dissolved in acetonitrile (15 ml) and methyl iodide (1.12 ml,
 20 12.0 mmol) and potassium carbonate (2.76 g, 20.0 mmol) were added at room tempera-
 ture. The reaction mixture was stirred at room temperature for 16 hours. The reaction
 mixture was diluted with dichloromethane (50 ml) and water (50 ml). The phases were
 separated and the aqueous phase was extracted several times with dichloromethane. The
 combined organic extracts were dried over magnesium sulfate and concentrated. The

residue was purified by column chromatography on silica gel (eluent: ethyl acetate / *iso*-hexane) to give a 64:30:6 mixture of 2-methyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester, 3-methyl-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 1-methyl-5-trifluoromethyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (1.71 g, 76% yield).

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 4.32 (s, 3H, Me), 4.45 (q, 2H, CH₂) ppm.

Isomer 2 (middle) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 4.38 (s, 3H, Me), 4.45 (q, 2H, CH₂) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 4.30 (m, 3H, Me), 4.45 (q, 2H, CH₂) ppm.

The same method was used with ethyl iodide as reagent to give 2-ethyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-ethyl-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (3.4:1 mixture).

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.65 (t, 3H, Me), 4.45 (q, 2H, CH₂), 4.6 (q, 2H, CH₂) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.55 (t, 3H, Me), 4.45 (q, 2H, CH₂), 4.8 (q, 2H, CH₂) ppm.

20

The same method was used with *iso*-propyl iodide as reagent to give 2-*iso*-propyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-*iso*-propyl-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (4.5:1 mixture).

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.65 (d, 6H, Me), 4.45 (q, 2H, CH₂), 4.95-4.5 (m, 1H, CH) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.7 (d, 6H, Me), 4.45 (q, 2H, CH₂), 5.4-5.5 (m, 1H, CH) ppm.

The same method was used with cyclopentyl iodide as reagent to give 2-cyclopentyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester.

¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.7-1.8 (m, 2H, CH₂), 1.9-2.0 (m, 2H, CH₂), 2.2-2.3 (m, 4H, CH₂), 4.45 (q, 2H, CH₂), 5.1 (m, 1H, CH) ppm.

30

The same method was used with allyl iodide as reagent to give 2-allyl-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-allyl-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (4:1 mixture).

Isomer 1 (major): ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 4.45 (q, 2H, CH₂), 5.1 (d, 2H, CH₂), 5.35-5.45 (m, 2H, CH₂), 6.0-6.1 (m, 1H, CH) ppm.

The same method was used with 2-methoxy-ethyl iodide as reagent to give 2-(2-methoxy-ethyl)-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-(2-methoxy-ethyl)-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (4:1 mixture).

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 3.35 (s, 3H, Me), 3.9 (t, 2H, CH₂), 4.45 (q, 2H, CH₂), 4.7 (t, 2H, CH₂) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 3.3 (s, 3H, Me), 3.8 (t, 2H, CH₂), 4.45 (q, 2H, CH₂), 4.95 (t, 2H, CH₂) ppm.


The same method was used with cyclobutylmethyl iodide as reagent to give 2-(cyclobutyl-methyl)-5-trifluoromethyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 3-(cyclobutyl-methyl)-5-trifluoromethyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (4:1 mixture).

Isomer 1 (major) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.8-2.0 (m, 4H, CH₂), 2.0-2.15 (m, 2H, CH₂), 2.95-3.1 (m, 1H, CH), 4.55 (q, 2H, CH₂), 4.65 (d, 2H, CH₂) ppm.

Isomer 2 (minor) ¹H-NMR (400 MHz, CDCl₃): 1.4 (t, 3H, Me), 1.8-2.0 (m, 4H, CH₂), 2.0-2.15 (m, 2H, CH₂), 2.85-2.95 (m, 1H, CH), 4.55 (q, 2H, CH₂), 4.78 (d, 2H, CH₂) ppm.

The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.

Example I19: Preparation of 2-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 3-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester



To a solution of 2*H*-[1,2,3]triazole-4-carboxylic acid (734 mg, 6.5 mmol) in
5 toluene (10 ml), was added trimethylorthoacetate (2.48 ml, 19.5 mmol). The reaction
mixture was heated at reflux for 16 hours. The reaction mixture was allowed to cool to
room temperature and was concentrated. The residue was purified by column chromato-
graphy on silica gel (eluent: 10-30% ethyl acetate in hexane) to give 2-methyl-2*H*-
[1,2,3]triazole-4-carboxylic acid methyl ester (isomer A) (40 mg, 4% yield) and 3-
10 methyl-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester (isomer B) (223 mg, 24%
yield).


Isomer A ¹H-NMR (400 MHz, CDCl₃): 3.96 (s, 3H, Me), 4.28 (s, 3H, Me), 8.05 (s, 1H, CH) ppm.

15 The same method was used with triethylorthoacetate as reagent to give 2-ethyl-
2*H*-[1,2,3]triazole-4-carboxylic acid methyl ester (isomer A) and 3-ethyl-3*H*-[1,2,3]-
triazole-4-carboxylic acid methyl ester (isomer B).

Isomer A ¹H-NMR (400 MHz, CDCl₃): 1.41 (t, 3H, Me), 1.60 (t, 3H, Me), 4.43 (q, 2H, CH₂), 4.55 (q, 2H, CH₂), 8.04 (s, 1H, CH) ppm.


The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.

25 Example I20: Preparation of 4,5-dibromo-1*H*-[1,2,3]triazole



To a solution of 1*H*-[1,2,3]triazole (1.26 ml, 21.7 mmol) in water (10 ml) at 50°C, was added bromine (1.5 ml, 29 mmol). The reaction mixture was stirred at 50°C for 1.5 hours. The white solid (2.375 g) was isolated via filtration and washed with water (5 ml). To the combined filtrates was added more bromine (1.5 ml, 29 mmol). The reaction mixture was stirred at room temperature for 20 hours. More white solid (1.83 g) was isolated via filtration and washed with water (5 ml). To the combined filtrates was added more bromine (1.5 ml, 29 mmol). The reaction mixture was stirred at room temperature for 20 hours. More white solid (375 mg) was isolated via filtration and washed with water (5ml). The white solids were combined and dried to give 4,5-dibromo-1*H*-[1,2,3]-triazole (4.92 g, 93% yield). M.p. 194.7°C.


Example I21: Preparation of 4,5-dibromo-1-methyl-1*H*-[1,2,3]triazole and 4,5-dibromo-2-methyl-2*H*-[1,2,3]triazole



To a solution of 4,5-dibromo-1*H*-[1,2,3]triazole (2.26 g, 10 mmol) (Example I20) and triethyl amine (1.5 ml, 10 mmol) in dichloromethane (50 ml), was added methyl iodide (625 μ l, 10 mmol). The reaction mixture was stirred at room temperature for 24 hours. More triethyl amine (0.75 ml, 5 mmol) and more methyl iodide (312 μ l, 5 mmol) were added and the mixture was stirred for 3 hours. The reaction mixture was quenched by addition of aqueous ammonium chloride (saturated) (15 ml). The phases were separated and the organic phase was dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: 10-30% ethyl acetate in hexane) to give 4,5-dibromo-2-methyl-2*H*-[1,2,3]triazole (isomer B) (625 mg, 26% yield) and 4,5-dibromo-1-methyl-1*H*-[1,2,3]triazole (isomer A) (825 mg, 34% yield).


Isomer A ¹H-NMR (400 MHz, CDCl₃): 4.09 (s, 3H, Me) ppm.

Isomer B ¹H-NMR (400 MHz, CDCl₃): 4.18 (s, 3H, Me) ppm.

Example I22: Preparation of 4-bromo-1,5-dimethyl-1*H*-[1,2,3]triazole

To a solution of 4,5-dibromo-1-methyl-1*H*-[1,2,3]triazole and 4,5-dibromo-2-methyl-2*H*-[1,2,3]triazole (1.5 g, 6.23 mmol) (Example I21) in tetrahydrofuran (25 ml) at -80°C, was slowly added n-butyl lithium (2.5M in THF) (3 ml, 7.48 mmol) followed 20 minutes later by methyl iodide (775 μ l, 12.46 mmol). The reaction mixture was stirred at -80°C for 2 hours. The reaction mixture was allowed to warm to room temperature and quenched with by addition of aqueous hydrochloric acid (1M). The mixture was extracted with dichloromethane, the organic extract dried over magnesium sulfate and concentrated to give a mixture of 4-bromo-1,5-dimethyl-1*H*-[1,2,3]triazole (isomer A) and 4-bromo-2,5-dimethyl-2*H*-[1,2,3]triazole (isomer B) (1.096 g, 89% yield). Isomer A ¹H-NMR (400 MHz, CDCl₃): 2.30 (s, 3H, Me), 4.00 (s, 3H, Me) ppm. Isomer B ¹H-NMR (400 MHz, CDCl₃): 2.24 (s, 3H, Me), 4.10 (s, 3H, Me) ppm.

Example I23: Preparation of 4-bromo-5-bromomethyl-1-methyl-1*H*-[1,2,3]triazole and 4-bromo-5-bromomethyl-2-methyl-2*H*-[1,2,3]triazole




The mixture of 4-bromo-1,5-dimethyl-1*H*-[1,2,3]triazole and 4-bromo-2,5-dimethyl-2*H*-[1,2,3]triazole (Example I22) (950mg, 4.32 mmol) were dissolved in carbon tetrachloride (15ml). N-bromosuccinimide (NBS) (845mg, 4.75 mmol) and 2,2'-azobisisobutyronitrile (AIBN) (71 mg, 0.43 mmol) were added under nitrogen. The reaction mixture was stirred and irradiated with a UV lamp. After a short time, the mixture was refluxing with the heat of the lamp. The mixture was filtered, the solid was washed with dichloromethane and the combined filtrates were concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give 4-bromo-

5-bromomethyl-1-methyl-1*H*-[1,2,3]triazole (isomer C) (422 mg, 38% yield) and 4-bromo-5-bromomethyl-2-methyl-2*H*-[1,2,3]triazole (isomer D) (373 mg, 34% yield). Isomer C ¹H-NMR (400 MHz, CDCl₃): 4.12 (s, 3H, Me), 4.45 (s, 2H, CH₂) ppm. Isomer D ¹H-NMR (400 MHz, CDCl₃): 4.17 (s, 3H, Me), 4.45 (s, 2H, CH₂) ppm.

5

The bromomethyl intermediates were coupled as described in Example I39.

Example I24: Preparation of 5-hydroxy-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester




10

4-Methoxybenzyl azide (preparation described in e.g. J. Chem. Soc., Perkin Trans. 1, 1982 (2), 627-630) (42 g, 0.253 mol) was dissolved in dry dimethylsulfoxide (272 ml) and powdered potassium carbonate (139 g, 1 mol) was added. The reaction mixture was stirred at room temperature while diethyl malonate (56 g, 0.35 mol) was added. The reaction mixture was stirred at 40°C for 72 hours. The reaction mixture was cooled to 0°C and quenched by addition of aqueous hydrochloric acid (5M) (675 ml). The mixture was stirred at room temperature for 2 hours. The solid was isolated via filtration, washed with water and hexane and dried to give 5-hydroxy-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester as an off white solid (47.5 g, 68% yield). ¹H-NMR (400 MHz, CDCl₃): 1.29 (t, 3H, Me), 3.72 (s, 3H, Me), 4.25 (q, 2H, CH₂), 5.27 (s, 2H, CH₂), 7.07 (q, 4H, CH) ppm.

20

Example I25: Preparation of 5-methoxy-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester



5-Hydroxy-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester (26.18 g, 0.944 mol) (Example I24) was dissolved in dry N,N-dimethylformamide (300 ml) and rhodium(II) acetate dimer (300 mg) was added. The reaction mixture was cooled to 20°C and (trimethylsilyl)diazomethane (TMSCHN₂) (2M in diethyl ether) (142 ml, 0.284 mol) was added over 2 hours and the reaction mixture stirred at room temperature for 16 hours. The reaction mixture was cooled to 0°C and quenched by sequential addition of methanol (75 ml), glacial acetic acid (5 ml) and water (1 ml). The mixture was extracted three times with ethyl acetate. The combined organic extracts were washed three times with brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: 10-55% ethyl acetate in hexane) to give 5-methoxy-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester as a straw coloured oil (15.2 g, 55% yield).
¹H-NMR (400 MHz, CDCl₃): 1.41 (q, 3H, Me), 3.80 (s, 3H, Me), 4.13 (s, 3H, Me), 4.41 (t, 2H, CH₂), 5.31 (s, 2H, CH₂), 7.1 (q, 4H, CH) ppm.

5-Methoxy-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester was deprotected as described in Example I13 to give 5-methoxy-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester.

¹H-NMR (400 MHz, CDCl₃): 1.41 (t, 3H, Me), 4.11 (s, 3H, Me), 4.47 (q, 2H, CH₂) ppm.

5-Methoxy-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester was methylated with methyl iodide according to the method described in Example I14 to give 5-methoxy-1-methyl-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester (isomer A) and 5-methoxy-2-methyl-2H-[1,2,3]triazole-4-carboxylic acid ethyl ester (isomer B).


Isomer A $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.39 (q, 3H, Me), 4.15 (s, 3H, Me), 4.24 (s, 3H, Me), 4.40 (q, 2H, CH_2) ppm.

Isomer B $^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.35 (t, 3H, Me), 3.99 (s, 3H, Me), 4.07 (s, 3H, Me), 4.36 (q, 2H, CH_2) ppm.

5

The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.

10 Example I26: Preparation of 5-difluoromethoxy-1-(4-methoxy-benzyl)-1H-[1,2,3]-triazole-4-carboxylic acid ethyl ester



To a solution of 5-hydroxy-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester (1.0 g, 3.606 mmol) (Example I24) in N,N-dimethylformamide (18 ml) was added potassium carbonate (1.568 g, 11.36 mmol). The reaction mixture was heated to 80°C and ethyl 2-chloro-2,2-difluoroacetate (1.715 g, 10.8 mmol) added at 80°C over 10 minutes. The reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was allowed to cool to room temperature and was quenched by addition of water (5 ml), ethyl acetate (10 ml) and aqueous hydrochloric acid (2M) (9 ml). The phases were separated and the aqueous phase extracted twice with more ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: 10-40% ethyl acetate in hexane) to give 5-difluoromethoxy-1-(4-methoxy-benzyl)-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester of a straw coloured oil which solidified on standing (0.726 g, 62% yield).

¹H-NMR (400 MHz, CDCl₃): 1.41 (t, 3H, Me), 3.80 (s, 3H, Me), 4.43 (q, 2H, CH₂), 5.39 (s, 2H, CH₂), 6.88 (d, 2H, CH), 7.3 (d, 2H, CH), 7.32 (t, 1H, CHF₂) ppm.

5-Difluoromethoxy-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester was deprotected as described in Example I13 to give 5-difluoromethoxy-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester.

¹H-NMR (400 MHz, CDCl₃): 1.43 (t, 3H, Me), 4.48 (t, 2H, CH₂), 7.05 (t, 1H, CHF₂) ppm.


5-Difluoromethoxy-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester was methylated with methyl iodide according to the method described in Example I14 to give 5-difluoromethoxy-1-methyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (isomer A) and 5-difluoromethoxy-2-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (isomer B).

Isomer A ¹H-NMR (400 MHz, CDCl₃): 1.41 (t, 3H, Me), 4.49 (s, 3H, Me), 4.41 (q, 2H, CH₂), 7.19 (t, 1H, CHF₂) ppm.

Isomer B ¹H-NMR (400 MHz, CDCl₃): 1.41 (t, 3H, Me), 4.18 (s, 3H, Me), 4.42 (q, 2H, CH₂), 6.92 (t, 1H, CHF₂) ppm.

The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.

Example I27: Preparation of 2-(4-bromo-4,4-difluoro-but-2-ynyloxy)-tetrahydro-pyran



2-Prop-2-ynyloxy-tetrahydro-pyran (10.0 g, 71.3 mmol) was dissolved in dry tetrahydrofuran (175 ml) under nitrogen and the solution was cooled to -40°C. n-Butyl lithium (1.6 M in hexane) (44.6 ml, 71.3 mmol) was added over 5 minutes, keeping the temperature between -35°C and -40°C. The reaction was stirred for 15 minutes, then dibromodifluoromethane (14.89 g, 71.3 mmol) was added in one portion and the reaction mixture was allowed to warm to room temperature over 1 hour. The reaction mixture was

quenched with aqueous potassium dihydrogenphosphate (10%) and extracted three times with diethyl ether. The combined organic extracts were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: diethyl ether / hexane) to give 2-(4-bromo-4,4-difluoro-but-2-ynoxy)-tetrahydro-pyran as a colourless oil (17.6 g, 91.7% yield).
¹H-NMR (400 MHz, CDCl₃): 1.5-1.9 (m, 6H, CH₂), 3.5-3.6 (m, 1H, CH₂), 3.8-3.9 (m, 1H, CH₂), 4.4 (m, 2H, CH₂), 4.8 (m, 1H, CH) ppm.


The same method was used with acetic anhydride as the reagent to give 5-(tetrahydro-pyran-2-yloxy)-pent-3-yn-2-one.

¹H-NMR (400 MHz, CDCl₃): 1.5-1.85 (m, 6H, CH₂), 1.9-2.08 (s, 3H, Me), 3.53 (m, 1H, CH₂), 3.82 (m, 1H, CH₂), 4.29 (m, 1H, CH₂), 4.33 (m, 1H, CH₂), 4.8 (m, 1H, CH) ppm.

The same method was used with methyl chloroformate as the reagent to give 5-(tetrahydro-pyran-2-yloxy)-pent-3-yn-2-one.

¹H-NMR (400 MHz, CDCl₃): 1.5-1.85 (m, 6H, CH₂), 3.56 (m, 1H, CH₂), 3.8 (s, 3H, Me), 3.82 (m, 1H, CH₂), 4.4 (s, 2H, CH₂), 4.81 (m, 1H, CH) ppm.

Example I28: Preparation of 4-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1H-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-4-(tetrahydro-pyran-2-yloxymethyl)-1H-[1,2,3]triazole




- 2-(4-Bromo-4,4-difluoro-but-2-ynoxy)-tetrahydropyran (Example I27) (10.0 g, 37 mmol) was dissolved in toluene (250 ml), 4-methoxybenzyl azide (preparation described in e.g. J. Chem. Soc., Perkin Trans. 1, 1982 (2), 627-630) (6.0 g, 37 mmol) was added and the mixture was heated to reflux for 16 hours. The mixture was cooled to room temperature and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give a 2:1-mixture of 4-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1*H*-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-4-(tetrahydro-pyran-2-yloxy-methyl)-1*H*-[1,2,3]triazole (14.39 g, 89% yield).
- Major isomer ¹H-NMR (400 MHz, CDCl₃): 1.5-1.8 (m, 6H, CH₂), 3.5-3.6 (m, 2H, CH₂), 3.8 (s, 3H, Me), 4.55 (d, 1H, CH₂), 4.55-4.6 (m, 1H, CH), 4.75 (d, 1H, CH₂), 5.5 (s, 2H, CH₂), 6.85 (d, 2H, CH), 7.2 (d, 2H, CH) ppm.
- Minor isomer ¹H-NMR (400 MHz, CDCl₃): 1.5-1.8 (m, 6H, CH₂), 3.8 (s, 3H, Me), 3.85-3.95 (m, 2H, CH₂), 4.65 (d, 1H, CH₂), 4.75-4.8 (m, 1H, CH), 4.9 (d, 1H, CH₂), 5.52 (s, 2H, CH₂), 6.85 (d, 2H, CH), 7.25 (d, 2H, CH) ppm.

- The same method was used with 5-(tetrahydro-pyran-2-yloxy)-pent-3-yn-2-one as the starting material to give a mixture of 1-[1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1*H*-[1,2,3]triazol-4-yl]-ethanone and 1-[3-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-3*H*-[1,2,3]triazol-4-yl]-ethanone.
- ¹H-NMR (400 MHz, CDCl₃): 1.5-1.85 (m, 6H, CH₂), 2.63-2.7 (s, 3H, Me), 3.5-3.58 (m, 1H, CH₂), 3.79-3.80 (s, 3H, Me), 4.63-4.73 (m, 1H, CH), 4.8 (m, 1H, CH₂), 5.06 (d, 2H, CH₂), 5.68-5.8 (s, 2H, CH₂), 6.84 (m, 2H, CH), 7.22-7.3 (m, 2H, CH) ppm.

- The same method was used with 4-(tetrahydro-pyran-2-yloxy)-but-2-ynoic acid methyl ester as the starting material to give a mixture of 1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 3-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester.
- ¹H-NMR (400 MHz, CDCl₃): 1.5-1.8 (m, 6H, CH₂), 3.54-3.85 (m, 1H, CH₂), 3.78-3.79 (s, 3H, Me), 3.91-3.95 (s, 3H, Me), 4.63-4.82 (m, 1H, CH), 4.74-4.85 (d, 1H, CH₂), 4.99-5.01 (d, 2H, CH₂), 5.64-5.82 (s, 2H, CH₂), 6.84 (m, 2H, CH), 7.2-7.3 (m, 2H, CH) ppm.

Example I29: Preparation of [5-(bromo-difluoro-methyl)-3-(4-methoxy-benzyl)-3H-[1,2,3]triazol-4-yl]-methanol and [5-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-1H-[1,2,3]triazol-4-yl]-methanol



5

The 2:1-mixture of 4-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1H-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-4-(tetrahydro-pyran-2-yloxymethyl)-1H-[1,2,3]triazole (Example I28) (10.5 g, 24.8 mmol) was dissolved in methanol (100 ml), and p-toluene sulfonic acid monohydrate (5.4 g, 28.3 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the residue purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give a 2:1-mixture of [5-(bromo-difluoro-methyl)-3-(4-methoxy-benzyl)-3H-[1,2,3]triazol-4-yl]-methanol and [5-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-1H-[1,2,3]triazol-4-yl]-methanol as a colourless oil (7.04 g, 82% yield).

15

Major isomer ¹H-NMR (400 MHz, CDCl₃): 3.8 (s, 3H, Me), 4.81 (s, 2H, CH₂), 5.8 (s, 2H, CH₂), 6.85 (d, 2H, CH), 7.2 (d, 2H, CH) ppm.

Minor isomer ¹H-NMR (400 MHz, CDCl₃): 3.8 (s, 3H, Me), 4.83 (s, 2H, CH₂), 5.9 (s, 2H, CH₂), 6.85 (d, 2H, CH), 7.25 (d, 2H, CH) ppm.


20

The same method was used with the mixture of 1-[1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1H-[1,2,3]triazol-4-yl]-ethanone and 1-[3-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-3H-[1,2,3]triazol-4-yl]-ethanone as the

starting material to give a mixture of 1-[5-hydroxymethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-yl]-ethanone and 1-[5-hydroxymethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-yl]-ethanone. The mixture was used without further purification.

5 The same method was used with the mixture of 1-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 3-(4-methoxy-benzyl)-5-(tetrahydro-pyran-2-yloxymethyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester as the starting material to give a mixture of 5-hydroxymethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 5-hydroxymethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester. The
10 mixture was used without further purification.

Example I30: Preparation of 4-(bromo-difluoro-methyl)-5-bromomethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-4-bromomethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole
15



The 2:1-mixture of [5-(bromo-difluoro-methyl)-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-yl]-methanol and [5-(bromo-difluoro-methyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-yl]-methanol (Example I29) (7.0 g, 20 mmol) was dissolved in dichloro-
20 methane (100 ml) and triphenyl phosphine (6.3 g, 24.0 mmol) was added. The reaction mixture was cooled to 0°C and a solution of carbon tetrabromide (7.96 g, 24.0 mmol) in dichloromethane (10 ml) was added dropwise. The reaction mixture was stirred for 2


hours at 0°C, concentrated and the residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give a 3:1-mixture of 4-(bromo-difluoromethyl)-5-bromomethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-4-bromomethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole as a colourless oil (7.35 g, 89% yield).

Major isomer ¹H-NMR (400 MHz, CDCl₃): 3.8 (s, 3H, Me), 4.35 (s, 2H, CH₂), 5.61 (s, 2H, CH₂), 6.9 (d, 2H, CH), 7.25 (d, 2H, CH) ppm.

Minor isomer ¹H-NMR (400 MHz, CDCl₃): 3.78 (s, 3H, Me), 4.6 (s, 2H, CH₂), 5.61 (s, 2H, CH₂), 6.9 (d, 2H, CH), 7.25 (d, 2H, CH) ppm.

10

Example I31: Preparation of methanesulfonic acid 5-acetyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-ylmethyl ester and methanesulfonic acid 5-acetyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-ylmethyl ester



15


To a solution of the mixture of 1-[5-hydroxymethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-yl]-ethanone and 1-[5-hydroxymethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-yl]-ethanone (3.19 g, 12.2 mmol) in dichloromethane (75 ml) was added methanesulfonyl chloride (0.95 ml, 12.2 mmol) followed by addition of triethylamine (1.87 ml, 13.4 mmol) at room temperature. The reaction mixtures were stirred at room temperature for 2 hours. The reaction mixtures were concentrated and re-dissolved in acetonitrile. The solids were removed by filtration and washed with acetonitrile. The combined filtrates were concentrated to give a mixture of methanesulfonic acid 5-acetyl-

20

1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-ylmethyl ester and methanesulfonic acid 5-acetyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-ylmethyl ester. The mixture was used without further purification.

5 The same method was used with the mixture of 5-hydroxymethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 5-hydroxymethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester as the starting material to give a mixture of 5-methanesulfonyloxymethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 5-methanesulfonyloxymethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester. The mixture was used without further purification.

Example I32: Preparation of 4-(bromo-difluoro-methyl)-5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2*H*-[1,2,3]triazole



20 The mixture of 4-(bromo-difluoro-methyl)-5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole (Example I40) (200 mg, 0.43 mmol) was dissolved in trifluoroacetic acid (245 mg, 2.15 mmol) and anisole (69 mg, 0.64 mmol). The mixture was heated to 60-65°C for 3 hours. The mixture was diluted with fluorobenzene and concentrated.

The residue was dissolved in dry methanol (10 ml) and trimethylsilyl diazomethane (TMSCHN₂) (2M in hexane) (3 ml, 6 mmol) was added dropwise over 10 minutes. More trimethylsilyl diazomethane (TMSCHN₂) (2M in hexane) (4 ml, 8 mmol) was added and the mixture stirred for 15 minutes. The reaction mixture was concentrated and the residue purified by column chromatography on silica gel (eluent: ethyl acetate / hexane), to give 4-(bromo-difluoro-methyl)-5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl 2*H*-[1,2,3]triazole (110 mg, 72% yield).

¹H-NMR (400 MHz, CDCl₃): 1.41 (s, 6H, Me), 2.82 (s, 2H, CH₂), 4.21 (s, 3H, Me), 4.4 (s, 2H, CH₂) ppm.

10

The same method was used with the mixture of 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-yl]-ethanone and 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-yl]-ethanone (Example I40) as the starting material to give 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2*H*-[1,2,3]triazol-4-yl]-ethanone.

15

¹H-NMR (400 MHz, CDCl₃): 1.44 (s, 6H, Me), 2.72 (s, 3H, Me), 2.83 (s, 2H, CH₂), 4.61 (s, 2H, CH₂) ppm.

1-[5-(5,5-Dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2*H*-[1,2,3]triazol-4-yl]-ethanone was reacted with methyl iodide as described in Example I14 to give 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2*H*-[1,2,3]triazol-4-yl]-ethanone.

20

¹H-NMR (400 MHz, CDCl₃): 1.41 (s, 6H, Me), 2.83 (s, 2H, CH₂), 3.96 (s, 3H, Me), 4.22 (s, 3H, Me), 4.58 (s, 2H, CH₂) ppm.


25

The same method was used with the mixture of 5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl ester (Example I40) as the starting material to give 5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2*H*-[1,2,3]triazole-4-carboxylic acid methyl ester, which was reacted with methyl iodide as described in Example I14 to give 5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid methyl ester.

30

$^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.41 (s, 6H, Me), 2.87 (s, 2H, CH_2), 3.97 (s, 3H, Me), 4.3 (s, 3H, Me), 4.57 (s, 2H, CH_2) ppm.


Example I33: Preparation of 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2H-[1,2,3]triazol-4-yl]-ethanol



1-[5-(5,5-Dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2H-[1,2,3]triazol-4-yl]-ethanone (Example I32) (408 mg, 1.52 mmol) was dissolved in methanol (10 ml) at room temperature. Sodium borohydride (29 mg, 0.76 mmol) was added in one portion at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by addition of water and the mixture concentrated. The residue was partitioned between dichloromethane and water and the phases separated. The organic extract was dried over magnesium sulfate and concentrated to yield 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2H-[1,2,3]triazol-4-yl]-ethanol as a colourless oil (375 mg, 91% yield).

$^1\text{H-NMR}$ (400 MHz, CDCl_3): 1.39 (s, 3H, Me), 1.4 (s, 3H, Me), 1.58 (d, 3H, Me), 2.8 (s, 2H, CH_2), 4.11 (s, 3H, Me), 4.36 (s, 2H, CH_2), 5.08 (m, 1H, CH) ppm.

Example I34: Preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-5-(1-fluoro-ethyl)-2-methyl-2H-[1,2,3]triazole




To a solution of 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-2H-[1,2,3]triazol-4-yl]-ethanol (Example I33) (375 mg, 1.39 mmol) in dichloromethane (10 ml) under nitrogen was added (diethylamino)sulfur trifluoride (DAST) (0.46 ml, 3.48 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by addition of

aqueous sodium bicarbonate (saturated) and the mixture extracted with dichloromethane. The combined organic extracts were dried over magnesium sulfate and concentrated to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-5-(1-fluoro-ethyl)-2-methyl-2*H*-[1,2,3]triazole as an oil (282 mg, 74% yield).

- 5 ¹H-NMR (400 MHz, CDCl₃): 1.39 (s, 3H, Me), 1.41 (s, 3H, Me), 1.76 (d, 3H, Me), 2.81 (s, 2H, CH₂), 4.15 (s, 3H, Me), 4.3 (d, 1H, CH₂), 4.4 (d, 1H, CH₂), 5.86 (m, 1H, CH) ppm.

Example I35: Preparation of 1,5-dimethyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester


10 ester



- 2-Diazo-3-oxo-butiric acid ethyl ester (5 g, 32 mmol) was dissolved in tetrahydrofuran (50 ml) and acetic acid (6 ml) and methylhydrazine was passed through the solution until a white precipitate crystallised out. More acetic acid (10 ml) was added and the solution was refluxed for 2 days. The reaction mixture was concentrated, the residue diluted with water, extracted with ethyl acetate, washed three times with aqueous sodium bicarbonate (saturated), water and brine, dried and concentrated to give 1,5-dimethyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (4.4 g, 81% yield).
- 15 ¹H-NMR (400 MHz, CDCl₃): 1.41 (t, 3H, Me), 2.49 (s, 3H, Me), 3.92 (s, 3H, Me), 4.3 (q, 2H, CH₂) ppm.
- 20

The ester was reduced as described in Example I6, the alcohol brominated as described in Example I7, and the bromomethyl intermediate coupled as described in Example I39.

Example I36: Preparation of 5-cyclopropyl-1-methyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester




3-Cyclopropyl-2-diazo-3-oxo-propionic acid ethyl ester (preparation described in
 5 J. Org. Chem. 1950 (15) 74-80) (1 g, 5.5 mmol) was dissolved in dichloroethane (15 ml).
 Methylamine (340 mg, 10.9 mmol) was added followed by titanium tetrachloride (1M in
 dichloromethane) (5.5 ml, 5.5 mmol) to give an orange precipitate. The reaction mixture
 was heated to reflux. After addition of water, the mixture was concentrated, extracted
 with ethyl acetate, washed with aqueous sodium bicarbonate (saturated), water and brine,
 10 dried over magnesium sulfate and concentrated. The residue was purified by column
 chromatography on silica gel (eluent: ethyl acetate, iso-hexane) to give 5-cyclopropyl-1-
 methyl-1*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (740 mg, 71 % yield).
¹H-NMR (400 MHz, CDCl₃): 0.98 (m, 2H, CH₂), 1.19 (m, 2H, CH₂), 1.42 (t, 3H, Me),
 1.84 (m, 1H, CH), 4.09 (s, 3H, Me), 4.41 (q, 2H, CH₂) ppm.

15

The ester was reduced as described in Example I6, the alcohol brominated as
 described in Example I7, and the bromomethyl intermediate coupled as described in
 Example I39.

20 Example I37: Preparation of 5-cyclopropyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester




Ammonia (approximately 200 mg) was condensed into a flask at -78°C,
 dichloroethane (15ml) was added, followed by 3-cyclopropyl-2-diazo-3-oxo-propionic
 acid ethyl ester (preparation described in J. Org. Chem. 1950 (15) 74-80). Titanium
 25 tetrachloride (1M in dichloromethane) (5.5 ml, 5.5 mmol) was added to give an orange
 precipitate. The solution was warmed to room temperature, then heated to reflux for 16

hours. The reaction was quenched by addition of water (1 ml) and concentrated. The residue was extracted with ethyl acetate, washed with aqueous sodium bicarbonate (saturated), water and brine, dried over magnesium sulfate and concentrated to give 5-cyclopropyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester as an orange oil (960 mg, 96% yield) which solidified on standing.

¹H-NMR (400 MHz, CDCl₃): 1.03 (m, 2H, CH₂), 1.10 (m, 2H, CH₂), 1.40 (t, 3H, Me), 2.56 (m, 1H, CH), 4.44 (q, 2H, CH₂) ppm.

Example I38: Preparation of 5-cyclopropyl-2-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester and 5-cyclopropyl-3-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester



5-Cyclopropyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (Example I37) (110 mg, 0.61 mmol) was dissolved in *N,N*-dimethylformamide (5 ml), potassium carbonate (168 mg, 1.22 mmol) was added, followed by methyl iodide (0.057 ml, 0.91 mmol). The solution was stirred at room temperature for 3 hours. The reaction mixture was quenched by addition of water (10 ml) and the mixture extracted with ethyl acetate. The organic layer was washed with aqueous hydrochloric acid (1*N*), water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica (eluent: ethyl acetate, dichloromethane, iso-hexane) to give 5-cyclopropyl-2-methyl-2*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (51 mg, 43% yield) and 5-cyclopropyl-3-methyl-3*H*-[1,2,3]triazole-4-carboxylic acid ethyl ester (46 mg, 39% yield).

Isomer A ¹H-NMR (400 MHz, CDCl₃): 0.92 (m, 2H, CH₂), 1.02 (m, 2H, CH₂), 1.40 (t, 3H, Me), 2.50 (m, 1H, CH), 4.12 (s, 3H, Me), 4.42 (q, 2H, CH₂) ppm.


Isomer B ¹H-NMR (400 MHz, CDCl₃): 1.01 (m, 2H, CH₂), 1.12 (m, 2H, CH₂), 1.41 (t, 3H, Me), 2.39 (m, 1H, CH), 4.23 (s, 3H, Me), 4.41 (q, 2H, CH₂) ppm.

The esters were reduced as described in Example I6, the alcohols brominated as described in Example I7, and the bromomethyl intermediates coupled as described in Example I39.

5

3) Methods of couplings and oxidations

Example I39: Preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole and 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole



10

The 4:1-mixture of 4-bromomethyl-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole and 4-bromomethyl-2,5-dimethyl-2H-[1,2,3]triazole (954 mg, 4.59 mmol) (Example I7) was stirred in ethanol (15 ml) before thiourea (384 mg, 5.05 mmol) was added. The reaction mixture was stirred at room temperature until the entire solid had dissolved. 3-Methanesulfonyl-5,5-dimethyl-4,5-dihydro-isoxazole (prepared according to EP 1364946) (893 mg, 5.05 mmol) and the potassium carbonate (698 mg, 5.05 mmol) were added to the reaction mixture and the reaction mixture was heated at reflux for 2.5 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was partitioned between ethyl acetate (20 ml) and water (20 ml). The phases were separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to yield a 4:1-mixture of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole and 4-(5,5-dimethyl-4,5-dihydro-

25

isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2*H*-[1,2,3]triazole as a colourless oil (1.05 g, 89% yield).


¹H-NMR (400 MHz, CDCl₃): 1.41 (s, 6H, Me), 2.80 (s, 2H, CH₂), 4.17 (d, 3H, Me), 4.34 (s, 2H, CH₂), 5.52 (d, 2H, CH₂) ppm.

5 ¹H-NMR (400 MHz, CDCl₃): 1.42 (s, 6H, Me), 2.30 (s, 3H, Me), 2.82 (s, 2H, CH₂), 4.09 (s, 3H, Me), 4.27 (s, 2H, CH₂) ppm.

The same method was used with 4-bromomethyl-2-methyl-5-trifluoromethyl-2*H*-[1,2,3]triazole as the starting material to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2-methyl-5-trifluoromethyl-2*H*-[1,2,3]triazole.

¹H-NMR (400 MHz, CDCl₃): 1.43 (s, 6H, Me), 2.83 (s, 2H, CH₂), 4.23 (s, 3H, Me), 4.40 (s, 2H, CH₂) ppm.

15 Example I40: Preparation of 4-(bromo-difluoro-methyl)-5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole



20 4-(Bromo-difluoro-methyl)-5-bromomethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole and 5-(bromo-difluoro-methyl)-4-bromomethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole (Example I30) (687 mg, 1.67 mmol) and 2-(5,5-dimethyl-4,5-dihydro-isoxazol-3-yl)-isothiourea hydrochloride (prepared as described in WO 06/068092) (305 mg, 1.67 mmol) were dissolved in acetonitrile (10 ml). Potassium carbonate (576 mg,

4.17 mmol) was added and the mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched by addition of water and extracted several times with ethyl acetate. The combined organic extracts were washed with water, brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give the desired product as a 9:1-
5 mixture of isomers (660 mg, 86% yield).

¹H-NMR (400 MHz, CDCl₃) (major): 1.45 (s, 6H, Me), 2.74 (s, 2H, CH₂), 3.8 (s, 3H, Me), 4.31 (s, 2H, CH₂), 5.68 (s, 2H, CH₂), 6.89 (d, 2H, CH), 7.3 (d, 2H, CH) ppm.

¹H-NMR (400 MHz, CDCl₃) (minor): 1.45 (s, 6H, Me), 2.84 (s, 2H, CH₂), 3.8 (s, 3H, Me), 4.43 (s, 2H, CH₂), 5.6 (s, 2H, CH₂), 6.89 (d, 2H, CH), 7.3 (d, 2H, CH) ppm.
10


The same method was used with the mixture of methanesulfonic acid 5-acetyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-ylmethyl ester and methanesulfonic acid 5-acetyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-ylmethyl ester (Example I31) as the
15 starting material to give a mixture of 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazol-4-yl]-ethanone and 1-[5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazol-4-yl]-ethanone.

¹H-NMR (400 MHz, CDCl₃): 1.52 (s, 6H, Me), 2.68-2.73 (s, 2H, CH₂), 2.62-2.72 (s, 3H, Me), 3.8 (s, 3H, Me), 4.43-4.53 (s, 2H, CH₂), 5.77-5.81 (s, 2H, CH₂), 6.85 (m, 2H, CH),
20 7.2-7.3 (m, 2H, CH) ppm.

The same method was used with the mixture of 5-methanesulfonyloxymethyl-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 5-methanesulfonyloxymethyl-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl
25 ester (Example I31) as the starting material to give a mixture of 5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-1-(4-methoxy-benzyl)-1*H*-[1,2,3]triazole-4-carboxylic acid methyl ester and 5-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-3-(4-methoxy-benzyl)-3*H*-[1,2,3]triazole-4-carboxylic acid methyl
30 ester.

¹H-NMR (400 MHz, CDCl₃): 1.52-1.53 (s, 6H, Me), 2.75-2.85 (s, 2H, CH₂), 3.8 (s, 3H, Me), 3.92-3.97 (s, 3H, Me), 4.43-4.53 (s, 2H, CH₂), 5.77-5.81 (s, 2H, CH₂), 6.85 (m, 2H, CH), 7.2-7.3 (m, 2H, CH) ppm.


Example I41: Preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole



5

2-(5,5-Dimethyl-4,5-dihydro-isoxazol-3-yl)-disulfide (Example I5) (300 mg, 1.15 mmol) and sodium hydroxide (88 mg, 2.19 mmol) were dissolved in dry ethanol (10 ml) and sodium borohydride (88 mg, 2.30 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 10 minutes. 4-Bromomethyl-2,5-dimethyl-2H-[1,2,3]triazole (Example I7, Example I11) (460 mg, 2.42 mmol) was added. The reaction mixture stirred at room temperature for 30 minutes and then concentrated. The residue was partitioned between water and ethyl acetate. The phases were separated and the organic phase was washed water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: 0-50% ethyl acetate / hexane) to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (470 mg, 85% yield).
¹H-NMR (400 MHz, CDCl₃): 1.42 (s, 6H, Me), 2.30 (s, 3H, Me), 2.82 (s, 2H, CH₂), 4.09 (s, 3H, Me), 4.27 (s, 2H, CH₂) ppm.

Example I42: Alternative preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole




tert-Butyl lithium (1.7 M in hexane) (1.12 ml, 1.89 mmol) was added to diethyl ether (5 ml) at -78°C. A solution of 4-bromomethyl-2,5-dimethyl-2H-[1,2,3]triazole (Example I7, Example I11) (300 mg, 1.58 mmol) in diethyl ether (5 ml) was added at -78°C and the reaction mixture stirred at -78°C for 5 minutes. A solution of 2-(5,5-di-

25


methyl-4,5-dihydro-isoxazol-3-yl)-disulfide (Example I5) (410 mg, 1.58 mmol) in tetrahydrofuran (5 ml) was added at -78°C and the reaction mixture stirred at -78°C for 10 minutes. The reaction mixture was allowed to warm to room temperature within 1 hour. The reaction mixture was quenched by addition of aqueous ammonium chloride (saturated) and the mixture extracted with ethyl acetate. The combined organic extracts were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: 0-50% ethyl acetate / hexane) to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (154 mg, 41% yield).

Example I43: Alternative preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-yl-sulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole




2-(5,5-Dimethyl-4,5-dihydro-isoxazol-3-yl)-disulfide (Example I5) (137 mg, 0.53 mmol) was dissolved in N,N-dimethylformamide (4 ml) and potassium carbonate (290 mg, 2.1 mmol) and sodium hydroxymethylsulfinate (Rongalite) (323 mg, 2.1 mmol) were added. The mixture was cooled to 0°C and 4-bromomethyl-2,5-dimethyl-2H-[1,2,3]-triazole (Example I7, Example I11) (200 mg, 1.05 mmol) was added dropwise as a solution in N,N-dimethylformamide (3 ml). The mixture was stirred at room temperature for 1.5 hours and then poured into water. The mixture was extracted several times with diethyl ether. The combined organic extracts were washed three times with water, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / *iso*-hexane) to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (170 mg, 67.2%).

Example I44: Preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfinylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole



- 5 4-(5,5-Dimethyl-4,5-dihydro-isoxazole-3-sulfinylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (Example I39) (75% pure, 3.53g) was dissolved in dichloromethane and 3-chloroperoxybenzoic acid (MCPBA) (60% by weight) (4.2 g, 14.6 mmol) was added at 0°C. The mixture was stirred for 30 minutes at 0°C. The reaction mixture was quenched by addition of aqueous sodium metabisulfite (20%) (80 ml) and the mixture stirred for 10
- 10 minutes. The phases were separated and the aqueous phase was washed with aqueous sodium bicarbonate (saturated), water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / *iso*-hexane) to give 4-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfinylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (2.52 g, 89.7% yield)
- 15 ¹H-NMR (400 MHz, CDCl₃): 1.5 (s, 3H, Me), 1.51 (s, 3H, Me), 2.32 (s, 3H, Me), 3.05 (d, 1H, CH₂), 3.18 (d, 1H, CH₂), 4.1 (s, 3H, Me), 4.3 (d, 1H, CH₂), 4.35 (d, 1H, CH₂) ppm.

Example I45: Preparation of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfonylmethyl)-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole and 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfonylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole



5

The 4:1-mixture of 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole and 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (Example I39) (672 mg, 2.6 mmol) was dissolved in dichloromethane (30 ml) and 3-chloroperoxybenzoic acid (MCPBA) (1.46 g, 6.51 mmol) was added. The solution was stored at room temperature for 16 hours. The reaction mixture was quenched by addition of aqueous sodium metabisulfite (10%). The mixture was diluted with water and aqueous sodium hydroxide (2M) was added. The phases were separated and the aqueous phase extracted with dichloromethane. The combined organic extracts were washed twice with aqueous sodium hydroxide (2M), dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole (430 mg, 70% yield) as a white solid and 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfanylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (82 mg, 57% yield) as a white solid.

15

¹H-NMR (400 MHz, CDCl₃): 1.51 (s, 6H, Me), 3.05 (s, 2H, CH₂), 4.21 (s, 3H, Me), 4.77 (s, 2H, CH₂), 5.57 (d, 2H, CH₂) ppm.

¹H-NMR (400 MHz, CDCl₃): 1.50 (s, 6H, Me), 2.36 (s, 3H, Me), 3.01 (s, 2H, CH₂), 4.14 (s, 3H, Me), 4.64 (s, 2H, CH₂) ppm.


25

The same method was used with 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-yl-sulfonylmethyl)-2-methyl-5-trifluoromethyl-2H-[1,2,3]triazole as the starting material to give 4-(5,5-dimethyl-4,5-dihydro-isoxazol-3-ylsulfonylmethyl)-2-methyl-5-trifluoromethyl-2H-[1,2,3]triazole.

- 5 ¹H-NMR (400 MHz, CDCl₃): 1.51 (s, 6H, Me), 3.09 (s, 2H, CH₂), 4.29 (s, 3H, Me), 4.83 (s, 2H, CH₂) ppm.

4) Methods for halogenations and alkylations


- 10 Example P1: Preparation of 4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-difluoromethyl]-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole



- 4-(5,5-Dimethyl-4,5-dihydro-isoxazole-3-sulfonylmethyl)-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole (Example I45) (117 mg, 0.4 mmol) was stirred in dry tetrahydrofuran (2 ml) under nitrogen at 0°C. 1-Ethyl-2,2,4,4,4-pentakis(dimethylamino)-2-lambda⁵,4lambda⁵-catenadi(phosphazene) (P₂-Et) (0.28 ml, 0.82 mmol) was added dropwise, and then N-fluorobenzene sulfonimide (NFSI) (257 mg, 0.82 mmol) was added in one portion. The reaction was stirred for 1 hour at room temperature. The reaction mixture was concentrated and the residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give Compound No. 1.01 of Table 1 as a white solid (66 mg, 50% yield).
- 20

The same method was used to synthesise the following compounds:
Compound No. 1.05 and 1.09 of Table 1.

Example P2: Preparation of 4-[chloro-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-methyl]-5-fluoromethyl-2-ethyl-2H-[1,2,3]triazole




4-(5,5-Dimethyl-4,5-dihydro-isoxazole-3-sulfonylmethyl)-5-fluoromethyl-2-
 5 methyl-2H-[1,2,3]triazole (Example I45) (152 mg, 0.52 mmol) was dissolved in
 tetrahydrofuran (2 ml) at room temperature under nitrogen and 1-ethyl-2,2,4,4,4-
 pentakis(dimethylamino)-2-lambda⁵,4lambda⁵-catenadi-(phosphazene) (P₂-Et) (0.18 ml,
 0.55 mmol) was added. N-Chlorosuccinimide (NCS) (73 mg, 0.55 mmol) was then added
 in one portion, and the reaction mixture was stirred for 1 hour. The reaction mixture was
 10 concentrated and the residue was purified by column chromatography on silica gel
 (eluent: ethyl acetate / hexane) to give Compound No. 1.02 of Table 1 as a colourless oil
 (116 mg, 68% yield).

The same method was used to synthesise the following compound:

15 Compound No. 1.06 of Table 1.

Example P3: Preparation of 4-[chloro-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-fluoro-methyl]-5-fluoromethyl-2-methyl-2H-[1,2,3]triazole



20 4-[Chloro-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-methyl]-5-fluoro-
 methyl-2-ethyl-2H-[1,2,3]triazole (Example P2) (116 mg, 0.36 mmol) was dissolved in
 tetrahydrofuran (2 ml) under nitrogen and 1-ethyl-2,2,4,4,4-pentakis(dimethylamino)-2-
 lambda⁵,4lambda⁵-catenadi(phosphazene) (P₂-Et) (0.13 ml, 0.38 mmol) was added at
 room temperature. N-Fluorobenzene sulfonimide (NFSI) (118 mg, 0.38 mmol) was

added in one portion at room temperature and the reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was concentrated and the residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give Compound No. 1.03 of Table 1 as a white solid (85 mg, 69% yield).


5

The same method was used to synthesise the following compounds:

Compound No. 1.07 and 1.10 of Table 1.

Example P4: Preparation of 4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-fluoro-
methyl]-2,5-dimethyl-2H-[1,2,3]triazole

10




4-(5,5-Dimethyl-4,5-dihydro-isoxazole-3-sulfonylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (Example I45) (112 mg, 0.4 mmol) was stirred in dry tetrahydrofuran (3 ml) under nitrogen at 0°C. 1-*tert*-Butyl-2,2,4,4,4-pentakis(dimethylamino)-2- λ^5 ,-4 λ^5 -catenadi(phosphazene) (P_2-t-Bu) (2M in THF) (0.2 ml, 0.4 mmol) was added dropwise at 0°C, and N-fluorobenzene sulfonimide (NFSI) (130 mg, 0.4 mmol) was added in one portion at 0°C. The reaction was stirred for 30 minutes at room temperature. The reaction mixture was concentrated and the residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give Compound No. 1.04 of Table 1 as a white solid (35 mg, 29.3% yield).

20

The same method was used to synthesise the following compounds:

Compound No. 1.11, 1.12 and 1.28 of Table 1.


Example P5: Preparation of 4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfinyl)-difluoro-methyl]-2,5-dimethyl-2H-[1,2,3]triazole



4-(5,5-Dimethyl-4,5-dihydro-isoxazole-3-sulfinylmethyl)-2,5-dimethyl-2H-[1,2,3]triazole (Example I44) (200 mg, 0.78 mmol) and N-fluorobenzene sulfonimide (NFSI) (516 mg, 1.64 mmol) were dissolved in dry tetrahydrofuran under nitrogen and cooled to -78°C. Lithium hexamethyldisilazide (LiHMDS) (1M solution in THF) (1.64 ml, 1.64 mmol) was added dropwise at -78°C and the solution was stirred and allowed to warm slowly to -20°C over 3 hours. The reaction mixture was quenched at -20°C by addition of several drops of aqueous ammonium chloride (saturated). The mixture was allowed to warm to room temperature, concentrated onto silica gel and purified by column chromatography on silica gel (eluent: hexane / ethyl acetate) to give Compound No. 1.08 of Table 1 (160 mg, 70% yield).

The same method was used to synthesise the following compounds:
Compound No. 1.16, 1.18, 1.27, 1.36, 1.44, 1.47, 1.49, 1.51 and 1.58 of Table 1,
Compound No. 2.07 of Table 2, and
Compound No. 3.03 and 3.10 of Table 3.


Example P6: Preparation of 4-(bromo-difluoro-methyl)-5-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-difluoro-methyl]-2-methyl-2H-[1,2,3]triazole



4-(Bromo-difluoro-methyl)-5-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonylmethyl)-2-methyl-2*H*-[1,2,3]triazole (see Example I32 and Example I45) (500 mg, 1.3 mmol) and *N*-fluorobenzene sulfonimide (NFSI) (820 mg, 2.6 mmol) were dissolved in dry tetrahydrofuran under nitrogen and cooled to -78°C. Lithium hexamethyldisilazide (LiHMDS) (1M in THF) (2.8 ml, 2.8 mmol) was added dropwise at -78°C and the solution was stirred and allowed to warm slowly to room temperature over 4 hours. The reaction mixture was quenched at by addition of aqueous ammonium chloride (saturated) and was extracted several times with ethyl acetate. The combined organic fractions were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / hexane) to give Compound No. 1.59 of Table 1 (209 mg, 37% yield) and 4-(bromo-difluoro-methyl)-5-[difluoro-(4-fluoro-5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-methyl]-2-methyl-2*H*-[1,2,3]triazole (100 mg, 17.4% yield).

The same method was used to synthesise the following compounds:
Compound No. 1.13, 1.15, 1.17, 1.23, 1.26, 1.29, 1.32, 1.35, 1.41, 1.43, 1.48, 1.50, 1.52, 1.54, 1.57, 1.61 and 1.63 of Table 1,
Compound No. 3.04 and 3.07 of Table 3, and
Compound No. 4.01 of Table 4.

Example P7: Preparation of 5-cyclopropyl-4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfinyl)-fluoro-methyl]-1-methyl-1*H*-[1,2,3]triazole and 5-cyclopropyl-4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfinyl)-difluoro-methyl]-1-methyl-1*H*-[1,2,3]triazole



5-Cyclopropyl-4-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfinylmethyl)-1-methyl-1*H*-[1,2,3]triazole (95 mg, 0.34 mmol) was dissolved in dry tetrahydrofuran (5

ml) and cooled to -78°C. Lithium hexamethyldisilazide (LiHMDS) (1M in THF) (0.51 ml, 0.51 mmol) was added dropwise and the solution was stirred for 5 minutes at -78°C. N-fluorobenzene sulfonimide (NFSI) (160 mg, 0.51 mmol) was added and the reaction mixture stirred for 2 hours at -78°C. The reaction mixture was quenched by addition of aqueous ammonium chloride (saturated) (3ml) and extracted with ethyl acetate. The organic phase was washed with water and brine, dried over magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (eluent: ethyl acetate / iso-hexane) to give Compound No. 2.10 of Table 2 (42 mg, 39% yield) and Compound No. 2.11 of Table 2 (45 mg, 44% yield).


The same method was used to synthesise the following compounds:

Compound No. 1.21, 1.22, 1.24, 1.25, 1.30, 1.31, 1.33, 1.34, 1.39, 1.40, 1.55, 1.56, 1.68 and 1.69 of Table 1,

Compound No. 2.03 and 2.04 of Table 2, and

Compound No. 3.05 and 3.06 of Table 3.

Example P8: Preparation of 5-cyclopropyl-4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-fluoro-methyl]-1-methyl-1H-[1,2,3]triazole and 5-cyclopropyl-4-[(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonyl)-difluoro-methyl]-1-methyl-1H-[1,2,3]-triazole



5-Cyclopropyl-4-(5,5-dimethyl-4,5-dihydro-isoxazole-3-sulfonylmethyl)-1-methyl-1H-[1,2,3]triazole (200 mg, 0.67 mmol) and N-fluorobenzene sulfonimide (NFSI) (338 mg, 1.07 mmol) were dissolved in dry tetrahydrofuran (10 ml) and 1-ethyl-2,2,4,4,4-pentakis(dimethylamino)-2-λ⁵,4λ⁵-catenadi(phosphazene) (P₂-Et)

(364 mg, 1.07 mmol) was added dropwise to give a yellow solution. After the addition was complete, the solution was stirred for 2 hours at room temperature. The mixture was evaporated onto silica gel and purified by column chromatography (eluent: ethyl acetate/dichloromethane/iso-hexane) to give Compound No. 1.66 of Table 1 (47 mg, 21% yield) and Compound No. 1.67 of Table 1 (115 mg, 54% yield).

The same method was used to synthesise the following compounds:


Compound No. 1.19, 1.20, 1.37, 1.38, 1.45 and 1.46 of Table 1,

Compound No. 2.01, 2.02, 2.05, 2.06, 2.08 and 2.09 of Table 2, and

Compound No. 3.01, 3.02, 3.08 and 3.09 of Table 3.

The compounds mentioned in the following Tables can be prepared in analogous manner.

Table 1: Compounds of formula I.1



I.1

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.01	2	F	F	Me	-CH ₂ F	54	1.57 (s, 6H, Me), 3.19 (s, 2H, CH ₂), 4.31 (s, 3H, Me), 5.54 (s, 2H, CH ₂).
1.02	2	Cl	H	Me	-CH ₂ F		1.53 (s, 3H, Me), 1.55 (s, 3H, Me), 3.15 (d, 1H, CH ₂), 3.2 (d, 1H, CH ₂), 4.25 (s, 3H, Me), 5.56 (dd, 1H, CH ₂), 5.68 (dd, 1H, CH ₂), 6.27 (s, 1H, CH).
1.03	2	Cl	F	Me	-CH ₂ F	80	1.55 (s, 3H, Me), 1.57 (s, 3H, Me), 3.15 (d, 1H, CH ₂), 3.2 (d, 1H, CH ₂), 4.29 (s, 3H, Me), 5.56 (d, 2H, CH ₂).
1.04	2	F	H	Me	Me		1.55 (s, 6H, Me), 2.4 (s, 3H, Me), 3.15 (d, 1H, CH ₂), 3.2 (d, 1H, CH ₂), 4.2 (s, 3H, Me), 6.52 (d, 1H, CH).
1.05	2	F	F	Me	Me	75	1.56 (s, 6H, Me), 2.45 (s, 3H, Me), 3.17 (s, 2H, CH ₂), 4.21 (s, 3H, Me).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.06	2	Cl	H	Me	Me		1.5 (s, 3H, Me), 1.55 (s, 3H, Me), 2.4 (s, 3H, Me), 3.1 (d, 1H, CH ₂), 3.15 (d, 1H, CH ₂), 4.15 (s, 3H, Me), 6.5 (s, 1H, CH).
1.07	2	Cl	F	Me	Me		1.55 (s, 6H, Me), 2.4 (s, 3H, Me), 3.25 (d, 1H, CH ₂), 3.4 (d, 1H, CH ₂), 4.35 (s, 3H, Me).
1.08	1	F	F	Me	Me		1.45 (s, 3H, Me), 1.46 (s, 3H, Me), 3.35 (s, 3H, Me), 2.9 (d, 1H, CH ₂), 3.15 (d, 1H, CH ₂), 4.1 (s, 3H, Me).
1.09	2	F	F	Me	-CF ₃	80	1.57 (s, 6H, Me), 3.19 (s, 2H, CH ₂), 4.38 (s, 3H, Me).
1.10	2	Cl	F	Me	-CF ₃	66-69	1.54 (s, 3H, Me), 1.56 (s, 3H, Me), 3.18 (d, 1H, CH ₂), 3.22 (d, 1H, CH ₂), 4.35 (s, 3H, Me).
1.11	2	F	H	Me	-CF ₃		1.56 (s, 3H, Me), 1.57 (s, 3H, Me), 3.17 (d, 1H, CH ₂), 3.23 (d, 1H, CH ₂), 4.34 (s, 3H, Me), 6.64 (d, 1H, CH).
1.12	2	F	H	Et	Et		1.30 (t, 3H, Me), 1.55 (s, 6H, Me), 1.59 (t, 3H, Me), 2.81 (q, 2H, CH ₂), 3.14 (d, 1H, CH ₂), 3.20 (d, 1H, CH ₂), 4.45 (q, 2H, CH ₂), 6.51 (d, 1H, CH).
1.13	2	F	F	Et	Et	50-51	1.35 (t, 3H, Me), 1.5-1.7 (m, 9H, Me), 2.7 (q, 2H, CH ₂), 3.35 (s, 2H, CH ₂), 4.45 (q, 2H, CH ₂).
1.15	2	F	F	Et	-CF ₃		1.57 (s, 6H, Me), 1.66 (t, 3H, Me), 3.19 (s, 2H, CH ₂), 4.62 (q, 2H, CH ₂).
1.16	1	F	F	Et	-CF ₃		1.50 (s, 6H, Me), 1.64 (t, 3H, Me), 3.06 (d, 1H, CH ₂), 3.26 (d, 1H, CH ₂), 4.59 (q, 2H, CH ₂).
1.17	2	F	F	¹ Pr	-CF ₃		1.55 (s, 6H, Me), 1.66 (d, 6H, Me), 3.19 (s, 2H, CH ₂), 4.97 (sept, 1H, CH).
1.18	1	F	F	¹ Pr	-CF ₃		1.49 (s, 6H, Me), 1.63 (d, 6H, Me), 3.06 (d, 1H, CH ₂), 3.26 (d, 1H, CH ₂), 4.93 (sept, 1H, CH).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.19	2	F	H	-CHF ₂	Me		1.56 (s, 3H, Me), 1.56 (s, 3H, Me), 2.68 (s, 3H, Me), 3.15 (d, 1H, CH ₂), 3.20 (d, 1H, CH ₂), 6.64 (d, 1H, CH), 7.60 (t, 1H, CH).
1.20	2	F	F	-CHF ₂	Me		1.56 (s, 6H, Me), 2.70 (s, 3H, Me), 3.19 (s, 2H, CH ₂), 7.62 (t, 1H, CH).
1.21	1	F	H	-CHF ₂	Me		1.48 (s, 3H, Me), 1.48 (s, 3H, Me), 2.65 (s, 3H, Me), 3.13 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 6.59 (d, 1H, CH), 7.56 (t, 1H, CH).
1.22	1	F	F	-CHF ₂	Me		1.49 (s, 3H, Me), 1.51 (s, 3H, Me), 2.66 (s, 3H, Me), 2.95 (d, 1H, CH ₂), 3.13 (d, 1H, CH ₂), 7.60 (t, 1H, CH).
1.23	2	F	F	-CH ₂ CH 2OCH ₃	-CF ₃		1.57 (s, 6H, Me), 3.18 (s, 2H, CH ₂), 3.35 (s, 3H, Me), 3.95 (t, 2H, CH ₂), 4.72 (t, 2H, CH ₂).
1.24	1	F	H	-CH ₂ CH 2OCH ₃	-CF ₃		4:1-Mixture of diastereomers Major Isomer: 1.4 (s, 3H, Me), 1.45 (s, 3H, Me), 2.97 (d, 1H, CH ₂), 3.22 (d, 1H, CH ₂), 3.33 (s, 3H, Me), 3.85-3.95 (m, 2H, CH ₂), 4.65-4.7 (m, 2H, CH ₂), 6.45 (d, 1H, CH). Minor Isomer: 1.5 (s, 3H, Me), 1.53 (s, 3H, Me), 3.05 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 3.35 (s, 3H, Me), 3.85-3.95 (m, 2H, CH ₂), 4.65-4.7 (m, 2H, CH ₂), 6.55 (d, 1H, CH).
1.25	1	F	F	-CH ₂ CH 2OCH ₃	-CF ₃		1.48 (s, 3H, Me), 1.49 (s, 3H, Me), 3.04 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 3.35 (s, 3H, Me), 3.93 (t, 2H, CH ₂), 4.69 (t, 2H, CH ₂).
1.26	2	F	F	Me	Et		1.29 (t, 3H, Me), 1.55 (s, 6H, Me), 2.83 (q, 2H, CH ₂), 3.16 (s, 2H, CH ₂), 4.21 (s, 3H, Me).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.27	1	F	F	Me	Et		1.29 (t, 3H, Me), 1.50 (s, 6H, Me), 2.79 (q, 2H, CH ₂), 3.01 (d, 1H, CH ₂), 3.23 (d, 1H, CH ₂), 4.18 (s, 3H, Me).
1.28	2	F	H	- ^c Pe	-CF ₃	85	1.52 (s, 3H, Me), 1.55 (s, 3H, Me), 1.7-1.8 (m, 2H, CH ₂), 1.85-1.95 (m, 2H, CH ₂), 2.1-2.3 (m, 4H, CH ₂), 3.15 (d, 1H, CH ₂), 3.21 (d, 1H, CH ₂), 5.05-5.15 (m, 1H, CH), 6.55 (d, 1H, CH).
1.29	2	F	F	- ^c Pe	-CF ₃		1.57 (s, 6H, Me), 1.7-1.8 (m, 2H, CH ₂), 1.85-1.95 (m, 2H, CH ₂), 2.15-2.3 (m, 4H, CH ₂), 3.18 (s, 2H, CH ₂), 5.05-5.1 (m, 1H, CH).
1.30	1	F	H	- ^c Pe	-CF ₃		3:2-mixture of diastereomers Major Isomer: 1.44 (s, 3H, Me), 1.46 (s, 3H, Me), 1.7-1.8 (m, 2H, CH ₂), 1.85-1.95 (m, 2H, CH ₂), 2.15-2.3 (m, 4H, CH ₂), 2.97 (d, 1H, CH ₂), 3.23 (d, 1H, CH ₂), 5.05-5.1 (m, 1H, CH), 6.45 (d, 1H, CH). Minor Isomer: 1.5 (s, 3H, Me), 1.55 (s, 3H, Me), 1.7-1.8 (m, 2H, CH ₂), 1.85-1.95 (m, 2H, CH ₂), 2.15-2.3 (m, 4H, CH ₂), 3.07 (d, 1H, CH ₂), 3.27 (d, 1H, CH ₂), 5.05-5.1 (m, 1H, CH), 6.54 (d, 1H, CH).
1.31	1	F	F	- ^c Pe	-CF ₃		1.49 (s, 6H, Me), 1.7-1.8 (m, 2H, CH ₂), 1.85-1.95 (m, 2H, CH ₂), 2.1-2.3 (m, 4H, CH ₂), 3.05 (d, 1H, CH ₂), 3.26 (d, 1H, CH ₂), 5.05-5.15 (m, 1H, CH).
1.32	2	F	F	-CH ₂ CH=CH ₂	-CF ₃		1.57 (s, 6H, Me), 3.18 (s, 2H, CH ₂), 5.16 (d, 2H, CH ₂), 5.39-5.46 (m, 2H, CH ₂), 6.04-6.14 (m, 1H, CH).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.33	1	F	H	-CH ₂ CH =CH ₂	-CF ₃		5:1-Mixture of diastereomers Major isomer: 1.45 (s, 3H, Me), 1.47 (s, 3H, Me), 3.00 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 5.10 (d, 2H, CH ₂), 5.33-5.44 (m, 2H, CH ₂), 6.00-6.10 (m, 1H, CH), 6.47 (d, 1H, CH). Minor isomer: 1.51 (s, 3H, Me), 1.54 (s, 3H, Me), 3.07 (d, 1H, CH ₂), 3.26 (d, 1H, CH ₂), 5.10 (d, 2H, CH ₂), 5.33-5.44 (m, 2H, CH ₂), 6.00-6.10 (m, 1H, CH), 6.55 (d, 1H, CH).
1.34	1	F	F	-CH ₂ CH =CH ₂	-CF ₃		1.49 (s, 6H, Me), 3.06 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 5.13 (d, 2H, CH ₂), 5.37-5.45 (m, 2H, CH ₂), 6.02-6.12 (m, 1H, CH).
1.35	2	F	F	Me	H		1.56 (s, 6H, Me), 3.17 (s, 2H, CH ₂), 4.31 (s, 3H, Me), 7.98 (s, 1H, CH).
1.36	1	F	F	Me	H		1.49 (s, 3H, Me), 1.50 (s, 3H, Me), 2.95 (d, 1H, CH ₂), 3.21 (d, 1H, CH ₂), 4.28 (s, 3H, Me), 7.89 (s, 1H, CH).
1.37	2	F	H	Et	H		1.54 (s, 3H, Me), 1.55 (s, 3H, Me), 1.60 (t, 3H, Me), 3.14 (d, 1H, CH ₂), 3.19 (d, 1H, CH ₂), 4.54 (q, 2H, CH ₂), 6.58 (d, 1H, CH), 7.94 (s, 1H, CH).
1.38	2	F	F	Et	H		1.56 (s, 6H, Me), 1.62 (t, 3H, Me), 3.17 (s, 2H, CH ₂), 4.57 (q, 2H, CH ₂), 7.98 (s, 1H, CH).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.39	1	F	H	Et	H		4:1-Mixture of diastereomers Minor diastereomer (20%) 1.42 (s, 3H, Me), 1.43 (s, 3H, Me), 1.57 (t, 3H, Me), 2.66 (d, 1H, CH ₂), 3.08 (d, 1H, CH ₂), 4.51 (q, 2H, CH ₂), 6.50 (d, 1H, CH), 7.86 (s, 1H, CH). Major diastereomer (80%) 1.47 (s, 3H, Me), 1.49 (s, 3H, Me), 1.57 (t, 3H, Me), 3.05 (d, 1H, CH ₂), 3.24 (d, 1H, CH ₂), 4.49 (q, 2H, CH ₂), 6.46 (d, 1H, CH), 7.83 (s, 1H, CH).
1.40	1	F	F	Et	H		1.49 (s, 3H, Me), 1.50 (s, 3H, Me), 1.60 (t, 3H, Me), 2.94 (d, 1H, CH ₂), 3.21 (d, 1H, CH ₂), 4.54 (q, 2H, CH ₂), 7.89 (s, 1H, CH).
1.41	2	F	F	ⁱ Pr	Me	94-95	1.56 (s, 6H, Me), 1.57 (d, 6H, Me), 2.45 (s, 3H, Me), 3.17 (s, 2H, CH ₂), 4.81 (sept, 1H, CH).
1.43	2	F	F	Me	-OCH ₃		1.55 (s, 6H, Me), 3.18 (s, 2H, CH ₂), 4.01 (s, 3H, Me), 4.13 (s, 3H, Me).
1.44	1	F	F	Me	-OCH ₃		1.49 (s, 6H, Me), 3.07 (dd, 1H, CH ₂), 3.24 (d, 1H, CH ₂), 3.99 (s, 3H, Me), 4.09 (s, 3H, Me).
1.45	2	F	H	Me	Br		1.56 (s, 3H, Me), 1.57 (s, 3H, Me), 3.17 (d, 1H, CH ₂), 3.23 (d, 1H, CH ₂), 4.27 (s, 3H, Me), 6.49 (d, 1H, CH).
1.46	2	F	F	Me	Br	96-99	1.57 (s, 6H, Me), 3.18 (s, 2H, CH ₂), 4.28 (s, 3H, Me).
1.47	1	F	F	Me	Br		1.50 (s, 6H, Me), 3.05 (d, 1H, CH ₂), 3.24 (d, 1H, CH ₂), 4.25 (s, 3H, Me).
1.48	2	F	F	-CH ₂ ^c B u	-CF ₃	66	1.54 (s, 3H, Me), 1.57 (s, 3H, Me), 1.75-1.95 (m, 4H, CH ₂), 2.1-2.2 (m, 2H, CH ₂), 2.95-3.05 (m, 1H, CH), 3.18 (s, 2H, CH ₂), 4.56 (d, 2H, CH ₂).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.49	1	F	F	-CH ₂ ^c B u	-CF ₃		1.45 (s, 6H, Me), 1.75-1.95 (m, 4H, CH ₂), 2.05-2.2 (m, 2H, CH ₂), 2.95-3.05 (m, 1H, CH), 3.05 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 4.55 (d, 2H, CH ₂).
1.50	2	F	F	Me	-CO ₂ Me		1.57 (s, 6H, Me), 3.22 (s, 2H, CH ₂), 3.98 (s, 3H, Me), 4.36 (s, 3H, Me).
1.51	1	F	F	Me	-CO ₂ Me		1.47 (s, 3H, Me), 1.49 (s, 3H, Me), 3.09 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 4.0 (s, 3H, Me), 4.33 (s, 3H, Me).
1.52	2	F	F	Me	-COMe		1.56 (s, 6H, Me), 2.62 (s, 3H, Me), 3.26 (s, 2H, CH ₂), 4.34 (s, 3H, Me).
1.54	2	F	F	Me	-OCHF ₂		1.56 (s, 6H, Me), 3.18 (s, 2H, CH ₂), 4.21 (s, 3H, Me), 6.88 (t, 1H, CH).
1.55	1	F	H	Me	-OCHF ₂		Diastereomer A: 1.45 (s, 3H, Me), 1.45 (s, 3H, Me), 3.01 (d, 1H, CH ₂), 3.26 (d, 1H, CH ₂), 4.14 (s, 3H, Me), 6.33 (d, 1H, CH), 6.86 (t, 1H, CH).
1.56	1	F	F	Me	-OCHF ₂		1.50 (s, 3H, Me), 1.50 (s, 3H, Me), 3.06 (d, 1H, CH ₂), 3.25 (d, 1H, CH ₂), 4.18 (s, 3H, Me), 6.87 (t, 1H, CH).
1.57	2	F	F	Et	Me		1.56 (s, 6H, Me), 1.58 (t, 3H, Me), 2.46 (s, 3H, Me), 3.17 (s, 2H, CH ₂), 4.47 (q, 2H, CH ₂).
1.58	1	F	F	Et	Me		1.49 (s, 6H, Me), 1.56 (t, 3H, Me), 2.42 (s, 3H, Me), 2.99 (d, 1H, CH ₂), 3.22 (d, 1H, CH ₂), 4.43 (q, 2H, CH ₂).
1.59	2	F	F	Me	-CF ₂ Br	oil	1.55 (s, 6H, Me), 3.19 (s, 2H, CH ₂), 4.45 (s, 3H, Me).
1.61	2	F	F	Me	-CHF ₂	oil	1.45 (s, 6H, Me), 3.20 (s, 2H, CH ₂), 4.32 (s, 3H, Me), 6.90 (t, 1H, CH).
1.63	2	F	F	Me	-CHFC H ₃		1.56 (s, 6H, Me), 1.78 (dd, 3H, Me), 3.3 (d, 1H, CH ₂), 3.4 (d, 1H, CH ₂), 4.29 (s, 3H, Me), 5.28 (dq, 1H, CH).


No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
1.65	2	F	F	Ph	Me	144-146	1.55 (s, 6H, Me), 2.57 (s, 3H, Me), 3.18 (s, 2H, CH ₂), 7.4-7.45 (m, 1H, CH), 7.45-7.5 (m, 2H, CH), 8.0-8.1 (m, 2H, CH).
1.66	2	F	F	Me	^c Pr		0.96 (m, 2H, CH ₂), 1.03 (m, 2H, CH ₂), 1.56 (s, 6H, Me), 2.10 (m, 1H, CH), 3.18 (s, 2H, CH ₂), 4.16 (s, 3H, Me).
1.67	2	F	H	Me	^c Pr		0.93 (m, 2H, CH ₂), 1.02 (m, 2H, CH ₂), 1.55 (s, 3H, Me), 1.55 (s, 3H, Me), 2.02 (m, 1H, CH), 3.15 (d, 1H, CH ₂), 3.21 (d, 1H, CH ₂), 4.14 (d, 3H, Me), 6.60 (d, 1H, CH).
1.68	1	F	F	Me	^c Pr		0.96 (m, 2H, CH ₂), 1.02 (m, 2H, CH ₂), 1.49 (s, 3H, Me), 1.49 (s, 3H, Me), 2.01 (m, 1H, CH), 3.02 (d, 1H, CH ₂), 3.24 (d, 1H, CH ₂), 4.12 (s, 3H, Me).
1.69	1	F	H	Me	^c Pr		0.92 (m, 2H, CH ₂), 1.02 (m, 2H, CH ₂), 1.41 (s, 3H, Me), 1.47 (s, 3H, Me), 1.97 (m, 1H, CH), 3.02 (d, 1H, CH ₂), 3.22 (d, 1H, CH ₂), 4.07 (s, 3H, Me), 6.44 (d, 1H, CH).

Key:

Me = methyl; Et = ethyl; ⁱPr = *iso*-propyl; ^cPr = cyclopropyl; ^cBu = cyclobutyl; ^cPe = cyclopentyl; s = singlet; d = doublet; t = triplet; q = quartet; dd = double doublet; dq =

5 double quartet; sept = septet; m = multiplet.

Table 2: Compounds of formula I.2



I.2


No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
2.01	2	F	H	^t Bu	H		1.54 (s, 3H, Me), 1.55 (s, 3H, Me), 1.72 (s, 9H, Me), 3.16 (s, 2H, CH ₂), 6.66 (d, 1H, CH), 8.06 (d, 1H, CH).
2.02	2	F	F	^t Bu	H		1.59 (s, 6H, Me), 1.76 (s, 9H, Me), 3.23 (s, 2H, CH ₂), 8.11 (s, 1H, CH).
2.03	1	F	H	^t Bu	H		1.46 (s, 3H, Me), 1.48 (s, 3H, Me), 1.70 (s, 9H, Me), 3.14 (d, 1H, CH ₂), 3.24 (d, 1H, CH ₂), 6.57 (d, 1H, CH), 7.93 (s, 1H, CH).
2.04	1	F	F	^t Bu	H		1.48 (s, 3H, Me), 1.51 (s, 3H, Me), 1.72 (s, 9H, Me), 2.97 (d, 1H, CH ₂), 3.12 (d, 1H, CH ₂), 7.98 (s, 1H, CH).
2.05	2	F	H	Me	Me		1.54 (s, 3H, Me), 1.54 (s, 3H, Me), 2.47 (d, 3H, Me), 3.14 (d, 1H, CH ₂), 3.19 (d, 1H, CH ₂), 4.00 (s, 3H, Me), 6.57 (d, 1H, CH).
2.06	2	F	F	Me	Me		1.56 (s, 6H, Me), 2.49 (t, 3H, Me), 3.19 (s, 2H, CH ₂), 4.03 (s, 3H, Me).
2.07	1	F	F	Me	Me		1.48 (s, 3H, Me), 1.52 (s, 3H, Me), 2.46 (t, 3H, Me), 3.02 (d, 1H, CH ₂), 3.13 (d, 1H, CH ₂), 4.01 (s, 3H, Me).
2.08	2	F	F	Me	^c Pr		0.97 (m, 2H, CH ₂), 1.17 (m, 2H, CH ₂), 1.57 (s, 6H, Me), 1.78 (m, 1H, CH), 3.22 (s, 2H, CH ₂), 4.11 (s, 3H, Me).
2.09	2	F	H	Me	^c Pr		0.75 (m, 1H, CH ₂), 0.98 (m, 1H, CH ₂), 1.17 (m, 2H, CH ₂), 1.56 (s, 3H, Me), 1.59 (s, 3H, Me), 1.77 (m, 1H, CH), 3.19 (d, 1H, CH ₂), 3.30 (d, 1H, CH ₂), 4.09 (s, 3H, Me), 6.47 (d, 1H, CH).
2.10	1	F	F	Me	^c Pr		0.91 (m, 2H, CH ₂), 1.18 (m, 2H, CH ₂), 1.48 (s, 3H, Me), 1.50 (s, 3H, Me), 1.74 (m, 1H, CH), 3.13 (d, 1H, CH ₂), 3.20 (d, 1H, CH ₂), 4.10 (s, 3H, Me).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
2.11	1	F	H	Me	^c Pr		0.80 (m, 1H, CH ₂), 1.05 (m, 1H, CH ₂), 1.17 (m, 2H, CH ₂), 1.36 (s, 3H, Me), 1.44 (s, 3H, Me), 1.69 (m, 1H, CH), 3.08 (d, 1H, CH ₂), 3.20 (d, 1H, CH ₂), 4.07 (s, 3H, Me), 6.53 (d, 1H, CH).

Key:

Me = methyl; ^cPr = cyclopropyl; ^tBu = *tert*-butyl; s = singlet; d = doublet; t = triplet; m = multiplet.

5

Table 3: Compounds of formula I.3


No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
3.01	2	F	H	Me	-CF ₃		1.57 (s, 3H, Me), 1.58 (s, 3H, Me), 3.16 (d, 1H, CH ₂), 3.20 (d, 1H, CH ₂), 4.37 (s, 3H, Me), 6.89 (d, 1H, CH).
3.02	2	F	F	Me	-CF ₃		1.58 (s, 6H, Me), 3.18 (s, 2H, CH ₂), 4.39 (s, 3H, Me).
3.03	1	F	F	Me	-CF ₃		1.5 (s, 3H, Me), 1.51 (s, 3H, Me), 2.9 (d, 1H, CH ₂), 3.2 (d, 1H, CH ₂), 4.35 (s, 3H, Me).
3.04	2	F	F	Me	Br	91-93	1.58 (s, 6H, Me), 3.17 (s, 2H, CH ₂), 4.32 (t, 3H, Me).
3.05	1	F	H	Me	Br		Minor diastereomer (40%) 1.49 (s, 3H, Me), 1.50 (s, 3H, Me), 3.09 (d, 1H, CH ₂), 3.24 (d, 1H, CH ₂), 4.28 (s, 3H, Me), 6.45 (d, 1H, CH). Major diastereomer (60%) 1.42 (s, 3H, Me), 1.50 (s, 3H, Me), 2.32 (d, 1H, CH ₂), 2.95 (d, 1H, CH ₂), 4.31 (s, 3H, Me), 6.47 (d, 1H, CH).

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
3.06	1	F	F	Me	Br	70-72	1.49 (s, 3H, Me), 1.53 (s, 3H, Me), 2.76 (d, 1H, CH ₂), 3.14 (d, 1H, CH ₂), 4.29 (t, 3H, Me).
3.07	2	F	F	ⁱ Pr	Me		1.57 (s, 6H, Me), 1.65 (d, 6H, Me), 2.49 (s, 3H, Me), 3.15 (s, 2H, CH ₂), 4.92 (sept, 1H, CH).
3.08	2	F	F	Me	^c Pr		1.03 (m, 2H, CH ₂), 1.17 (m, 2H, CH ₂), 1.57 (s, 6H, Me), 2.05 (m, 1H, CH), 3.15 (s, 2H, CH ₂), 4.21 (s, 3H, Me).
3.09	2	F	H	Me	^c Pr		0.99-1.08 (m, 3H, CH ₂), 1.16 (m, 1H, CH ₂), 1.55 (s, 3H, Me), 1.57 (s, 3H, Me), 1.89 (m, 1H, CH), 3.15 (s, 2H, CH ₂), 4.20 (s, 3H, Me), 6.73 (d, 1H, CH).
3.10	1	F	F	Me	^c Pr		1.00-1.09 (m, 3H, CH ₂), 1.25 (m, 1H, CH ₂), 1.48 (s, 3H, Me), 1.49 (s, 3H, Me), 1.95 (m, 1H, CH), 2.64 (dd, 1H, CH ₂), 3.14 (d, 1H, CH ₂), 4.19 (t, 3H, Me).

Key:

Me = methyl; ⁱPr = *iso*-propyl; ^cPr = cyclopropyl; s = singlet; d = doublet; t = triplet; dd = double doublet; m = multiplet.

5

Table 4: Compounds of formula I.4

I.4

No.	m	R ⁵	R ⁶	R ⁷	R ⁸	M.p. [°C]	¹ H-NMR (400 MHz, CDCl ₃)
4.01	2	F	F	Me	Me	73-75	1.57 (s, 6H, Me), 2.42 (s, 3H, Me), 3.24 (s, 2H, CH ₂), 3.93 (s, 3H, Me).

Key:

10 Me = methyl; s = singlet.

Biological ExamplesExample B1: Herbicidal action

Monocotyledonous and dicotyledonous test plants were sown in sterilised standard soil in seed trays each having 96 cells. After one day (pre-emergence) or after 8 to 9 days cultivation (post-emergence) under controlled conditions in a climatic chamber (cultivation at 23/17°C, day/night ; 13 hours light; 50-60% humidity; after application at 24/19°C, day/night), the plants were treated with an aqueous spray solution of 1000 mg/l of the active ingredient used (incl. 10% DMSO as solvent). The plants were grown on in the climatic chamber until the test was evaluated (10 = total damage to plant, 0 = no damage to plant) after 9 or 13 days.

Table B1 a: Application pre-emergence

	Comp	Rate	DIGSA	AGSTE	SETIT	POATR	AMARE	SETFA
15	1.01	1000	10	10	10	10	10	-
	1.03	1000	10	10	9	10	8	-
	1.04	1000	10	10	9	10	9	-
	1.05	1000	10	10	10	10	10	-
20	1.07	1000	10	10	9	10	9	-
	1.08	1000	10	10	-	10	10	9
	1.09	1000	10	10	10	10	10	-
	1.10	1000	10	10	10	10	10	-
	1.11	1000	10	10	10	10	10	-
25	1.12	1000	9	10	-	10	10	9
	1.15	1000	10	10	-	10	10	10
	1.16	1000	10	10	-	10	10	9
	1.17	1000	9	10	-	10	10	10
	1.18	1000	10	10	-	10	10	9
30	1.19	1000	10	10	-	10	10	10
	1.20	1000	10	10	-	10	10	9
	1.21	1000	10	10	-	10	10	10
	1.22	1000	10	10	-	10	10	9


	1.23	1000	10	10	-	10	10	10
	1.24	1000	10	10	-	10	10	9
	1.25	1000	10	10	-	10	10	9
	1.26	1000	10	10	-	10	10	10
5	1.27	1000	10	10	-	10	10	9
	1.28	1000	9	10	-	10	9	8
	1.29	1000	9	10	-	6	8	9
	1.30	1000	9	10	-	10	10	8
	1.31	1000	9	10	-	7	0	9
10	1.32	1000	10	10	-	10	10	10
	1.33	1000	10	10	-	10	4	6
	1.34	1000	10	10	-	10	9	10
	1.35	1000	9	10	-	10	10	9
	1.36	1000	10	10	-	10	9	9
15	1.37	1000	9	10	-	10	10	9
	1.38	1000	9	10	-	10	10	9
	1.39	1000	9	10	-	10	9	9
	1.40	1000	9	10	-	10	10	9
	1.41	1000	10	10	-	10	10	9
20	1.43	1000	10	10	-	0	10	10
	1.44	1000	10	10	-	0	10	9
	1.45	1000	10	10	-	10	9	9
	1.46	1000	10	10	-	10	10	9
	1.47	1000	9	10	-	10	10	9
25	1.48	1000	10	10	-	6	9	9
	1.49	1000	10	10	-	10	9	9
	2.01	1000	9	10	-	0	3	9
	2.02	1000	9	9	-	9	3	8
	2.03	1000	9	8	-	4	2	5
30	2.04	1000	2	6	-	0	0	6
	3.01	1000	10	10	8	10	5	-
	3.02	1000	10	10	10	10	10	-
	3.03	1000	9	10	-	10	10	8

3.04	1000	9	10	-	10	10	9
3.05	1000	10	10	-	10	8	9
3.06	1000	9	10	-	10	10	9

- 5 DIGSA = *Digitaria sanguinalis*; AGRTE = *Agrostis tenius*; SETIT = *Setaria italica*;
SETFA = *Setaria faberi*; POATR = *Poa trivialis*; AMARE = *Amaranthus retroflexus*.

What is claimed is:

1. A compound of formula



5 wherein

R^1 and R^2 are each independently of the other hydrogen, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ haloalkyl, $\text{C}_3\text{-C}_8$ cycloalkyl or $\text{C}_3\text{-C}_8$ cycloalkyl- $\text{C}_1\text{-C}_3$ alkyl, or

R^1 and R^2 together with the carbon atom to which they are bonded form a $\text{C}_3\text{-C}_7$ ring,

R^3 and R^4 are each independently of the other hydrogen, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ haloalkyl,

10 $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_3\text{-C}_8$ cycloalkyl- $\text{C}_1\text{-C}_{10}$ alkyl or $\text{C}_1\text{-C}_6$ alkoxy- $\text{C}_1\text{-C}_{10}$ alkyl, or

R^3 and R^4 together with the carbon atom to which they are bonded form a $\text{C}_3\text{-C}_7$ ring, or

R^1 with R^3 or R^4 and together with the carbon atoms to which they are bonded form a

$\text{C}_5\text{-C}_8$ ring, or

R^2 with R^3 or R^4 and together with the carbon atoms to which they are bonded form a

15 $\text{C}_5\text{-C}_8$ ring;


R^5 is halogen or $\text{C}_1\text{-C}_6$ haloalkyl;

R^6 is hydrogen, cyano, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxycarbonyl, halogen or $\text{C}_1\text{-C}_6$ haloalkyl;

m is 0, 1 or 2;

n is 1, 2 or 3; and

20 Y is one of the following groups



wherein

R^7 is hydrogen, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkylcarbonyl, formyl, $\text{C}_1\text{-C}_{10}$ haloalkylcarbonyl, $\text{C}_1\text{-C}_{10}$ alkoxycarbonyl, $\text{C}_1\text{-C}_{10}$ haloalkyl, cyano, $\text{C}_2\text{-C}_{10}$ alkenyl, $\text{C}_2\text{-C}_{10}$ alkynyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl- $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkylcarbonyl- $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkylsulfonyl, $\text{C}_1\text{-C}_{10}$ haloalkylsulfonyl, $\text{C}_1\text{-C}_{10}$ alkoxy- $\text{C}_1\text{-C}_{10}$ alkyl or phenyl which is optionally substituted by one to five substituents selected from cyano, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ haloalkyl or halogen; or

25 C_{10} cycloalkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl- $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkylcarbonyl- $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkylsulfonyl, $\text{C}_1\text{-C}_{10}$ haloalkylsulfonyl, $\text{C}_1\text{-C}_{10}$ alkoxy- $\text{C}_1\text{-C}_{10}$ alkyl or phenyl which is optionally substituted by one to five substituents selected from cyano, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ haloalkyl or halogen; or

R^7 is $-\text{CONR}^{13}\text{R}^{14}$ or $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} are independently of each other hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 cycloalkyl, C_1 - C_6 alkylcarbonyl, C_1 - C_6 haloalkylcarbonyl, C_1 - C_6 alkylsulfonyl, C_1 - C_6 haloalkylsulfonyl, or R^{13} and R^{14} together form a C_3 - C_8 alkylene group which optionally contains one oxygen, sulfur, amino or C_1 -

5 C_6 alkylamino group;

R^8 is hydrogen, C_1 - C_{10} alkyl, C_1 - C_{10} alkylcarbonyl, formyl, C_1 - C_{10} haloalkylcarbonyl, C_1 - C_{10} alkoxycarbonyl, C_1 - C_{10} haloalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} alkyl, halogen, cyano, C_1 - C_{10} alkoxy or C_1 - C_{10} haloalkoxy, or

10 R^8 is $-\text{CONR}^{15}\text{R}^{16}$, $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$ or $-\text{NR}^{15}\text{R}^{16}$ wherein R^{15} and R^{16} are independently of each other hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 cycloalkyl, C_1 - C_6 alkylcarbonyl, C_1 - C_6 haloalkylcarbonyl, C_1 - C_6 alkylsulfonyl, C_1 - C_6 haloalkylsulfonyl, or R^{15} and R^{16} together form a C_3 - C_8 alkylene group which optionally contains one oxygen, sulfur, amino or C_1 - C_6 alkylamino group;

and to N-oxides, salts and optical isomers of compounds of formula I.

15

2. A compound according to claim 1 in which R^1 and R^2 are independently C_1 - C_{10} alkyl or C_1 - C_{10} haloalkyl.

3. A compound according to claim 1 or claim 2 in which R^1 and R^2 are both methyl.

20

4. A compound according to any one of claims 1 to 3 in which R^3 and R^4 are independently hydrogen, C_1 - C_{10} alkyl or C_1 - C_{10} haloalkyl.

5. A compound according to any one of claims 1 to 4 in which R^3 and R^4 are both

25


hydrogen.

6. A compound according to any one of claims 1 to 5 in which R^5 is halogen or trifluoromethyl.

30

7. A compound according to any one of claims 1 to 6 in which R^5 is fluoro or chloro.


8. A compound according to any one of claims 1 to 7 in which R⁶ is hydrogen, methoxycarbonyl, C₁-C₆alkyl or halogen.
9. A compound according to any one of claims 1 to 8 in which R⁶ is hydrogen or fluoro.
10. A compound according to any one of claims 1 to 9 in which m is 1 or 2.
11. A compound according to any one of claims 1 to 10 in which m is 2.
12. A compound according to any one of claims 1 to 11 in which n is 1.
13. A compound according to any one of claims 1 to 12 in which Y is one of the following groups



14. A compound according to any one of claims 1 to 13 in which R⁷ is hydrogen, C₁-C₁₀alkyl, C₁-C₁₀haloalkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₁₀cycloalkyl, C₃-C₁₀cycloalkyl-C₁-C₁₀alkyl, C₁-C₁₀alkoxy-C₁-C₁₀alkyl or phenyl which is optionally substituted by one to five substituents selected from cyano, C₁-C₁₀alkyl, C₁-C₁₀haloalkyl or halogen.
15. A compound according to any one of claims 1 to 14 in which R⁷ is hydrogen, methyl, ethyl, *iso*-propyl, *tert*-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, allyl, propargyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclobutylmethyl, methoxymethyl, 2-methoxy-ethyl or phenyl.
16. A compound according to any one of claims 1 to 15 in which R⁸ is hydrogen, C₁-C₁₀alkyl, C₁-C₁₀alkylcarbonyl, formyl, C₁-C₁₀alkoxycarbonyl, C₁-C₁₀haloalkyl, C₃-C₁₀cycloalkyl, halogen, cyano, C₁-C₁₀alkoxy or C₁-C₁₀haloalkoxy.

17. A compound according to any one of claims 1 to 16 in which R⁸ is hydrogen, methyl, ethyl, acetyl, formyl, methoxycarbonyl, monofluoromethyl, difluoromethyl, trifluoromethyl, bromodifluoromethyl, 1-fluoro-ethyl, cyclopropyl, fluoro, chloro, bromo, cyano, methoxy, difluoromethoxy, trifluoromethoxy or 2,2,2-trifluoroethoxy.


18. A process in which a compound of formula (Id) is formed



- by reacting a compound of formula VIII wherein R⁶ and Y are as defined in claim 1, R^P is hydrogen, halogen or C₁-C₆haloalkyl and M^B is selected from the group comprising MgCl, MgBr, ZnBr and Li,




with a compound of formula IX,



- wherein R¹, R², R³ and R⁴ are as defined in claim 1, optionally in the presence of a diluent.


19. A process in which a compound of formula (Id) is formed



- by reacting a compound of formula IIa wherein R⁶ and Y are as defined in claim 1, R^P is hydrogen, halogen or C₁-C₆haloalkyl and X^C is functional group that may be cleaved as a radical,




with a compound of formula IX,



wherein R^1 , R^2 , R^3 and R^4 are as defined in claim 1 with a radical initiator or a precursor thereof, optionally in the presence of a base and optionally in the presence of a diluent.

5

20. A process in which a compound of formula (Id) is formed




by reacting a compound of formula II wherein R^6 and Y are as defined in claim 1, R^P is hydrogen, halogen or C_1 - C_6 haloalkyl, and X^A is a leaving group selected from the group comprising halogen, an alkylsulfonate, an arylsulfonate, or a haloalkylsulfonate,

10




with a compound of formula IX



wherein R^1 , R^2 , R^3 and R^4 are as defined in claim 1 with in the presence of a reducing agent, optionally in the presence of a base and optionally in the presence of a diluent.

15

21. A compound of formula IX



wherein R^1 , R^2 , R^3 and R^4 are as defined in claim 1.

20

22. A herbicidal composition which comprises a herbicidally effective amount of a compound of formula I in addition to formulation adjuvants.

23. A method of controlling plants which comprises applying a herbicidally effective amount of a compound of formula I, or of a composition comprising such a compound, to the plants or to the locus thereof.
- 5 24. A composition according to claim 22, which comprises a further herbicide in addition to the compound of formula I.
25. A composition according to claim 22, which comprises a safener in addition to the compound of formula I.

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2007/000184

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D413/12 A01N43/80 C07D261/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, EMBASE, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 364 946 A1 (KUMIAI CHEMICAL INDUSTRY CO [JP]; IHARA CHEMICAL IND CO [JP]) 26 November 2003 (2003-11-26) compounds of table 9, pages 140(11th), 141(23rd) and 142(22nd) & WO 02/062770 A (KUMIAI CHEMICAL INDUSTRY CO [JP]; IHARA CHEMICAL IND CO [JP]; NAKATANI) 15 August 2002 (2002-08-15) cited in the application	1-25
Y	EP 1 405 853 A1 (KUMIAI CHEMICAL INDUSTRY CO [JP]; IHARA CHEMICAL IND CO [JP]) 7 April 2004 (2004-04-07) compounds of page 47(8th), 48(19th) and 49(26th) -/-	1-25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the International search

30 March 2007

Date of mailing of the International search report

10/04/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, Didier

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2007/000184

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& WO 03/000686 A (KUMIAI CHEMICAL INDUSTRY CO [JP]; IHARA CHEMICAL IND CO [JP]; NAKATANI) 3 January 2003 (2003-01-03) cited in the application -----	
Y	WO 2005/104848 A (SYNGENTA PARTICIPATIONS AG [CH]; SYNGENTA LTD [GB]; RUEEGG WILLY THADD) 10 November 2005 (2005-11-10) abstract; claims -----	1-25
Y	US 2005/256004 A1 (TAKAHASHI SATORU [JP] ET AL) 17 November 2005 (2005-11-17) page 5, par. [0068]; claims -----	1-25
Y	JP 2005 035924 A (KUMIAI CHEMICAL INDUSTRY CO; IHARA CHEMICAL IND CO) 10 February 2005 (2005-02-10) abstract -----	1-25
A,P	WO 2006/024820 A (SYNGENTA LTD [GB]; PLANT ANDREW [GB]; BOEHMER JUTTA ELISABETH [GB]; BL) 9 March 2006 (2006-03-09) cited in the application -----	1-25
A	EP 1 203 768 A1 (KUMIAI CHEMICAL INDUSTRY CO [JP] KUMIAI CHEMICAL INDUSTRY CO [JP]; IHA) 8 May 2002 (2002-05-08) abstract; claims & WO 01/12613 A (KUMIAI CHEMICAL INDUSTRY CO [JP]; IHARA CHEMICAL IND CO [JP]; NAKATANI) 22 February 2001 (2001-02-22) cited in the application -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2007/000184

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1364946	A1	26-11-2003	BR 0207025 A 17-02-2004
		CA 2438547 A1 15-08-2002	
		CN 1491217 A 21-04-2004	
		CN 1673221 A 28-09-2005	
		CZ 20032148 A3 17-12-2003	
		HU 0400723 A2 30-08-2004	
		WO 02062770 A1 15-08-2002	
		MX PA03006615 A 20-06-2005	
		NZ 527032 A 29-07-2005	
		RU 2286989 C2 10-11-2006	
		SK 10052003 A3 04-05-2004	
		US 2004110749 A1 10-06-2004	
		YU 62803 A 03-03-2006	
WO 02062770	A	15-08-2002	BR 0207025 A 17-02-2004
		CA 2438547 A1 15-08-2002	
		CN 1491217 A 21-04-2004	
		CN 1673221 A 28-09-2005	
		CZ 20032148 A3 17-12-2003	
		EP 1364946 A1 26-11-2003	
		HU 0400723 A2 30-08-2004	
		MX PA03006615 A 20-06-2005	
		NZ 527032 A 29-07-2005	
		RU 2286989 C2 10-11-2006	
		SK 10052003 A3 04-05-2004	
		US 2004110749 A1 10-06-2004	
		YU 62803 A 03-03-2006	
EP 1405853	A1	07-04-2004	WO 03000686 A1 03-01-2003
			US 2004259734 A1 23-12-2004
WO 03000686	A	03-01-2003	EP 1405853 A1 07-04-2004
			US 2004259734 A1 23-12-2004
WO 2005104848	A	10-11-2005	AU 2005237241 A1 10-11-2005
			CA 2563218 A1 10-11-2005
			EP 1755397 A1 28-02-2007
US 2005256004	A1	17-11-2005	AU 2003254863 A1 25-02-2004
			BR 0313241 A 09-08-2005
			WO 2004014138 A1 19-02-2004
			UA 78071 C2 15-02-2007
JP 2005035924	A	10-02-2005	NONE
WO 2006024820	A	09-03-2006	AR 050793 A1 22-11-2006
EP 1203768	A1	08-05-2002	AT 318801 T 15-03-2006
			AU 769834 B2 05-02-2004
			AU 6472500 A 13-03-2001
			BR 0013251 A 16-04-2002
			CA 2380499 A1 22-02-2001
			CN 1368965 A 11-09-2002
			CZ 20020461 A3 15-05-2002
			DE 60026318 T2 10-08-2006
			HU 0202799 A2 28-01-2003
			WO 0112613 A1 22-02-2001
			RU 2237664 C2 10-10-2004

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2007/000184

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1203768	A1	UA 73520 C2	15-12-2004
		US 6841519 B1	11-01-2005
		ZA 200200392 A	16-01-2003
WO 0112613	A 22-02-2001	AT 318801 T	15-03-2006
		AU 769834 B2	05-02-2004
		AU 6472500 A	13-03-2001
		BR 0013251 A	16-04-2002
		CA 2380499 A1	22-02-2001
		CN 1368965 A	11-09-2002
		CZ 20020461 A3	15-05-2002
		DE 60026318 T2	10-08-2006
		EP 1203768 A1	08-05-2002
		HU 0202799 A2	28-01-2003
		RU 2237664 C2	10-10-2004
		UA 73520 C2	15-12-2004
		US 6841519 B1	11-01-2005
		ZA 200200392 A	16-01-2003